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The neuroinflammatory response to peripheral nerve injury is associated with 
chronic pain and significant changes in the expression profiles of RNAs in neurons, glia 
and infiltrating immune cells: a neuro-immune triad. Chronic constriction injury (CCI) 
of the rat sciatic nerve provides an opportunity to mimic neuropathic injury and 
quantitatively assess behavior and differential gene expression in individual animals. 
Macrophages that phagocytose intravenously injected nanoemulsion carrying the non-
steroidal anti-inflammatory, NSAID, Celecoxib, naturally accumulate at the site of 
injury resulting in relief of CCI behavioral hyper-sensitivity.  It is not known beyond the 
inhibition of cyclooxygenase-2 (COX-2) activity and the reduction in prostaglandin E2 
(PGE2), what gene expression may be altered by this treatment. Previously, we showed 
that a single intravenous injection of nanoemulsion containing celecoxib (0.24 mg/kg) 
reduced inflammation of the sciatic nerve and relieved pain-like behavior for up to 6 
days. To elucidate aspects of the molecular mechanisms underlying CCI pain as well as 
pain relief, I assessed an NSAID-loaded nanoemulsion macrophage-targeted therapy to 
explore changes in RNA expression in both pain and pain-relieved states. Sciatic nerve 
and dorsal root ganglia (DRG) tissue from CCI animals was used to evaluate the 
expression profiles utilizing quantitative polymerase chain reactions (qPCR) and RNA 
sequencing, respectively. In the injured sciatic nerve treated with drug-loaded 
nanoemulsion, I observed mRNA changes consistent with the reduced recruitment of 
macrophages evident by a reduction in chemokine and cytokine mRNA expression. 
 vi 
Furthermore, genes associated with selective adhesion of macrophages, as well as 
changes in the neuronal and glial associated mRNAs were observed. Moreover, several 
neuroactive genes were found to respond to the celecoxib loaded nanoemulsion in 
animals receiving pain relief as compared to animals that received drug-free vehicle 
including: Monoamine oxidase B (MAOB), NMDA-Receptor 2b (Grin2b), Calcium 
channel TRPV3, Interleukin IL-6, Voltage-dependent Calcium channel subunit alpha 1B 
(Cacna1b/C2v2.2), Integrin alpha M (Itgam/Cd11b), Sodium channel Nav1.7 (Scn9a), 
and Preprotachykinin-1 (Tac1), which produces neurokinin A and substance P.  
The transcriptome of the ipsilateral DRGs was assessed using high throughput 
RNA sequencing to provide insight into the molecular mechanisms involved in the 
underlying neuroimmune response. Comparing the DRG transcriptome of CCI animals 
treated with celecoxib-loaded nanoemulsion (CXB-NE) as well as drug-free (vehicle) 
nanoemulsion (DF-NE) to naïve, unoperated rats revealed significant differential RNA 
expression of 115 genes. Differential expression of particular transcripts was validated 
by quantitative PCR in the DRG and the bioinformatics tool PANTHER (protein 
annotation through evolutionary relationship) revealed that the differentially expressed 
genes involved in the neuroinflammatory response are associated with several key 
signaling mechanisms. This study showed that by directly inhibiting COX-2 activity in 
infiltrating macrophages at the site of injury on the sciatic nerve, there was a subsequent 
change in RNA expression in cell bodies of the DRG.  While it is not surprising that 
peripheral nerve injury is associated with extensive changes in the expression profile of 
RNAs in the associated DRG, it is clear that attenuating the activity of COX-2 and the 
corresponding reduction in PGE2 at the site of injury results in changes in the 
 vii 
transcriptome of the associated DRG reflecting pain relief as well as the partial reversal 
of the gene expression profiles in the injured sciatic nerve associated with chronic pain.  
Overall, it can be concluded that by solely targeting COX-2 production in macrophages 
in the CCI model, there is a direct effect of gene expression changes related to cells 
associated with the neuroimmune triad, the axon regeneration process, and the chronic 
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Chapter 1: Introduction   
1.1 Chronic neuropathic pain 
Pain is an important sensation. Acute pain serves to notify the body of an event 
that may be dangerous or damaging. However, when pain lasts longer than normal 
healing or occurs in the absence of a noxious stimuli and persists, it is known as chronic1. 
Chronic pain can be a debilitating disease to those who suffer from it.  It is documented 
that chronic pain affects 1 in 3 Americans over a lifetime and cost up to 600 billion 
dollars annually in lost wages, hospital and treatment costs, and related expenses2.  This 
research focuses on peripheral neuropathic pain – a type of chronic pain that occurs as a 
result of damage or injury to the peripheral nervous system. Symptoms of chronic pain 
are characterized variously as being spontaneous, occurring randomly in time and 
dispersed without patterns throughout the body.  Chronic pain can also present as an 
exaggerated sensitivity to noxious stimuli, called hyperalgesia, or as a painful response to 
an innocuous stimuli, known as allodynia. Pain is often associated with inflammation, 
which signals the peripheral nervous system in various ways.  The peripheral nerve 
signals are then transmitted to the central nervous system where they are ultimately 
interpreted as pain. Treating chronic pain has been elusive as most current treatments fail 
to target the underlying mechanisms, instead focusing on the symptoms associated with 
inflammation in the periphery or aspects of the interpretation of nociceptive signals by 
the central nervous system.  
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that targets 
the underlying inflammatory response by inhibiting cyclooxygenase 1 and 2 (COX-1 and 
COX-2). Although, still used to supplement the treatment of chronic pain, NSAIDs are no 
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longer used as a primary treatment due to the high incidence of adverse events such as 
cardiac-related deaths3.  For this and other reasons, epidemiological studies report that 
many patients with neuropathic pain (peripheral neuropathy) do not receive appropriate 
treatment that provides relief 4.  One reason is that treatments fail to target the underlying 
cellular and molecular mechanisms of neuropathy.  For instance, opioid agonists are 
commonly used, however, they merely treat the symptom of pain and tend to exacerbate 
the neuroimmune interactions associated with the loss of opioid efficacy 5-8.  
Additionally, the adverse effects of long-term opioid use including addiction, may 
outweigh the benefits of its moderate effectiveness to relieve neuropathic pain 
symptoms4.  
Peripheral neuropathy is characterized by a dynamic molecular and cellular 
response, consisting of two phases that can each contribute to hypersensitivity and pain. 
First, neuropathy is associated with a change in the immune cell microenvironment 
surrounding the damaged neurons leading to localized neuroinflammation 5, 9. Second, 
injured axons degenerate distally followed by axon regeneration 10-12. In combination, 
chronic pain results from altered neuronal activity that emerges from the interplay 
between the injured neurons with neighboring glial cells and the infiltrating immune 
system leading to long term changes in gene expression that may affect the pain 
phenotype.  This research utilizes a chronic pain model in rats [chronic constriction 
injury; CCI] to study the changes that occur in RNA expression at the site of injury and in 
the associated dorsal root ganglia (DRG), and furthermore this research focuses on 




 I hypothesized that RNA expression changes would occur after CCI both at the 
site of injury and at its corresponding cell bodies within the dorsal root ganglia.  
Furthermore, that these RNA expression changes will not be confined to changes within a 
single cell type, but multiple cell types associated with the neuroimmune triad.  In 
addition, when macrophage-targeted nanomedicine is given to animals in the pain state, 
differences in RNA expression would be noted beyond the NSAID-loaded macrophages 
with alterations in RNA expression evident in neurons, glial cells, and other immune 
cells. We expect that after nerve injury, as well as after treatment with NSAID-loaded 
nanomedicine, differences will be seen in the underlying biological pathways, including 
axon regeneration, the immune response, and in signaling.  
 
1.2 Chronic constriction injury (CCI) and the rat as a model of hypersensitivity  
Small animal models enable scientists to study the molecular and cellular biology 
of neuropathic pain in a manipulatable setting.  Chronic constriction injury (CCI) as a 
model of peripheral mononeuropathy was first described for the rat in 1988 by Bennett 
and Xie13 (Figure 1A, B).  CCI causes intraneural edema at and around the common 
sciatic nerve. In this model, four chromic gut sutures are loosely ligated around the sciatic 
nerve, leading to inflammation and pain. In sham control animals, the common nerve is 
exposed and isolated, but no sutures are used.  Naïve controls receive no surgical 
intervention.  The pain-like behavioral signs associated with CCI include mild to 
moderate autotomy, guarding, excessive licking, limping of the ipsilateral hindpaw, and 
avoidance of placing weight on the injured side 14 .  Hypersensitive, pain-like behaviors 
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for CCI develop within a week and include thermal hyperalgesia, mechanical allodynia, 


































Figure 1. Chronic constriction injury in rats.  Chronic constriction 
injury (CCI) can be used to mimic chronic pain symptoms as seen in 
humans, including mechanical allodynia and hyperalgesia. (A) The 
sciatic nerve of the rat is exposed in the rat hindleg under anesthetic 
and aseptic conditions, where 4 loose ligatures are tied around the 
common sciatic nerve to induce neuroinflammation. (B) The common 
sciatic nerve stems from the corresponding from lumbar (L4-L6) dorsal 
root ganglia sensory neurons and (C) splits distally into the sural, tibial, 
and peroneal nerves, which innervate the lower limb. (D) On the left, 
ipsilateral CCI nerve on day 12 demonstrating diffuse inflammation of 
the entire common sciatic nerve. On the left, contralateral common 
sciatic nerve (no CCI surgery performed). Illustrations in (A,B) by 
Robert Hoggard.  
 
 







CCI is a reliable and reproducible model that mimics the peripheral neuropathic 
pain states in human such as complex regional pain syndrome13. CCI has also been 
extensively reported on in the literature to describe aspects of the molecular mechanisms 
associated with spontaneous pain and abnormal sensation14. Furthermore, the procedure 
has the advantage that the sciatic nerve itself can be easily identified and removed post-
CCI due to its large size and accessibility.  CCI has been documented to last for up to 3 
months13, possibly because the dissolution of chromic gut sutures over time249.  
Twelve days after CCI surgery, the dissected ipsilateral sciatic nerve is 
neuroanatomically different than its contralateral counterpart (Figure 1D). Like other 
peripheral nerves, the sciatic nerve has an epineural sheath surrounding myelinated and 
unmyelinated axons as well as a perineurial layer containing vasculature, Schwann cells, 
immune cells and fibroblasts.  In the injured nerve, one significant difference is 
inflammation, which is present in the fasciculated nerve fibers, evident in histological 
examination of the dissected nerve (Figure 1D). 
The CCI injury caused by nerve constriction persists for at least seven weeks13 
and can last months18; however, distinct from the acute surgical pain, ‘chronic’ pain-like 
behavior begins as early as day 3 post-surgery.  Prior to day 3, animals experience 
transient acute post-operational pain, a well-studied phenomenon in both humans and 
animals17. Although CCI shows many of the symptoms consistent with neuropathy in 
humans, it also elicits thermal hyperalgesia, which is not a symptom of clinical 





1.3 Role of Neuroinflammation in Pain 
Neuroinflammation is accompanied by the infiltration of leukocytes and increased 
production of inflammatory mediators within the peripheral nervous system (PNS) or 
central nervous system19. Neuroinflammation in the PNS results in a complex and 
persistent feedback loop that is established to cause more inflammatory signaling within 
the injured axons, immune cells, and Schwann cells 20,21. Innate immunity is an integral 
part of neuroinflammation, whereby the release of danger-associated molecular patterns 
(DAMPs) in response to injury stimulate pattern recognition receptors that induce 
inflammasome formation234, 235, 236. Although a multitude of inflammatory molecules 
contribute to neuroinflammation, IL-18 has been shown to be a central mediator in CCI, 
contributing to an increase in other central cytokines such as IL-120.  Each of these are 
unique in that they are involved in activating the inflammasome machinery, which in 
turns leads to an increased pain response in CCI animals. The inflammasome is a 
multimeric protein complex responsible for cleaving the inactive precursor pro-IL-1 and 
pro-IL into their proteolytically active forms234, 239 in macrophages, T cells, mast cells, 
and neutrophils 237. Activation and increased expression of IL-1 and IL-18 leads to the 
production of different cell surface receptors within the site of injury that can ultimately 
affect signaling and expression changes in the cell bodies of the dorsal root ganglia and in 
the dorsal horn of the spinal cord20,22-24.  
 
1.3.1 Involvement of nociceptive neurons in neuroinflammation and pain 
Distinguishing between pain and nociception is an important concept in biology. 
Pain is an unpleasant sensory and emotional experience associated with actual or 
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potential tissue damage1 and is always subjective.  On the other hand, nociception, first 
described by Sir Charles Sherrington as the biological detection of a noxious event, 
which may include psychological and other responses to it25. When there is increased 
pain due to normally noxious stimuli, it is referred to as hyperalgesia. Whereas when 
nociceptors respond to a stimulus that is normally innocuous, it is referred to as allodynia. 
Primary sensory neurons are the main conveyors of painful stimuli and act as nociceptors.  
Their cell bodies are located within dorsal root ganglia or trigeminal ganglia, with 
peripheral terminals innervating the skin and muscle and central terminals in the dorsal 
horn of the spinal cord or trigeminal nucleus of the brain. The sciatic nerve is composed 
of a mixed population of motor and sensory axons with innervation stemming from 
predominantly L4 and L5 DRGs (approximately 95%), and with some innervation from 
the cell bodies in L6 DRG (approximately 5%). 
Nociceptors are considered the first-responders to tissue injury, given their wide 
somatosensory distribution and their ability to quickly propagate many sensory signals26. 
Nociceptors have receptive endings that have a relatively high stimulus threshold, 
allowing for detection of possible damaging stimuli. Nociceptors can be encapsulated (or 
free) and are commonly associated with slowly conducting unmyelinated C fibers, lightly 
myelinated Aδ fibers, and heavily myelinated Aβ fibers of small- and large-diameter15-17. 
Additionally, subpopulations of nociceptors can be classified based on the cell content 
and receptor expression.  Pain sensitization is defined as an increased responsiveness of 
nociceptor neurons to their normal or subthreshold afferent input 1. During inflammation, 
nociceptor’s thresholds are reduced, leading to an increase in action potentials and 
neuronal activity.  
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Peripheral sensitization, a major mechanism underlying the pain response, can be 
defined as the increased responsiveness and reduced threshold of nociceptive neurons in 
the periphery to the stimulation of their receptive fields, such as that developing upon 
inflammation27. A review by Watkins and Grace (2014)9 outlines the RNA and protein 
expression changes in IL-1β, TrpV ion channels, voltage-gated sodium channels, Toll-
like receptors (TLRs), and cell adhesion molecules.  These are all accompanied with 
peripheral sensitization leading to the development of central sensitization (spontaneous 
discharge within the spinal cord primary nociceptive neurons), as well as an altered glial 
environment, changes in peripheral cell signaling, and molecular changes to the 
nociceptors themselves – each of which contribute to the underlying neuroimmune 
response. 
 
1.3.2 Involvement of Immune Cells and Glia in neuroinflammation and pain 
Extravasation of blood-borne (hematogenous) immune cells such as macrophages, 
T cells and neutrophils into damaged tissue along with the resident immune cells 
(macrophages, mast cells, endothelial cells), activation of glial cells, such as Schwann 
cells and satellite cells all contribute to the inflammatory state in CCI (Figure 2). After 
the in-concert production of both pro- and anti-inflammatory mediators, nociceptor 
neurons which express the molecules for pain signaling (Ras/MAP, NF-B, JAK/STAT, 
Phosphoinositol 3/IP3) become activated.  This, in turn results in the activation of their 
respective second messengers such as calcium or cAMP, followed by the influence of 
signaling cascades such as kinases including PKA, CAMK, PI3K, MAPKs, ERK, and 
JNK89. Among other things, the activation of these signaling kinases leads to a 
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hyperexcitable state of cells involved in the neuroimmune triad, contributing to the 
activation of the pain state, by leading to long-term changes in gene expression within 
each of the involved cell types. 
The activation of immune- and immune-like glial cells exhibit distinct temporal 
profiles to the peripheral nerve, DRG, spinal cord and brain. Initially, neutrophils are the 
first leukocyte to become activated and infiltrate the site of injury.  This response peaks 
within hours and lasts up to three days. In the peripheral nerve, it is accompanied by 
complement activation28, mast cell degranulation29, and dedifferentiation of resident 
Schwann cells into phagocytic (or ensheathing) Schwann cells30. It is followed by the 
extravasation of circulating monocytes within three days of injury.  Research in male rats 
has shown that circulating monocytes differentiate into tissue macrophages where they 
peak as the prominent infiltrating immune cell type present at the injured sciatic nerve 
between day 3 and beyond23. Within days to weeks after macrophage activation and 
infiltration, T cells are recruited19, 23, 31, 32. In the DRG cell bodies, resident satellite cells 
and macrophages become activated within 24 hours of injury and continue to be 
expressed for at least three weeks after the initial injury30.  
Schwann cell activation begins at the site of injury signified by an unknown axon 
death alert signal33. Activated Schwann cells are referred to as ensheathing Schwann 
cells, and no longer myelinate the axon, but instead aide in the repair process.  These 
ensheathing cells contribute to the neuroimmune response in a multitude of ways.  They 
promote the survival of injured neurons via the secretion and production of neurotrophic 
growth factors (including GDNF, BDNF, NGF, and VEGF)33. They serve to recruit more 
immune cells, specifically macrophages, to the distal stump, via the secretion of 
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cytokines (such as TNF-α, IL-1α, IL-1β, IL-6, and MCP-1)33. These dedifferentiated 
Schwann cells contribute to the breakdown of injured myelinated axons at the distal 
stump with autophagic mechanisms, acting more like phagocytic cells, and less like 
myelin-producing Schwann cells33.  The clearing of myelin at the site of injury and 
guidance via the formation of Bungner bands, which occur after Schwann cells become 
deinnervated and the remaining basement membrane forms endoneurial tubes that 
contribute to axonal regeneration33,34.   
In neuropathic pain, T cells experience a shift in T-cell subset responses and T-
cell related cytokine expression profiles that change later in the neuroimmune response 
compared to other immune cells35. Several subtypes of T cells exist in neuropathic pain 
including helper T cells including Th1, Th2, Th17 and regulatory T cells, although the 
role of each still remains elusive. Helper T cells can be identified as being CD4-positive. 
TH1 cells produce predominantly pro-inflammatory cytokines such as IFN-γ and TNF-α 
and TH2 cells release anti-inflammatory cytokines IL-4 and IL-1035. Regulatory T cells 
and Th17 are both involved in the adaptive immune response and produce IL-17, whose 
role in neuropathic pain has become better understood36, 37. IL-17 is solely produced by 
these subsets of T cells and plays an active role in modulating immune responses by 
enhancing the production of TNF-α, IL-1β, and granulocyte colony stimulating factor (G-
CSF), which is a neutrophil-mobilizing factor36 . Additionally, T cell release of IL-17 is 
regulated by IL-23 and IL-15 after CCI36, 38, 39. Stoll and colleagues have analyzed the 
temporal expression pattern of IL-17 in the sciatic nerve of mice after CCI. They found 
that IL-17 expression peaked on day 7 and its’ regulators, IL-23 and IL-15, peaked 
earlier.  Additionally, they found IL-17-positive T cells in the endoneurium (the layer 
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surrounding an individual nerve) of the injured nerve one-week post injury, during peak 
pain behavior, suggesting T cell’s role in the chronic immune response underlying CCI-
induced nerve injury. 
Neutrophil accumulation at the site of injury peaks 24 hours after injury, 
accumulating in the endoneurium and are found to persist up to 7 days after injury 40. 
Neutrophils are attracted by an increase in the release of nerve growth factor (NGF), 
chemokine (C-X-C motif) ligand 1 (CXCL1) and leukotriene B4 26. Aside from the initial 
release of inflammatory mediators from the injured nerve tissue, neutrophil degranulation 
also contributes to the milieu of mediators, adding to inflammatory signals41. Seven days 
after CCI, neutrophil count increased three-fold in the ipsilateral DRG compared to 
sham41. This was accompanied by neutrophil degranulation characterized by an increased 
expression of the macrophage-recruiting MCP-1 mRNA in the ipsilateral DRG41. 
Neutrophil degranulation results in the release of chemotactic factors specific to 
monocytes40, cytokines (TNF-α, IFN-γ, IL-8), chemokines, monocyte adhesion molecules 
(integrins such as MAC-1, CD11b/CD18 complex; and selectins), prostaglandins and 
leukotrienes, as well as pre-formed receptors42. Neutrophil activation and proliferation 
serve in the initial recruitment of macrophages and other immune cells26, 42 as well as 
leading to further sensitization of nociceptive neurons40. 
Like neutrophils, mast cells can degranulate, leading to subsequent changes in the 
neuroimmune cross-talk at the site of injury. Upon degranulation, mast cells release pain-
producing substances that activate or sensitize nociceptors43. Resident mast cells 
surrounding peripheral nerves facilitate recruitment of neutrophils, T cells and 
macrophages to the site of inflammation by their production and release of nerve growth 
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factor (NGF) and other inflammatory mediators41,43, 44.  NGF binds nerve growth factor 
receptors (trkA) on nociceptive neurons and other peripheral cell types leading to 
activation of signaling mechanisms that further the recruitment of additional 
inflammatory cells43, 45. The dynamic milieu of inflammatory mediators present can 
induce activity in axons in ways that can influence retrograde transport of signaling 
molecules to the cell body of the DRG neurons, thereby affecting gene expression of 
those cells43. It has been recently found by our lab that degranulating mast cells are 
involved in the CCI response following the pain-relieving administration of non-steroidal 
anti-inflammatory (NSAID) drug-loaded nanoemulsion (CXB-NE) that selectively 
targets cyclooxygenase-2 production in circulating monocytes and activated 
macrophages. Saleem et. al. (2019)46 found a reduction of mast cell numbers in CCI 
animals given CXB-NE compared to those given drug-free (vehicle) nanoemeulsion (DF-
NE) in the ipsilateral sciatic nerve, with no detectable difference at the ipsilateral DRG46. 
Overall, immune and immune-like glial cells release inflammatory mediators that 
modulate nociceptor neuron activity and pain sensitivity, which in turn cause nociceptors 
to release neuropeptides and neurotransmitters that act on immune and immune-glial cells 
to modulate their function by leading to gene expression changes26. The inflammatory 
mediators include neurotransmitters, growth factors, neurotrophins, cytokines, 
chemokines, and various small molecules such as Substance P, calcitonin gene-related 
peptide (CGRP), bradykinin, ATP, growth factors, and prostaglandins. These molecules, 
along with the cells that secrete and produce them, act in concert to influence the 
development and maintenance of neuropathic pain and the further recruitment of immune 
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and immune-like glial cells, contributing to this cascade of neuroinflammation that leads 
to chronic pain. 
 
1.3.3 Macrophages play a major role in neuroinflammation and pain 
Monocyte-derived macrophages are known to play a role in peripheral nerve 
injury at the site of injury in the sciatic nerve and later at the level of the neuronal cell 
bodies in the dorsal root ganglia (DRG)46, 50-53. Recent studies have shown the importance 
of macrophages at the DRG in the induction and maintenance of pain250. Hematogenous 
macrophages accumulate preferentially around injured axons36 guided by molecular cues 
such as monocyte chemoattractant protein-1 (MCP-1)54 , the lesser studied monocyte 
chemoattractant protein-5 (MCP-5), and the leukocyte adhesion complex of MAC1, 
which is formed by the integrins, ITGAM/CD11b and ITGB2/CD18 55. Monocyte entry 
is mediated, in part,  by the release of MCP-1.  MCP-1 is produced in injured nerve and 
other immune cells and functions by binding to chemokine receptor CCR2 on the 
monocyte-derived macrophage56.  The role of MCP-5 is not known in the pathogenesis of 
neuropathic pain. Macrophages [and other leukocytes] functions are modulated by the 
highly abundant αM and β2 integrins ITGAM/CD11b and ITGB2/CD18, respectively, 
which form a heterodimer known as MAC1 or CR355. MAC-1 is normally present in an 
inactive confirmation in circulating monocytes, but is rapidly activated to mediate 
leukocyte adhesion, migration, and accumulation at the sites of inflammation55.  Blocking 
this complex and its ligands and ablation of genes encoding CD11b or CD18 decrease the 
severity of inflammation in many animal models55.  
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Macrophages exert their influence in multiple ways (Figure 2) including the 
production and secretion of cytokines/chemokines or through a gap-junction like 
connection, which pass small molecules with neurons52. Resident and hematogenous 
macrophages produce the pro-inflammatory cytokine IL-6 and increase expression of 
cyclooxygenase 2 (COX-2), which produces prostaglandin E2 (PGE2), all of which 
contribute to the inflammatory response32, 51 (Figure 2).  In the sciatic nerve after injury, 
it has been previously shown that several molecules were specifically associated with 
CD68-positive, CD11b-positive and MAC1-positive macrophages including; TNF-α, IL-
6, IL-18, MIF (macrophage migration inhibitory factor), CCL3 (macrophage 
inflammatory protein 1-α/chemokine (C-C motif) ligand 3), and CCL4 (macrophage 






Figure 2. Macrophages play a key role in regulating neuropathic pain. 
Macrophages exert their overall effect by interacting with other 
neuroimmune cells and changing expression in key genes and proteins 
involved in neuroinflammation, leading to overall changes in the gene 
transcriptome of the neuroinflammatory cells involved. 
 
 
1.4 Mechanism of Celecoxib 
Non-steroidal anti-inflammatory drugs (NSAIDs) were once utilized to treat 
neuropathic pain, however, due to the lack of efficacy and adverse events associated with 
some NSAIDs, they are no longer mentioned in current neuropathic pain treatment 
guidelines1. This can be attributed to the detrimental adverse events associated with the 
‘coxib’ class of NSAIDs in clinical trials3.  ‘Coxibs’ are selective cyclooxygenase-2 
(COX-2) inhibitors and include drugs such as celecoxib. When given orally, COX-2 
inhibitors have been associated with a high risk of acute myocardial infarction (MI). 
Studies examining the risk of myocardial infarction (MI) in patients taking NSAIDs such 
as CXB have presented conflicting results3.  
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NSAIDs such as Celecoxib, posses an active COX-2 binding site, in which the 
enzyme cyclooxygenase-2 will bind upon induction. Celecoxib acts to attenunate 
production of prostaglandins from arachidonic acid by blocking cyclooxygenases59. 
Prostaglandins have been shown to produce hyperalgesia and lead to nociceptor 
sensitization via a direct action on the sensory neurons60.  In addition, PGE2 has the 
ability to modulate voltage-gated sodium channels in sensory neurons via enhancing the 
excitability and leading to PGE2-induced hyperalgesia60, 61. COX-2 expression is 
enhanced in multiple cell types, including macrophages. Inflammasome induction in 
macrophages leads to secretion of IL-18 and IL-1β, both of which are cleaved 
proteolytically from their precursors via the activation of caspase-1.  Both of these 
cytokines can induce COX and subsequent PGE2 production62-64. PGE2 in turn stimulates 
the production of other inflammatory mediators such as the calcitonin gene-related 
peptide, CGRP, contributing to the positive feedback loop created by the dynamic 
neuronal-immune cell-and glial interactions65. Following peripheral nerve injury, there is 
a marked upregulation of many inflammatory mediators in the endoneurium of the 
injured nerve, including COX-266. Many inflammatory mediators such as growth factors, 
cytokines (IL-1β, IL-6, and TNF-α), and intracellular calcium increases have been shown 
to induce COX-2 expression via downstream signaling activation of NF-κB and MAPK 
pathways67. Membrane lipids are broken down by phospholipase A2 resulting in an 
increase arachidonic acid (AA) in the lipid bilayer.  AA is a precursor in the production 
of prostaglandins, where the COX reaction via PGH2 is the rate limiting step in the 
production of PGE2 (Figure 3). PGE2 is a key mediator in peripheral sensitization68. It 




Figure 3. COX-2 induction leads to the production of PGE2, a potent 
inflammatory mediator. COX is the rate limiting step in the production 
of prostaglandins (PGs). After nerve injury, arachidonic acid is released 
from cell membranes, ultimately leading to the induction of COX-2 and 
subsequent PGE2 production. 
 
1.5 Celecoxib-loaded nanomedicine  
 Dr. Jelena Janjic (Duquesne University Graduate School of Pharmaceutical 
Sciences) has developed theranostic nanoemulsions that can treat neuropathic pain71-73. 
Theranostic nanoemulsions have a drug-loading capability (and thus act as a therapeutic) 
and can also carry a near infrared fluorescent dye (NIRF) as a diagnostic to see where the 
packaged particle is delivered to after intravenous tail vein administration46, 48, 49,  71, 73.  
CXB is a selective COX-2 inhibitor (Figure 4) that attenuates COX-2 activity leading to 
a reduction in PGE2 production46, 48, 71. When CXB is packaged in a nanoemulsion (~140 
µm in size) and delivered intravenously, the droplets are directly phagocytosed by 
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circulating monocytes, which then accumulate as macrophages at the site of injury.  The 
effect on CCI pain relief for the CXB nanoemulsion represents a 2000-fold reduction in 







Figure 4. The mechanism of Celecoxib-loaded nanoemulsion. 
Celecoxib (CXB) inhibits COX-2 production. (A) COX-2 is induced 
during neuroinflammation and can be selectively inhibited by 
Celecoxib, preventing PGE2 production.  (B) The Janjic group has 
designed and developed a perfluorocarbon (PFC) theranostic 
nanoparticle, which can be loaded with a therapeutic agent (in this case 
Celecoxib) and a near infrared red (NIR) dye that is phagocytosed by 






Janjic and co-workers demonstrated feasibility of targeting cyclooxygenase-2 
(COX-2) enzyme in macrophages both in vitro and in vivo 48, 71, 73. A single dose of 
CXB-NE (0.24 mg/kg of celecoxib) provided pain relief for up to 6 days in the CCI rat 46, 
48. The same nanoemulsions have been loaded with NIRF dye allowing for the 
visualization of inflammation at the site of injury in vivo46, 74. Previous work (in 
conjunction with my work) has observed that at the site of injury there is a reduction in 
inflammation as visualized in live animals by near infrared fluorescence (NIRF)46-48 and a 
significant reversal in pain-like behavior46, 49,71. With immunohistochemical studies, the 
Pollock laboratory noted a nearly 50% reduction in the density of infiltrating 
macrophages at the site of injury when CXB-NE is given compared to CCI DF-NE 
animals46, 47.  Within the DRG, a macrophage reduction was also seen on day 12, 
however, macrophage density was 40% less compared to the injured sciatic nerve, with 
the most dramatic reduction seen in macrophage density on day 18 within the DRG47. 
Furthermore, for the macrophages that remain in the injured sciatic nerve even while 
treated with celecoxib-loaded nanoemulsion (CXB-NE), there was a reduction in PGE2 
production46, 48 and a shift in M1 to M2 polarity46. A reduction in mast cell numbers as 
well as a reduction in mast cell degranulation46 when CXB-NE is present has also been 
shown.  
 
1.6 Gene expression changes as a driver of chronic pain 
Ultimately, nerve damage leads to changes in expression of genes involved in 
nociception. Furthermore, the interplay between the gene expression changes within 
damaged neurons, resident and hematogenous immune cells, and the immune-like glial 
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cells is known to exacerbate the heightened nociceptive response.  These dynamic 
neuroimmune interactions appear to be responsible for neuropathic pain9, 40, 75.  
The three-way communication and mutual activation of the neurons, glia and 
immune cells drives subsequent changes in intracellular signaling pathways26 and 
additional changes in gene expression76. Gene expression changes are not restricted to the 
site of injury on the sciatic nerve but are also evident proximally in the cells of the 
DRG47, 49. For example, Vasudeva et al. (2014)47 has previously shown GAP43, NPY and 
TRPV1 mRNA expression changes in the DRG and furthermore, that TRPV1 protein 
expression changes in specific CCI DRG cell bodies of neurons that innervate the 
affected foot (identified by DiD retrograde labeling)47. In other studies, qPCR of mRNA 
expression in the injured sciatic nerve for 84 neuroinflammatory genes revealed several 
distinct differences between naïve, CCI and CCI treated with pain-relieving therapy49.  
Changes in the expression of mRNAs for cytokines and chemokines is consistent with the 
inflammation and corresponding infiltration of macrophages at the site of injury (MCP-1, 
IL-18, IL-1β)20, 46. 
 
1.7 Specific Aims  
To investigate the molecular cell biology of chronic pain from chronic 
constriction injury and the effects of the targeted celecoxib therapy, I have assessed RNA 
changes in the injured sciatic nerve and the DRG. I hypothesized that injured CCI 
animals given CXB-NE will exhibit changes in RNA expression 12 days post-injury 
compared to CCI given DF-NE as well as sham and naïve negative controls that are 
involved in the production of inflammatory mediators, and neuroinflammatory and pain 
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response.  Furthermore, I also hypothesized that attenuation of this cross-talk would 
result when COX-2 inhibition is targeted to a single cell type – the macrophage.  COX-2 
inhibition in macrophages using CXB-NE would influence cells within and near the site 
of injury would lead to the alleviation of pain behavior noted in injured animals.   
Each of the specific aims follows the same schedule of experiments as noted in 
Figure 5.  CCI and sham surgeries are performed on day zero, mechanical allodynia 
behavioral testing (described in Section 2.3) is performed consecutively 1 day after 
surgery until euthanasia and tissue collection on day 12.  In addition, nanoemulsion 
injection (described in brief in Section 2.4 and in detail in Section A.2) is conducted one-
week post-surgery and LiCOR live animal imaging is performed on days 8 and 11 
(described in Section 2.5). 
 
Figure 5. Sequence of experimental events.  CCI/sham surgeries are 
performed on day zero, behavioral testing on days 1-12, tail-vein 
injection of nanomedicine on day 8, and live animal imaging on day 11. 
 
Specific Aim 1:  Evaluate differences in mRNA expression in the sciatic nerve in 
response to peripheral nerve injury and celecoxib-loaded nanoemulsion (CXB-NE) 
therapy at day 12 post chronic constriction injury using a quantitative PCR gene 
array. 
First, I assessed mRNA expression in the injured sciatic nerve through 
quantitative PCR of a collection of 84 genes associated with neuroinflammation. In this 
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study, I evaluated the molecular expression changes at the site of injury on day 12 post-
CCI surgery, a time of significant pain-like hypersensitivity for untreated animals or 
maximum pain relief for treated animals. Comparison of the expression profiles of 
mRNAs in the injured nerve to mRNA from comparable sciatic nerve were acquired from 
sham surgical animals as well as CCI animals treated with nanoemulsion containing 
celecoxib (CXB-NE) or vehicle nanoemulsion that is drug free (DF-NE). Here I 
hypothesized that by inhibiting COX-2 and by attenuating the production of PGE2 in 
circulating monocytes and tissue macrophages, there would be a subsequent change in 
macrophage signaling, including integrins, cytokines, and the involvement of other cell 
types that participate in releasing inflammatory mediators at the site of injury that leads to 
decreased pain behaviors when administered at a chronic pain state in rats. In addition, I 
believed signaling involved in neuro-immuno-glial cross-talk would be dampened at the 
site of injury indicated by a decrease in expression of the genes involved in these 
pathways. To further understand changes in key macrophage-related genes, 
immunohistochemistry of the macrophage marker CD11b was assessed within the site of 
injury using confocal microscopy. 
I was able to demonstrate significant changes in the neuroinflammatory mRNAs 
present within the injured sciatic nerve including genes associated with macrophages as 
well as neurons and Schwann cells among other cell types in this study.  This research 
illustrates the need to better understand the molecular mechanisms involved in this 
neuroinflammatory-mediated multi-cellular response, and how by inhibiting only COX-2, 
we are able to alter the expression of several genes at the site of injury while changing the 
pain-like behavior state. 
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Specific Aim 2: Assess the transcriptome of RNA expression changes in the dorsal 
root ganglia (DRG) under the same conditions of Aim 1 using RNA Sequencing.     
Within the corresponding DRG are the cell bodies for the injured axons found 
within the sciatic nerve, as well as infiltrating immune cells and glial cells. Thus, gene 
expression profiling of RNAs differentially expressed here may shed light on the 
molecular phenomena occurring at the site of injury on the one hand as well as the basis 
of the neurophysiological signaling associated with hypersensitivity, which is sent on to 
the central nervous system. RNA sequencing of L4-L5 DRGs allow for the exploration of 
the molecular and biological mechanisms of neuropathic pain through the analyses of 
whole transcriptome changes after nerve injury. RNA sequencing of L4-L5 DRGs allow 
for the exploration of the molecular and biological mechanisms of neuropathic pain 
through the analyses of whole transcriptome changes after nerve injury. Using RNA 
sequencing, several studies have previously examined pain-associated changes in 
expressed RNA in the DRG24, 77-79.  Here I hypothesized that ultimately, the inflammatory 
milieu and tissue response at the site of injury would be communicated to the DRG where 
changes in expression profiles are of particular importance given that these cells are a 
component of primary sensory neurons, acting as the bridge between the peripheral and 
central nervous system.  I have reported differential expression of the RNA transcriptome 
in the cells of the DRG when the animal is experiencing significant pain as compared to a 
naïve normal and also CCI animals under the influence of an anti-inflammatory pain-
relieving celecoxib nanoemulsion. The pain-relieving therapy relies on reducing 
prostaglandin E2 (PGE2). By utilizing high throughput RNA sequencing, we reveal 
transcriptome changes in the DRG associated with the celecoxib-nanoemulsion pain-
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relief in males.  I find differential expression of RNAs associated with neurons, activated 
glial cells, multiple immune cells, as well as inflammatory mediators. Additionally, while 
I confirm a subset of genes previously reported in literature that are known to respond to 
drug therapy80, 81, I go on to reveal genes differentially expressed that have not been 
previously identified as ‘pain’ genes. RNAs described in this study are inclusive of both 
protein-coding and non-protein-coding, including annotated long non-coding RNAs 



















Chapter 2: Methods 
 
As adapted from: 
A. Stevens, L. Liu, D. Bertovich, J.M. Janjic, J.A. Pollock. Differential expression of 
neuroinflammatory mRNAs in the rat sciatic nerve following chronic constriction 
injury and pain-relieving nanoemulsion NSAID delivery to infiltrating 
macrophages. International Journal of Molecular Sciences 2019; 20(21): 5269. 
Doi.org/10.3390/ijms20215269. 
A. Stevens, M. Saleem, B. Deal, J.M. Janjic, J.A. Pollock. Targeted COX-2 inhibiting 
nanomedicine results in pain-relief and differential expression of RNA in the 
dorsal root ganglia of injured male rats. Molecular Pain In Press 2020. 
M. Saleem*, A. Stevens*, B. Deal, L. Liu, J. M. Janjic, J. A. Pollock. A new best 
practice for validating tail vein injections in rat with near infrared labeled agents. 




The University of Pittsburgh Genomics Research Core (Dr. Janette Lamb and colleagues) 
performed RNA sequencing of L4-L5 DRG RNA for the three conditions tested.  
The University of Pittsburgh Genomics Analysis Core (Dr. Uma Chandran and 








2.1 Animals and Ethics Statement 
Adult male Sprague-Dawley rats (Hilltop Animals, Springdale, PA) weighing 225-
250 g at the time of surgery were used in all protocols that were performed in accordance 
with the guidelines outlined in the Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health and the regulations of the Institutional Animal Care and 
Use Committee (IACUC) at Duquesne University and the approved protocol #1501-01.  
Animals were acclimated to standard living conditions and kept on a 12-hour light, 12-
hour dark cycle and given food and water ad libitum. Animals were socially housed, kept 
on paper bedding, and given special diet (Research Diets, Inc, New Brunswick, NJ; 
catalog #AIN-93G) to avoid autofluorescence during imaging. Efforts were made to 
minimize the number of animals used and the time experiencing pain. The sample size 
was calculated based on power analysis of our previous work and the statistical 
significance of the data accumulated in the various tests applied to each animal and its 
recovered tissues.  Specific Aim 1 (corresponding Chapter 3) used 3 to 8 animals per 
condition and Specific Aim 2 (corresponding Chapter 4) used a sample size of 3-4 per 
condition. 
 
2.2 Chronic Constriction Injury (CCI) 
Chronic constriction injury (CCI) was performed13,46-48 as it emulates peripheral 
neuropathic pain by causing intraneural edema at and around the common sciatic nerve. 
Briefly, animals were anesthetized using respiratory isoflurane. All surgical procedures 
were performed under aseptic conditions. The biceps femoris and gluteus superficialis 
muscles were exposed and separated on the hindleg, followed by exposure and isolation 
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of the sciatic nerve. Four chromic gut sutures were loosely ligated around the common 
sciatic nerve, separated by 1 mm gaps. The muscle and skin layers were then closed. In 
this procedure, chromic gut sutures contribute to the neuroinflammatory response. In 
sham control animals, the common nerve is exposed and isolated, but no sutures were 
used. Naïve controls received no surgical intervention.  
 
2.3 Behavioral testing 
Mechanical allodynia testing was conducted two days prior to surgery and the 
following days post-operatively, days 3, 4, 5, 8, 11, and 12. All behavioral testing was 
conducted blinded to surgery and treatment. Testing was performed in naïve, sham, CCI 
CXB-NE, and CCI DF-NE rats using the up-down method as described previously46, 82, 83. 
Calibrated Semmes-Weinstein von Frey monofilaments were applied to the plantar 
surface of the right and left hind paws in the region innervated by the common sciatic 
nerve. The monofilaments were applied in ascending order of gram force ranging from 
0.41 to 15.13 gram force. The 50% paw withdrawal threshold was calculated using the 
median lethal dose (LD50), and treatment groups were analyzed by two-way ANOVA 
and Tukey’s post-hoc test using GraphPad Prism 8.0 46. 
 
2.4 Intravenous tail vein injections (See Appendix A for detailed protocol) 
The celecoxib loaded nanoemulsion (CXB-NE) and the drug-free nanoemulsion (DF-
NE)84, 85 were injected intravenously through the right lateral tail vein on day 8 post-
surgery74. Rats were lightly anesthetized with isoflurane and given 0.24 mg/kg of 
celecoxib nanoemulsion (or drug-free vehicle) using a 27-gauge needle. By near infrared 
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imaging of the tail vein before and after injection, we can establish whether the injection 
was optimal (injected directly into the tail vein and little residual fluorescence is shown) 
or suboptimal (injected subcutaneously with a high degree of fluorescence in the tail)74. 
When injected into the bloodstream, the nanoparticle is phagocytosed by circulating 
monocytes and naturally delivered to the site of injury, which has been confirmed in 
previous studies, where those cells differentiate into tissue macrophages46-48. 
 
2.5 Near Infrared Fluorescence (NIRF) Imaging  
On day 11 post-surgery, live NIRF imaging was conducted on lightly anaesthetized 
(1.5% Isoflurane) rats. The left and right hindlegs were imaged on the LiCOR Pearl 
Impulse Small Animal Imager (Lincoln, NE). Near infrared dye accumulates at the site of 
injury superficial to the site of incision on the hindleg as it picked up by monocyte-
derived macrophages47. Images are acquired in the 700 nm channel and a white light 
channel (to reveal the animal’s posture) and analyzed with LiCOR Image Studio Lite 
(version 5.0) as based on previous studies47. A hand-drawn region of interest (ROI) is 
drawn over the sciatic nerve region on the hindleg and relative fluorescence is calculated 
(total fluorescence divided by area within the ROI) and normalized to background.  
 
2.6 Tissue Dissection and Preparation for Histology or RNA Studies 
Rats were euthanized by CO2 asphyxiation in a chamber on day 12. For Specific Aim 
1 (corresponding Chapter 3), right and left sciatic nerves were dissected immediately 
upon euthanasia. Sciatic nerve tissues for immunohistochemistry were post-fixed in 4% 
paraformaldehyde (PFA), moved to 0.4% PFA after 24 hours, and within 1 week, placed 
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in a 30% sucrose 1X PBS solution before being mounted in OCT medium and cut 
longitudinally in 20 µm sections. Sciatic nerve tissue for RNA studies were not fixed, but 
immediately transferred to RNAlater (Life Technologies, New York) and kept at -20°C 
until RNA extraction was performed. For Specific Aim 2 (corresponding Chapter 4), 
lumbar level 4 and 5 (L4 and L5) dorsal root ganglia (DRG) were collected immediately 
following euthanasia, transferred to RNAlater and kept at -20°C until RNA extraction 
was performed. 
 
2.7 RNA extraction and cDNA conversion 
Total RNA was extracted from intact ipsilateral and contralateral sciatic nerves and DRG 
using the RNAeasy Plus Mini Kit (Qiagen) according to the kit’s instructions. Tissue 
disruption and homogenization was done with a mortar and pestle and then with 
QiaShredder columns (Qiagen). RNA quality and concentration were assessed on the 
NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Delaware) and was 
determined by running a sample with RNA loading dye (Ambion, USA) on a 1% agarose 
gel and inspecting for distinct 18S and 28S bands, indicating lack of degradation. 
Quantity was determined by A260/A280 measurement. All samples had A260/A280 
ratios of 1.9−2.3. Total RNA was used for complimentary DNA conversion by the RT2 
First Strand Kit (Qiagen). Three to eight animals per condition were used. For RNA 
sequencing tissues (Chapter 3), RNA quantification was performed using a Qubit 
(Thermo Fisher Scientific, USA) and integrity was measured with Tape Station (Agilent, 
USA). Only RNA samples with a minimum RNA integrity number (RIN) value above 
6.6 were used for sequencing248. 
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2.8 Quantitative PCR and Analysis  
For Specific Aim 1 (Chapter 3), RT2 RNA Quality Control PCR Array (Qiagen, 
PARN-999Z) was used to assess each sample prior to gene expression profiling. Gene 
expression profiling was analyzed by RT2 Rat Neuropathic and Inflammatory Pain Arrays 
(Qiagen, PARN-162Z) on the ABI StepOnePlus cycler (Applied Biosystems, USA) with 
RT2 SYBR green with ROX (Qiagen) according to manufacturer’s instructions. Each 
array contains 84 genes related to neuropathic pain and inflammation (Table 5), 5 
housekeeping genes, and 7 controls. Each array was performed in triplicate and 
normalized to Rplp1 in the sciatic nerve or Gapdh in the DRG.  
Data presented in Chapter 3 49 was initially analyzed with Qiagen’s RT2 profiler PCR 
Array Data Analysis software. A list of differentially expressed genes was identified 
using a 2-tailed Student’s t-test. Changes in gene expression between the pain group and 
the control group were illustrated as a fold increase/decrease (shown as fold regulation) 
and were considered to be upregulated/downregulated, respectively. The criteria were a P 
value <.05 and a mean difference equal to or greater than 2-fold. Next, a subset of 
differentially expressed genes were further analyzed by individual RT2 primer assays 
(Qiagen) following the Livak method86. Fold change values were calculated compared to 
the sham control group. A 2-tailed Student’s t-test, standard deviation and error were 
calculated. The results were expressed as means with standard deviations. For the 
significance test, a one-way analysis of variance followed by post hoc testing and 
Tukey’s multiple comparison test with GraphPad Prism (version 7.3, San Diego, CA). A 




2.9 Immunohistochemistry and Microscopy 
For Specific Aim 1 (Chapter 3), sciatic nerves from naïve, CCI CXB-NE, and 
CCI DF-NE rats (3 per condition) were used for immunohistochemistry to explore the 
CD68 macrophage (Abcam, ab125212, 1:100), and CD11b (Life Technologies, 
MA181606, 1:100) macrophage infiltration. Tissue sections were post-fixed in 4% PFA 
solution in 1X PBS, permeabilized with 0.3% Triton X-100 solution, blocked with 1X 
PBS normal donkey serum, and stained with primary and secondary antibodies. The 
sections were washed and incubated overnight with secondary 1:200 Alexa Fluor 
antibodies (Invitrogen, Carlsbad, CA) and then washed and mounted with Prolong Gold 
DAPI nuclear stain (Invitrogen). All stained sections were viewed on the Nikon Eclipse 
Ni-U microscope and images were acquired with the Nikon NIS-Elements software. 
 
2.10 RNA Sequencing and Analysis 
For Specific Aim 2 (Chapter 4), to determine genes involved in the 
neuroinflammatory response perpetuated by chronic constriction injury (CCI) in 
receiving celecoxib-loaded nanoemulsion (CXB-NE) versus those receiving vehicle (DF-
NE), total RNA from pooled L4 and L5 DRGs from an individual animal was analyzed 
using an Illumina sequencer 12 days after CCI surgery. Library preparation was 
performed according to manufacturer’s instructions using the Takara SMARTer Stranded 
Total RNA-Seq Kit, Pico input Mammalian v1 (Mountain View, CA), with two ng total 
RNA input.  Total RNA is converted to cDNA via reverse transcription with random 
hexamers and proprietary code-switching technology maintained the RNA strand 
information.  Five cycles of PCR added barcode sequencing indexes followed by double 
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SPRI size selection.  Ribosomal cDNA was depleted via the cleavage with Zap-R and 
mammalian specific R-probes.  Remaining library was enriched with twelve cycles PCR 
followed by SPRI bead reaction clean up. Library was loaded on a NextSeq500 (Illumina, 
USA) at 1.8 pM with 20% Phi-X.  The sequences were trimmed and reads with a 
minimum of 75 base pairs were used. RNA sequencing was performed by the Genomics 
Research Core at the University of Pittsburgh. 
 The resulting sequencing data were mapped to the Rattus norvegicus reference 
genome from ENSEMBL using HISAT whole genome and SALMON whole 
transcriptome mapping. Reads per kilobase per million (RPKM) mapped reads were 
calculated for each gene hit count to determine expression levels. Relative differential 
expression analysis for each transcript between the groups was calculated as the number 
of readings mapping to each transcript normalized by the transcript length and the total 
number of mapped reads using Student’s t-test. Differential expression analysis was done 
in conjunction with the Genomics Analysis Core at the University of Pittsburgh. 
Heatmaps were generated using Prism 8 Version 8.4.2. Genes with expressed RNAs 
shared between all three conditions (Naïve, CXB-NE, and DF-NE) and 57 genes that had 
an FDR ≤0.05 and considered to be statistically significant amongst the three conditions 
were mapped with the Log2 of the counts per million (CPM). 
 
2.11 Gene Ontology and Enrichment Analysis 
For Specific Aim 2 (Chapter 4), genes previously annotated based on relevant 
functional gene ontology descriptions were compared to our dataset using Gene Ontology 
(GO) database. Gene Ontology (GO) annotations and functional enrichment analysis 
 
 34 
were applied to investigate the roles of all differentially expressed genes between CCI 
DF-NE and CCI CXB-NE animals. PANTHER pathway analysis based on functional 
classifications and GO analysis hierarchical categories according to the Biological 
Process, Molecular Function, and Cellular Components of the differentially expressed 
RNAs (http://www.pantherdb.org) of FDR ≤0.05 were used in Figure 3.  Reactome 
pathway analyses were also applied (FDR ≤0.05) (http://www.reactome.org) to elucidate 
annotated pathways involved in the pain state when CXB-NE is administered compared 
to DF-NE to the pain state. ).  KEGG Pathway functional analysis was performed using 
g:Profiler (version e99_eg46_p14_f929183) with a g:SCS multiple testing correction 
method applying a significance threshold of 0.05 247. All differentially expressed genes 
were applied to the Gene Expression Database (http://informatics.jax.org) to further 
demonstrate their individual roles in the maintenance and transduction of neuropathic 
pain under CCI conditions when COX-2 is attenuated in circulating monocytes.  
 
2.12 Literature search of neuroinflammatory genes 
A comprehensive literature search containing the search term chronic constriction 
injury (CCI), celecoxib, and each term category in Chapter 5 was conducted in peer-
reviewed primary literature databases (PubMed, Science Direct, PubMed Central, 
amongst others). In addition, the Gene Expression Database and Gene Ontology (GO) 






2.13 Validation of RNA Sequencing by Quantitative Real-time PCR 
For Specific Aim 2 (Chapter 4), the extracted total RNA from the DRGs was 
reverse transcribed into cDNA using RT2 First Strand Kit (Qiagen, Germantown, MD, 
USA) according to the manufacturer’s instructions. Quantitative PCR (qPCR) using 
pooled L4 and L5 DRG tissues from rats from the RNA sequencing study and additional 
rats were used. qPCR was performed using individual RT2 primer assays (Qiagen) on the 
ABI StepOnePlus cycler (Applied Biosystems, USA) with RT2 SYBR green with ROX 
(Qiagen) according to manufacturer’s instructions. Each reaction was performed in 
triplicate and normalized to the housekeeping gene Gapdh. Analysis was done using the 
Livak method86 where fold change values were calculated compared to the naive control 
group. A 2-tailed Student’s t-test, standard deviation and error were calculated. A one-
way analysis of variance followed by post hoc testing and Tukey’s multiple comparison 
test with GraphPad Prism (version 8, San Diego, CA). A P value ≤ 0.05 was considered 
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3.1 Contributions Statement 
Andrea Stevens did all work in this chapter except where noted below: 
Dylan Bertovich, PURE Undergraduate Research student in Dr. John A. Pollock’s 
laboratory, contributed to Figure 7, in which he was responsible for staining tissues and 
assisted in creating the figure. 
Lu Liu, Graduate Student in Dr. Jelena Janjic’s laboratory; preparation of nanoemulsion 
preparation and contributed to NIRF imaging. 
Jelena Janjic, Associate Professor in Graduate School of Pharmacy at Duquesne 
University and co-founder of Duquesne University’s Chronic Pain Research Consortium, 
together with Dr. Pollock, jointly designed the experimental approach for evaluating 
nanoemulsions in the CCI rat model for effects on neuropathic pain. Dr. Janjic conceived 
and designed the overall macrophage-targeted drug delivery approach with 
nanoemulsions, the nanoemulsion composition and processes for fabrication. 
John A. Pollock, Professor of Biology and Principle Investigator, jointly designed the 
approach to assess the differential expression of mRNAs (with Andrea Stevens); all 
experiments were performed by Andrea Stevens under the guidance of John A. Pollock.   
Original draft preparation by Andrea Stevens, additional writing and review was by all 
authors. 
3.2 Introduction 
Peripheral nerve injury underlying neuropathic pain affects over 100 million 
Americans and costs roughly $600 billion annually2. This type of injury can be modeled 
in small animals with chronic constriction injury (CCI) of peripheral nerves and is known 
to result in spontaneous pain-like behavior including amplified responses to painful 
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stimuli (hyperalgesia), non-painful stimuli (allodynia) and thermal hypersensitivity13,46,47. 
Peripheral nerve injury is characterized by a complex molecular and cellular response, 
consisting of two main components. First, the injury is associated with a change in the 
immune cell microenvironment surrounding the damaged neurons leading to a local 
response known as neuroinflammation5,9. Second, healing and axon regeneration are 
engaged10,11. The initial immune response consists of infiltration of immune cells to the 
site of injury at the sciatic nerve, activation of immune and glial cells, and Wallerian 
degeneration of distal nerve fibers87-89. This process includes the recruitment of 
circulating monocytes to the site of injury, which release pro-inflammatory cytokines, 
chemokines, trophic and growth factors that cause neuronal hypersensitivity in the 
periphery90. The neurons themselves exhibit neuronal plasticity91 leading to spontaneous 
firing, decrease in threshold, and an increase in responsiveness. Schwann cells along the 
injured axons dedifferentiate into an activated state where they switch from a myelinating 
phenotype to a phagocytic cell type, similar to macrophages. In addition, the injured 
neurons and Schwann cells produce and release inflammatory mediators92 such as 
cytokines, chemokines, neurotrophic factors, Substance P, and prostanoids that all 
contribute to the neuroinflammatory milieu.  
Monocyte-derived macrophages are known to play a role in peripheral nerve injury at 
the site of injury in the sciatic nerve and later at the level of the neuronal cell bodies in 
the dorsal root ganglia40, 46, 51-53. These hematogenous macrophages accumulate 
preferentially around injured axons36 guided by molecular cues such as monocyte 
chemoattractant protein-1 (MCP-1)54, the lesser studied monocyte chemoattractant 
protein-5 (MCP-5), and the leukocyte adhesion complex of MAC1, which is formed by 
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the integrins, ITGAM/CD11b and ITGB2/CD1855. Together with injured axons and 
activated Schwann cells, the infiltrating immune cells (macrophages, T cells, mast cells, 
and neutrophils) are crucial for normal function and recovery after nerve injury 40,93. Each 
cell type appears to exhibit profiles of gene expression that contribute to the production 
of inflammatory mediators that further influence the neuropathic pain state30, 31, 94, 95 . 
Schwann cells at the site of injury through the distal nerve dedifferentiate by altering 
gene expression94. Within two days of chronic constriction injury, the Schwann cells stop 
producing myelinating proteins, and in turn, increase the expression of regeneration-
associated genes such as GAP-43, neurotrophic factors and their receptors like GDNF, 
and cytokines such as IL-689. Hematogenous macrophages also produce the pro-
inflammatory cytokine IL-6 and increase expression of cyclooxygenase 2 (COX-2), 
which produces prostaglandin E2 (PGE2), all of which contribute to the inflammatory 
response 32, 51.  
Janjic and co-workers demonstrated feasibility of targeting cyclooxygenase-2 (COX-
2) enzyme in macrophages using cell specific delivery with near infrared labeled 
nanoemulsion (NE) loaded with non-steroidal anti-inflammatory (NSAID) drug, 
celecoxib (CXB)71, 73. The celecoxib loaded nanoemulsion (CXB-NE), when 
administered to CCI rats leads to significant reversal in pain-like behavior 46,71. CXB-NE 
selectively inhibits COX-2 enzyme leading to dramatically reduced production of PGE2 
in monocyte-derived macrophages at the site of injury48, 71-73. Not only does the single 
dose of CXB-NE (0.24 mg/kg of celecoxib) provide pain relief for about 6 days, we have 
observed that at the site of injury there is a reduction in inflammation as visualized in live 
animals by near infrared fluorescence (NIRF), as well as histologically visualized 
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reduction in the density of infiltrating macrophages at the site of injury46, 48. Furthermore, 
for the macrophages that remain in the injured sciatic nerve even while treated with 
celecoxib-loaded nanoemulsion (CXB-NE), there is a reduction in PGE2 production46, 48 
and a shift in M1 to M2 polarity46. We also seen a reduction in mast cell numbers as well 
as a reduction in mast cell degranulation46.  
To further explore the molecular cell biology of the resultant chronic pain and the 
effects of the targeted celecoxib therapy, we assessed mRNA expression in the injured 
sciatic nerve through quantitative PCR of a collection of 84 genes associated with 
neuroinflammation. In this study, we evaluated the molecular expression changes at the 
site of injury on day 12 post-CCI surgery, a time of significant pain-like hypersensitivity 
for untreated animals or maximum pain relief for treated animals. We compared the 
expression profile of mRNAs in the injured nerve to mRNA from comparable sciatic 
nerve acquired from sham surgical animals as well as CCI animals treated with 
nanoemulsion containing celecoxib (CXB-NE) or vehicle nanoemulsion that is drug free 
(DF-NE). We demonstrated significant changes in the neuroinflammatory mRNAs 
present within the injured sciatic nerve including genes associated with macrophages as 
well as neurons and Schwann cells among other cell types. Relative to vehicle (DF-NE), 
the mRNAs expressed in the drug treated (CXB-NE) exhibit decreased expression of 
seven known neuroinflammatory genes found in various cell types (Grin2b/NMDAR2b, 
IL-6, Itgam/Cd11b, Maob, Scn9a/Nav1.7, Tac1, TrpV3) and the increased expression of 
the neuronal Cacna1b/Cav2.2. Many of the changes evident in the sciatic nerve that result 
from injury and the changes in response to pain reliving therapy, may have their basis in 
regulated differential expression of key mRNAs. This research illustrates the need to 
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better understand the molecular mechanisms involved in this neuroinflammatory-
mediated multi-cellular response, and how by targeting only one inflammatory mediator, 
we are able to alter the expression of several genes while changing the pain-like behavior 
state. 
3.3 Materials and Methods (See Chapter 2 and Appendix A for detailed 
methodology) 
3.4 Results 
3.4.1 Relief of pain hypersensitivity in the CCI model with a drug-loaded 
nanoemulsion 
First demonstrated by Bennett and Xie13 chronic constriction injury (CCI) of a 
peripheral nerve is known to induce hypersensitivity, which is interpreted as neuropathic 
pain caused by the neuroinflammation. Here we reported that after baseline behavioral 
testing, CCI or sham surgery was performed on Day 1, followed by behavioral testing 
daily on days 2 through 12 post-surgery. The effects of celecoxib-loaded nanoemulsion 
(CXB-NE) treatment on CCI rats was determined by using the paw withdrawal threshold 
when probed with von Frey filaments of increasing diameter 82, 83. All CCI animals 
experienced mechanical allodynia one-week post-injury, with a maximum in pain-like 
behavior plateauing on day 8 (Figure 6A), at which time celecoxib-loaded nanoemulsion 
(CXB-NE) or drug-free nanoemulsion (DF-NE) is administered by tail vein injection 74. 
Data are expressed as the mean +/- SD (n=5 per group). Significance was determined by 
two-way ANOVA followed by Tukey’s post-hoc test (GraphPad Prism, version 7.0; P 
0.05). No statistically significant difference is evident in the comparison of sham control 
to the non-surgical naïve animal (P = 0.185). Furthermore, no statistically significant 
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difference was observed between CCI DF-NE animals compared to CCI animals 
receiving no nanoemulsion at all (P = 0.083). A statistically significant difference in 
allodynia is evident between sham and naïve controls compared to CCI starting on day 5 
post-surgery (P <0.0001). One day after the nanoemulsion celecoxib drug therapy, treated 
animals exhibited a statistically significant reduction in hypersensitivity ultimately to 
return to a withdrawal latency equivalent to sham/naïve within three days of the tail vein 
injection. On day 12, the drug treated CCI animals exhibited a statistically significant 
relief in pain-like behavior as compared to both the CCI DF-NE (vehicle) and the CCI 
only (no nanoemulsion) animals (0.624, P <0.0001). 
The nanoemulsion used in this study acts as both a therapeutic (delivering celecoxib) 
and diagnostic (loaded with a near infrared dye)46-48, 71, 74, 84. Live animal near infrared 
fluorescent (NIRF) imaging on day 11 demonstrated increased inflammation at the site of 
injury (Figure 1A and Figure 6A) as compared to naïve control animals (Figure 6B). 
CCI animals given the drug-loaded nanoemulsion (CXB-NE) exhibited a decreased NIRF 
signal as compared to DF-NE (Figure 6D), indicating a reduction in macrophage 
infiltration. Macrophages directly influence the milieu of inflammatory mediators such as 
cytokines and chemokines20. Although macrophages and other infiltrating immune cells 
accumulate at the site of injury post-CCI at day 12, neuronal-centric changes also 





Figure 6. CXB-NE ameliorates mechanical allodynia and inflammation in CCI-induced 
neuropathic male rats. (a) Mechanical stimulus evokes pain-like hypersensitivity in CCI animals. 
Treatment with CXB-NE provides a recovery from pain-like behavior comparable to sham and 
naïve control rats by day 12 (displayed as ****), but not in CCI rats given DF-NE. Data are 
expressed as a mean +/- SD with a n = 5 per group. Significance was determined by two-way 
ANOVA followed by Tukey’s multiple comparison test (p <0.0001). No statistical significance of 
difference of sham control compared to naïve, whereas the statistically significant difference is 
evident in the CCI animals compared to sham controls on days 5 through 8. (b-d) Live animal 
NIRF imaging on day 11 shows decreased fluorescence in CCI animals treated with CXB-NE (b), 
compared to those administered DF-NE (c). (d) Non-surgical naïve animals exhibit no 
fluorescence.  
3.4.2 Overview of mRNA expression changes for genes associated with CCI chronic 
pain  
While attenuating COX-2 activity at the site of injury through CXB-NE therapy, we 
examined the mRNA expression of 84 genes previously identified as associated with 
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neuropathic and inflammatory pain in the rat (Qiagen, PARN162-Z; Table 5). The 
dissected segment of the injured sciatic nerve includes axon fibers as well as myelinating 
Schwann cells and dedifferentiated Schwann cells, endothelial cells, and infiltrating 
macrophages among other activated immune cells. A quantitative analysis of the qPCR 
CT values for the mRNAs identified by all 84 genes was carried out using Qiagen’s RT2 
Profiler Array Software and displayed as a volcano plot between all data groups (Figure 
7). This software creates a ‘volcano plot,’ which displays statistical significance versus 
fold change, by plotting P-value against the fold regulation change with the significance 
of the differential expression. Here, fold regulation values greater than 1 indicate 
increased gene expression, whereas fold regulation values less than zero indicate reduced 
expression.  
In order to visualize gene expression changes of the entire 84 gene set, volcano plots 
were generated for each pairwise comparison (CCI DF-NE versus sham, CCI CXB-NE 
versus sham, and CCI DF-NE versus CCI CXB-NE). Illustrated in Figure 7, genes 
displaying statistically significant increased expression are shown in blue while reduced 
expression is indicated with red. Those that exhibited changes in expression but that are 
not statistically significant are shown in black. Because the printed graphic cannot 
support tags that name every data point, the differential expression of all the genes are 
listed in Table 1. Comparing CCI DF-NE animals (pain state) to the sham surgical 
control reveals that there were 24 of the 84 genes with increased expression and 16 genes 
with reduced expression (Figure 7A; Table 1A). In sham versus CCI CXB-NE animals 
(pain relieved), 19 genes showed increased expression and 14 exhibited decreased 
expression (Figure 7B; Table 1B). Comparing both CCI conditions (drug free to drug 
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treated), there were 7 genes upregulated and 1 downregulated (Figure 7C; Table 1C). 
The mRNA expression in sciatic nerve compared between naïve animals, sham surgical 
animals treated with CXB-NE, and sham surgical animals treated with DF-NE (vehicle), 
analyzed with one-way ANOVA revealed no statistically significant difference (Figure 
14). 
Under the influence of immune cells, glia and the neuronal cell bodies in the 
corresponding dorsal root ganglia, the axons that make up the sciatic nerve exhibit 
exaggerated responses marked by hyperexcitability as well as changes in local expression 
of key mRNAs encoding products involved in hyperalgesia pain-like behaviors. For 
example, Calcitonin Gene-Related Peptide (CGRP) mRNA encodes a calcitonin peptide 
involved in the maintenance of neuropathic pain96. CGRP is significantly reduced in the 
CCI pain state, but not responsive to the CXB-NE drug therapy (CCI CXB-NE exhibited 
a fold change of 0.13; CCI DF-NE 0.12 when compared to sham). Similarly, the 
Neurotrophic receptor tyrosine kinase 1 (Ntrk1) mRNA is also reduced in the CCI pain 
state, and not responsive to the CXB-NE drug therapy as compared to sham (CCI CXB-
NE fold change of 0.17 and CCI DF-NE fold change of 0.13). However, several mRNAs 
encoding ion channels exhibit significant differential expression in the sham surgical 
control versus the CCI celecoxib-loaded- (CXB-NE) and vehicle-loaded (DF-NE) 
nanoemulsions. These include Scn9a (Sodium voltage-gated channel, type IX or Nav1.7), 
TrpV3 (Transient receptor potential 3), and Cacna1b (Calcium voltage-gated channel 







Figure 7. Neuroinflammatory gene expression changes in mRNA of sciatic nerve isolated on day 
12 post-CCI injury, four days after nanoemulsion injection. In total, 84 genes associated with 
neuropathic and inflammatory pain were measured from Qiagen’s RT2 array (PARN-162Z). 
Qiagen’s RT2 profiler PCR Array Data Analysis software yielded differential expression of genes 
given as fold regulation in (a) CCI DF-NE compared to sham control, (b) CCI CXB-NE compared 
to sham, and (c) comparison of the two CCI conditions. Upregulated genes (blue), downregulated 
genes (red), and unchanged genes (black). P value <0.05, 2-tailed Student’s t-test. The differential 
expression and p values for all genes are listed in Table 1. 
 
Celecoxib selectively inhibits COX-2, blocking prostaglandin synthases [40]. 
Although induction of COX-2 occurs in multiple cells (Schwann cells, neurons, and 
macrophages), by directly targeting COX-2 and subsequent PGE2 production in only 
invading macrophages, we find that there is a reduction in PGE2 in the injured sciatic 
nerve46,47. In CCI CXB-NE, there is a marked increased expression in of Prostaglandin 
receptor 1 (Ptger1; fold change 2.29) and Prostaglandin E Synthase 2 (Ptges2; 2.21 fold 
change). However, there is no significant changes of expression for Prostaglandin 
receptors 3 and 4 (Ptger3 and Ptger4) when comparing the pain states with or without 
drug relative to sham control. Furthermore, no gene expression changes in any of the 
conditions were noted for other key mediators in the PGE2 pathway, including 
Prostaglandin E Synthase (Ptges), Prostaglandin E Synthase 3 (Ptges3), Prostaglandin-




When comparing CCI DF-NE (pain state) to sham, genes that exhibited increases in 
expression ranged from 1.68 fold for Gdnf to 30.5 fold for Mcp5, whereas downregulated 
expression ranged from -1.62 fold for Mapk3 to -11.03 Oprk1 (Figure 7A). In CCI CXB-
NE (pain relief) animals versus sham, 19 genes showed increased expression and 14 
exhibited decreased expression, ranging from a fold regulation of 11.02 in Mcp5 to -
14.23 in Scn9a (Nav1.7) (Figure 7B). Comparing both CCI DF-NE to CCI CXB-NE 
conditions, there were seven genes with elevated expression in the pain state relative to 
the drug treated pain-relief state and one gene that exhibited reduced mRNA expression 
(Figure 7C). Gene expression between naïve, sham CXB-NE, and sham DF-NE were 
compared and showed no statistically significant difference between these controls (See 
Section 3.6 for supplemental data). 
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Table 1. Gene list representing volcano plots in Figure 7. Expression changes are represented as fold 
regulation. Positive values indicate an increased expression, whereas negative values indicate decreased 
expression. (a) Genes differentially expressed in CCI DF-NE versus sham, (b) genes differentially 
expressed in CCI CXB-NE versus sham, (c) genes differentially expressed in CCI DF-NE versus CCI 
CXB-NE. One-way ANOVA with Tukey’s post-hoc testing with a P value 0.05 was performed. 












   Downregulated 




 P Value Gene Fold 
Regulation 
P Value  
Actb 6.61  0.0008 Cacna1b -6.35 0.006 
B2m 1.75  0.0002 Calca -7.91 0.002 
Adrb2 4.97  0.017 Cckbr -6.67 0.02 
Ccl12/Mcp5 30.5  >0.00001 Grm1 -6.67 0.02 
Ccr2 2.41  0.03 Grm5 -6.42 0.004 
Cd4 8.34  0.003 Kcnj6 -7.16 0.02 
Cnr2 2.68  0.045 Kcnq3 -5.76 0.03 
Comt 2.73  0.0004 Maob -6.18 0.0002 
Cx3cr1 12.47  0.0006 Mapk3 -1.62 0.016 
Ednra1 3.59  0.018 Ntrk1 -7.88 0.012 
Gch1 3.76  0.0002 Oprd1 -5.03 0.005 
Gdnf 1.68  0.059 Oprk1 -11.03 0.048 
Il-18 6.57  0.001 Opr1m -10.85 0.007 
Il-1α 8.81  0.04 Penk -5.21 0.03 
Il-1β 21.52  0.006 Ptger3 -2.19 0.002 
Il-6 12.5  0.01 Scn9a -6.89 0.003 
Itgam/Cd11b 12.12  >0.00001 
Itgb2/Cd18 11.49  >0.00001 
P2rx4 2.93  >0.00001 
P2rx7 3.5  0.016 
Prok2 5.42  0.03 
Ptger4 2.39  0.013 
Tlr2 12.22  >0.00001 
Tnf 7.76  >0.00001 
Actb 6.61  0.0008 
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2. CCI CXB-NE vs. Sham 
 
(C) CCI DF-NE vs. CCI CXB-NE 
 
3.4.3 Altered expression of key mRNAs involved in neuroinflammation  
By day 12; four days after the nanoemulsion injection, the drug treated animals 
behave as the sham and naïve, exhibiting no hypersensitivity while the vehicle treated 
animals exhibit un-abated hypersensitive pain-like behavior (Figure 6A). Each of the 
neuroinflammatory genes differentially expressed in the array are listed in Table 2, 
Upregulated 
CCI CXB-NE 
  Downregulated 
CCI CXB-NE  
  
Gene Fold Regulation P Value Gene Fold 
Regulation 
P Value  
Actb 8.18 0.002 Cacna1b -3.03 0.02 
B2m 1.84 0.009 Calca -7.5 0.003 
0.013 
Adrb2 4.9 0.02 Edn1 -2.25 0.007 
Alox5 2.38 0.03 Grm5 -7.64 0.02 
Ccl12/Mcp5 11.02 0.017 Il-2 -5.22 0.04 
Ccr2 2.58 0.02 Kcnq3 -5.7 0.00013 
Cd4 7.35 0.01 Maob -11.54 0.003 
Comt 1.89 0.03 Mapk3 -2.47 0.003 
Cx3cr1 7.78 0.009 Ntrk1 -5.98 0.03 
Gdnf 4.51 0.02 Oprd1 -5.31 0.01 
Il-18 4.27 0.04 Oprm1 -8.02 0.01 
Il-1β 6.06 0.03 Ptger3 -2.46 0.005 
Il-6 3.63 0.013 Scn9a -14.23 0.0009 
Itgam/Cd11b 5.06 0.0001 Trpv3 -9.12 0.0004 
Itgb2/Cd18 6.84 0.02    
P2rx4 2.28 0.01    
Ptger1 2.29 0.01    
Tlr2 7.12 0.01    
Tnf  5.64 0.02    
Upregulated  
CCI DF-NE 
  Downregulated 




P Value Gene Fold 
Regulation 
P Value  
Grin2b 2.37 0.021 Cacna1b -2.1 0.04 
Il-6 3.44 0.04 
Itgam/Cd11b 2.39 >0.00001 
Maob 1.87 0.007 
Scn9a 2.06 0.05 
Tac1 2.69 0.04 
Trpv3 5.33 0.01 
Grin2b 2.37 0.021 
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Table 3, and Table 4 according to their cell-specific expression based on past pain-
related studies in the literature. Each of the tables illustrates known roles for the 
described genes based on a literature review from PubMed. The differential RNA 
expression fold change described is from the data contained in this report for the analysis 
of the Neuropathic and Inflammatory pain RT2 array. Fold change of CCI CXB-NE rat 
sciatic nerve mRNAs relative to sham control and fold change of CCI DF-NE mRNAs 
relative to sham control were analyzed with Qiagen’s RT2 profiler PCR Array Data 
Analysis software, where statistically significant differentially expressed mRNAs were 
identified using a 2-tailed Student’s t-test, with a P value <0.05, as calculated by the 
Qiagen software. Changes in gene expression between the pain group and the control 
group are illustrated as a fold increase/decrease and are considered to be 
upregulated/downregulated, respectively. Genes previously associated with expression in 
neurons, Schwann cells, circulating monocytes, macrophages, and T cells (citations noted 
in the Tables 2, 3 and 4) are found to be expressed at high levels in the pain state in the 
present study. Additionally, a superset of this data can be found in Table 1. Table 2 and 
Table 3 list differential expression revealing that eighteen of the 84 genes that were 
previously reported as exhibiting neuronal expression are affected by our treatments. 
Additionally, 6 genes are associate with immune cell, and another 15 of the differentially 
expressed mRNAs are typically found in multiple cell types that include Schwann cells, 






Table 2. Differential expression of mRNAs typically associated with neurons. 
Gene Symbol Gene Description Fold change 
relative to 








Actb1 Beta-actin 6.61 8.18 NM_031144 97 
Cacna1b/Cav2.2 Calcium channel, voltage-
























Comt Catechol-O-methyltransferase 2.73 1.89 NM_012531 101, 102 
 
Ednra Endothelin receptor type A 3.59 0.44 NM_012550 103 
Grm1 Glutamate receptor, 
metabotropic 1 
 
















Kcnj6 Potassium inwardly-rectifying 
channel, subfamily J, member 
6 
0.14 Not detected NM_013192 106 
Kcnq3 Potassium voltage-gated 







Ntrk1/TrkA Neurotrophic tyrosine kinase 
receptor, type 1 
0.13 0.17 NM_021589 107, 108 










Orpk1 Opioid receptor, kappa 1 0.09 Not detected NM_017167 109 
Oprm1 Opioid receptor, mu 1 0.09 0.12 NM_013071 109 
P2rx4 Purinergic receptor P2X, 

















TrpV3 Transient receptor potential 
cation channel, subfamily V, 
member 3 






1 Denotes genes individually analyzed by qPCR.  
 
Ten of the differentially expressed genes that are revealed by the Qiagen RT2 Profiler 
Array software were re-analyzed with RNA from new animals utilizing individual qPCR 
assays with the same primers. In this way, the sample size was increased for each gene (n 
= 8-10 per condition). The genes chosen show statistically significant differential RNA 
expression in the Neuropathic and Inflammatory RT2 array analysis and are known to be 
involved in the neuroinflammatory response. Macrophage-associated genes analyzed 
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included Itgam/Cd11b (Figure 8A), Itgb2/Cd18 (Figure 8B), and Mcp5/Ccl12 (Figure 
8C). ITGAM/CD11b and ITGB2/CD18 form the integrin MAC-1 complex, which is 
responsible for the recruitment and adhesion of leukocytes to the site of injury55,121. The 
role of chemokine MCP-5 (monocyte chemotactic protein 5) in neuropathic pain has not 
been studied in the CCI model but is thought to behave like MCP-1, which is involved in 
the recruitment of monocytes/macrophages to injured tissue122. 
 
Table 3. Differential expression of mRNAs typically associated with immune cells. 
Gene 
Symbol 
Gene Description Fold change 
relative to 
sham for  
CCI DF-NE 
Fold change 
relative to  



























Cd41 CD4 cell  8.34 7.35 T Cells NM_012705 118 
Cnr2 Cannabinoid 
receptor 2 












































Ptgs2 Prostaglandin E 
synthase 2 

















Table 4. Differential expression of mRNAs typically associated with multiple cells in the periphery.  
Gene 
Symbol 
Gene Description Fold change 
relative to 
sham for  
CCI DF-NE 
Fold change 
relative to  





Cx3cr11 Chemokine (C-X3-C 










































































































Ptger1 Prostaglandin E 
receptor 1 



























































Other differentially expressed genes include Actb, Gdnf, Cd4, Cx3cr1, IL-1β, IL-6 
and IL-18. These expression profiles are associated with multiple cell types including 
neurons, Schwann cells, monocytes/macrophages, and T cells (Tables 2, 3 and 4). β-
actin and Cd4 (Figure 9A-B) are significantly increased in expression in the CCI 
condition relative to sham, but their expression level is not sensitive to the drug therapy 
CXB-NE treatment. Similarly, Cx3cr1/Gpr13 is increased in its mRNA expression in the 
CCI conditions relative to sham. While the Cx3cr1/Gpr13 in the drug treated CXB-NE 
condition is reduced relative to the DF-NE, the reduction is not statistically significant in 
this experiment (Figure 9C). Interestingly, Gdnf is significantly increased in its mRNA 
expression in the drug treated CXB-NE CCI condition (Figure 9D). IL-6, IL-1β and IL-
18 (Figure 10) all exhibit significantly increased mRNA expression in the CCI (DF-NE, 
pain-state) as compared to sham, and that they are also each responsive to the drug 
therapy. No expression was seen in sham animals. 
 
 
Figure 8. mRNA expression of macrophage-related genes at the site of injury. (a) Itgam/Cd11b 
mRNA is significantly elevated in the CCI pain-state (DF-NE) over sham, and is significantly 
reduced in the CXB-NE drug treated CCI condition. (b) Itgb2/Cd18 (integrin β-2) mRNA is 
significantly elevated in the CCI pain state (DF-NE) over sham, and is significantly reduced in the 
CXB-NE drug treated CCI condition. (c) Mcp-5 mRNA is significantly elevated in the CCI pain-
state (DF-NE) over sham, and is significantly reduced in the CXB-NE drug treated CCI condition. 
One way ANOVA with Tukey post-hoc analysis is considered statistically significant if P value < 
0.05. Sham = 6, CCI CXB-NE n = 8, CCI DF-NE n = 6.  
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3.4.4 Differential expression of mRNAs in the CCI (pain state) compared to celecoxib-
treated CCI (pain relieved) 
Genes that exhibited differential expression of mRNAs in the CCI conditions were 
compared to the mRNA expression levels in the drug treated condition (Table 1C). This 
helps to reveal genes where their expression is directly affected by CXB-NE COX-2 
inhibition in monocyte-derived macrophages in the sciatic nerve. Differential expression 
of the mRNAs between the CCI pain state and drug-treated pain state shows that seven 
genes are down-regulated and one gene is upregulated in the treated animals (Figure 11). 
Maob expression is elevated in the CCI pain-state (DF-NE) and exhibits a 
downregulation in CCI CXB-NE. The pro-inflammatory mediator interleukin-6 (IL-6) 
mRNA expression is primarily produced by Schwann cells, neurons, circulating 
monocytes and macrophages51 and exhibits an elevated pattern of expression that is 
decreased when CXB-NE is present. Itgam/Cd11b is expressed by circulating monocytes 
and macrophages55 and shows a 2-fold reduction in expression when circulating 
monocytes are targeted with celecoxib treatment in the CCI state. Grin2b/NMDAR2b, 
Scn9a/Nav1.7, Maob, Tac1 and TrpV3 are all exhibiting increased expression in the pain 
state, while reduced when CXB-NE provides relief and are each previously associated 
with neuronal expression111, 113-115. In contrast, the voltage-dependent calcium channel, 





Figure 9. mRNAs responsive to CCI. (a) Actin beta (Actb) mRNA expression is elevated in response 
to CCI treatment and is not responsive to CXB-NE drug therapy. (b) Cd4 is typically associated with 
T cells and is similarly responsive to CCI treatment but is not responsive to CXB-NE therapy. (c) 
Cx3cr1 (Chemokine CX-3-C motif, receptor 1) is expressed widely on the cell surface of neurons, 
macrophages, circulating monocytes, T cells, and Schwann cells. The mRNA expression is elevated 
in response to CCI treatment. (d) Gdnf (glial-derived neurotrophic factor) is produced by neurons 
and glial cells and appears to be responsive in the CCI condition to the CXB-NE drug therapy. One 
way ANOVA with Tukey post-hoc analysis is considered statistically significant if P value < 0.05. 
Sham = 6, CCI CXB-NE n = 8, CCI DF-NE n = 6.  
 
Figure 10. Cytokine mRNA expression at the site of injury. (a) cytokine IL-6 (interleukin-6) 
mRNA is significantly increased in response to CCI, and is significantly attenuated with CXB-NE 
drug therapy. (b) IL-1β (interleukin-1 beta) mRNA is significantly increased in response to CCI, 
and is significantly attenuated with CXB-NE drug therapy. (c) IL-18 (interleukin-18) are produced 
and released by multiple cell types at the site of CCI injury is significantly increased in response 
to CCI, and is attenuated with CXB-NE drug therapy. One WAY ANOVA with Tukey post-hoc 
analysis is considered statistically significant if p value < 0.05.  sham = 6, CCI CXB-NE n = 8, 
CCI DF-NE n = 6. 
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3.4.5 Identification of CD68 and CD11b macrophages within the site of injury  
Our previous studies show a decrease in the number of CD68 macrophages that 
infiltrate the injured nerve under the same conditions using CXB-NE46, 48. Anti-CD68 is a 
pan macrophage marker that has the ability to identify macrophages that are both 
phagocytic as well as cells that are actively producing and releasing cytokines and 
chemokines, whereas anti-CD11b is associated with more specific macrophages133. We 
find that the CD11b-positive cells also co-express CD68 in the pain state, but that not all 
CD68 positive cells are CD11b positive (Figure 12). CD11b-positive macrophages tend 
to be small and round in nature (Figure 12 A-D), where CD68-positive macrophages can 
also be large, foamy, and irregularly shaped (Figure 12 E-H). CD68 positive 
macrophages are found predominantly within the injured sciatic nerve, with low 
expression of CD11b positive macrophages (Figure 12 K,L), whereas CD11b/CD68 
positive macrophages are found primarily in the epineurium surrounding the nerve fibers 
(Figure 12 I,J). These findings are consistent with previous literature of neuropathic pain 
models showing protein expression of both CD11b positive and CD68 positive 
macrophages with immunohistochemistry 52, 58, 133. Parallel downregulation of CD11b 
macrophages is consistent with the reduction in expression of inflammatory mediators 





Figure 11. mRNA differential expression comparing CCI CXB-NE relative to CCI DF-NE 
animals. CCI animals given CXB-NE exhibit decreased expression of 7 known neuroinflammatory 
genes found in various cell types in the pain state and increased expression of the axonal Cacna1b 
gene when compared to CCI DF-NE animals.  One way ANOVA with Tukey post-hoc testing. 




Figure 12. A subset of CD68 positive macrophages co-express the integrin ITGAM/CD11b, 
detected with anti-CD11b antibody. Co-expressing cells are predominantly found in the 
epineurium (a-d), whereas the CD68 positive macrophages in the nerve track do not co-express 
CD11b (e-h). (i,j) reveals the co-expressing CD11b and CD68 cells predominate in the 








3.5.1 Peripheral nerve injury is associated with differential expression of 
neuroinflammatory mRNAs 
This study revealed that mRNA expression changes were seen directly at the site of 
injury where neuroinflammation is rampant. Furthermore, that within 4 days of 
celecoxib-loaded nanoemulsion administration, aside from a reduction in pain-like 
behavior and reduction in PGE2 production, shift in macrophage polarity and reduction in 
Mast Cell degranulation46, 48, we now find that the regulated expression of several 
mRNAs are responsive to the drug-therapy. This drug induced-differential expression of 
mRNAs for key neuroinflammatory genes is a result of the nanoemulsion drug being 
delivered to macrophages in the pain state.  
Overall, our data revealed changes in the mRNA expression of genes associated with 
neuroinflammation, which is consistent with phenotypic behavioral changes as 
demonstrated by the assessment of tactile allodynia of the affected hind leg. CCI animals 
demonstrate no significant allodynia during the initial Wallerian degeneration phase 
occurring between days 1 to 3 30 and show an decreased pain threshold during days 4 to 5 
and beyond 46, 48. By day 8 post-surgery, we observed a plateau in hypersensitivity that 
persists in un-treated animals46, 48. However, following intravenous injection of 
celecoxib-loaded nanoemulsion on the eighth day post-surgery, we showed that 
beginning as early as a day later, there was a significant reduction in mechanical 
allodynia, consistent with prior observations46, 48. We have previously demonstrated that 
this single dose (0.24 mg/kg) of celecoxib provides relief from hypersensitivity that lasts 
about 6 days46, 48. This represents greater than a 2000-fold reduction in dosage that would 
be needed were traditional daily oral dosing utilized134. This change in behavioral 
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phenotype overlaps with the prolonged neuroimmune response occurring in and around 
the site of injury. This is characterized by the changes in behavioral activity and 
activation of resident immune and immune-like glial cells56, 95, 135. In vivo imaging of the 
ipsilateral hindleg revealed an increased near infrared signal consistent with an 
accumulation of nanoemulsion-labeled macrophages at the site of injury, indicative of 
neuroinflammation associated with infiltrating macrophages 46-48. Immunohistochemical 
investigation of dissected sciatic nerves reveals that CCI CXB-NE animals on day 12 
exhibit a reduced infiltration of macrophages as compared to CCI DF-NE animals46, 48. 
COX-2 as well as with PGE2 are present in the injured rat sciatic nerves following CCI 
injury46, 48 suggesting injured nerve-derived invading macrophages may influence the 
neuroimmune cellular environment within the sciatic nerve through possible autocrine 
and paracrine pathways52. Here we showed that the heightened and persistent 
neuroimmune response in the peripheral nerve injury leads to changes in mRNA 
expression at the site of injury, and that it involves multiple cell types, including neurons, 
macrophages, Schwann cells, degranulating Mast cells and T cells; all of which 
contribute to the production of inflammatory mediators at the site of injury. 
 
3.5.2 Targeting COX-2 in macrophages contributes to a decrease in macrophage-
related mRNAs at the site of injury 
By directly targeting COX-2 enzyme and PGE2 production in invading macrophages 
at the site of injury, there was a subsequent decreased gene expression evident in 
Cd11b/Itgam and Cd18/Itgb2 beta-2 integrins when compared to sham control. 
Cd11b/Itgam and Cd18/Itgb2 are integrins that heterodimerize to form a complex known 
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as MAC-1 or CR3.  It is normally present in an inactive confirmation in circulating 
monocytes, but is quickly activated to mediate leukocyte adhesion, migration and 
accumulation of cells at the site of inflammation55. Previous studies have shown that by 
blocking MAC-1 and its’ ligands or the ablation of its genes encoding Cd11b or Cd18, 
leads to a decrease in severity of inflammation in animal models55. Given the attenuation 
in COX-2 activity and the reduction in PGE2 production in CXB-NE targeted 
macrophages48, the differential expression in Cd11b between CCI animals given drug 
versus drug-free CCI animals supports the observation that fewer macrophages are 
attracted to the site of injury. Here, we hypothesized that by inhibiting COX-2 and the 
production of PGE2 in circulating monocytes and tissue macrophages, there would be a 
subsequent change in macrophage signaling, including integrins, cytokines, and the 
involvement of genes associated with other cell types that participate in releasing 
inflammatory mediators at the site of injury that leads to decreased pain behaviors when 
administered at a chronic pain state in rats. Additionally, macrophages functions are 
dynamic with a shift in polarity when given celecoxib-loaded nanoemulsion46. Our lab 
has previously shown there is a nearly 30% reduction of M1 macrophages in the 
ipsilateral sciatic nerve of pain treated (CXB-NE) animals on day twelve 46. Temporally, 
there is multitude of surface markers used to identify macrophages after nerve injury135 . 
A study by Lee and Zhang58 showed that in injured nerves, macrophages exhibit 
heterogeneity, where a subpopulation identified by the MAC1 (CD11b/CD18) marker is 
cytokine/chemokine expressing and another subpopulation labeled by CD68 antibody is 
predominantly phagocytic (which is key for the regeneration process). Previously, our 
studies have shown that CD-68 positive macrophages are present in high number within 
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the damaged nerve (CCI DF-NE) compared to CCI animals receiving CXB-NE46, 48. We 
also demonstrated that the CD68 positive macrophages in the injured sciatic nerve can be 
distinguished as M1 (pro-inflammatory) and M2 (anti-inflammatory) by their expression 
of the costimulatory protein, Cluster of Differentiation 40 (CD40), or transferrin receptor 
(TFRC) respectively46. Utilizing the cytokine/chemokine secreting-specific antibody to 
CD11b, we were able to further identify additional phenotypically different macrophages 
in the CCI nerve. In a review by Ristoiu et al., (2013) they reported that in the sciatic 
nerve there is activation of CD11b-positive and CD68-positive macrophages after several 
neuropathy-induced animal models52. Our observation here is that at this moment in time 
(day 12 post CCI surgery), CD68-positive macrophages are found predominantly within 
the injured sciatic nerve, whereas CD11b/CD68-positive macrophages are found 
primarily in the epineurium surrounding the nerve fibers.  
 
3.5.3 COX-2 inhibition in macrophages leads to a reduction in pro-inflammatory 
cytokine mRNA 
Previous studies suggest that macrophage-derived PGE2 alters neural activity, 
influences the milieu of cytokines, and changes gene expression at the site of injury, all 
of which contribute to the chronic pain state46-48,51, 123, 136-139. Nerve injury results in a 
significant increased expression of IL-6 in injured nerves 51,92,140. IL-6 is also elevated in 
invading macrophages in vivo51, ensheathing Schwann cells and increased in T cells in 
response to possible increased PGE2 expression130. IL-6 is a pleiotropic cytokine where 
an increased production can be neurotrophic for neurons and can provide further signals 
that influence changes in neuronal and glial cell gene expression130. Consistent with 
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previous studies127, we found that IL-6 mRNA expression is elevated post-CCI in the 
ipsilateral sciatic nerve. Expression of IL-6 also plays a role in axonal regeneration when 
overexpression of the protein and its receptor results in improved nerve regeneration141-
142. 
The mRNA expression for cytokines IL-18 and IL-1β is increased in CCI DF-NE 
animal’s sciatic nerve, with IL-1β responding to CXB-NE treatment, showing decreased 
expression when nanoemulsion drug therapy is used. This is consistent with the 
observation that both IL-18 and IL-1β exhibit elevated expression at the protein level in 
the sciatic nerve of CCI rats, and that the activation of the inflammasome combined with 
the dominant role exhibited by IL-18 during chronic inflammation contributes to chronic 
pain20. 
Tachykinins are a family of conserved peptides encoded by the Tac1 gene, which 
generates substance P, neurokinin A, neuropeptide δ, and neuropeptide γ 143,144. These 
neuropeptides are mainly expressed in neuronal tissues in the central nervous system and 
in primary afferent neurons in the peripheral nervous system144. It has also been shown 
that substance P and neurokinin A are expressed in non-neuronal cells including 
macrophages and circulating monocytes144. Substance P is a neurotransmitter that has 
been implicated in chronic pain145. NMDA receptors like GRIN2b/NMDAR2 are present 
in primary afferents and evoke the release of substance P from their central terminals145. 
Interestingly, mRNAs encoding both substance P and GRIN2b/NMDAR2 are 
differentially expressed in the injured sciatic nerve and are responsive to CXB-NE. This 
suggests that the transcriptional regulation of GRIN2b/NMDAR2 as well as Tac1 
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mRNAs play a role in regulating pain transmission and that when COX-2 is attenuated in 
macrophages their co-regulation is similarly reduced. 
 
3.5.4 mRNAs are differentially expressed in pain relief versus the untreated pain state 
When comparing differential expression between the hypersensitive pain state (DF-
NE) and the pain-relieved state (CXB-NE), there are 8 of the 84 genes that exhibit 
differential expression; five of which are known to be expressed in neurons 112, 146, 147. Of 
these five, Grin2b/NMDAR2, Scn9a/Nav1.7, and Maob are expressed in neurons111,131, 146 
and there is an increase in the mRNA expression for these five genes in the injured sciatic 
nerve during hypersensitivity. Furthermore, when COX-2 activity is attenuated by the 
targeted delivery of nanoemulsion loaded with celecoxib, there is a reduction in this over-
expression. Changes in Nav1.7/Scn9a, Maob, and Cacna1b mRNA expression in chronic 
pain is thought to be involved in the maintenance of chronic pain in the peripheral 
nervous system148-150. The role of Trpv3 is not well understood in peripheral neuropathy 
though its expression has been reported in mouse peripheral nervous systems112 and the 
mRNA exhibited high expression levels in rat DRG in spared nerve injury models of 
neuropathic pain76. 
 
3.5.5 mRNAs at the site of injury contributing to anti-inflammation and regeneration 
The neurotrophic factor GDNF is known to have neuroprotective function in L4 and 
L5 DRG neurons after axotomy151. Here we seen increased expression of GDNF between 
sham surgical sciatic nerve and CCI nerve treated with CXB-NE. GDNF is a survival 
promoting factor for nociceptive neurons and has been shown to have analgesic 
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properties when spinal nerve ligation injured mice are injected with GDNF-expressing 
lentivirus152, suggesting GDNF mRNA have an anti-inflammatory role under neuropathic 
conditions. We also observed that β-actin (Act-β), which is associated and involved in 
growth cone formation 97,153, exhibited differential mRNA expression. Interestingly, β-
actin is often and mistakenly used as a “housekeeping gene” with the thought that its 
expression would remain unchanged after most nerve injuries. Our study revealed that, in 
fact, β-actin mRNA expression is altered upon CCI injury, with increased expression 
evident in CCI DF-NE animals. Drug-treated animals (celecoxib) exhibited a 
significantly higher level of expression over what is evident in the DF-NE condition. This 
increase in actin expression may be in response to the activation of peripheral nerve 
regenerative processes154. 
Here we reported that the chemokine MCP-5 appears to play a role in neuropathic 
pain. MCP-1 is known as one of the main proteins that activates and attracts circulating 
monocytes to the injured nerve54. MCP-5 is similar to MCP-1 and is known to attract 
circulating monocytes and T cells122. Expression of MCP-5 can be induced by 
macrophages and possibly Schwann cells, but its overall role in neuropathic remains 
unclear. Our study showed a dramatic increase in MCP-5 mRNA in the pain state in the 
damaged sciatic nerve. When animals are given intravenous injection of CXB-NE, there 
is a significant reduction in MCP-5 expression, indicating a role for this gene at the site 





3.5.6 Neuroinflammatory genes previously associated with cell bodies are differentially 
expressed at the site of injury 
Exploration of differential expression of neuroinflammatory genes in previous studies 
has focused on changes in the dorsal root ganglia (DRG) and the dorsal horn. The 
chemokine, fractalkine, is thought to be present only in DRG neurons during the 
neuropathic pain response155 with its receptor being expressed on a wide variety of cell 
types, including neutrophils, monocytes, CD8 T cells, Mast Cells, Natural Killer cells, 
fibroblasts, neurons, and endothelial cells80, 90. Interactions within the neuronal-glial-
immune-cell triad results in amplification of sensory signals so that responsivity to 
noxious as well as innocuous stimuli is intensified in ways that contribute to the pain-like 
behavior124. Verge and colleagues124 studied the fractalkine mRNA, showing that it is 
upregulated in DRG neurons as a result of CCI with a marked increase in expression of 
its G-Protein Coupled receptor, CX3CR1, in microglia as well as in neurons in the spinal 
cord. Here, we found that the mRNA expression of CX3CR1 is significantly increased in 
the periphery in the injured sciatic nerve in the drug-free nanoemulsion compared to 
sham. When treated with nanoemulsion loaded with celecoxib, the elevated expression of 
CX3CR1/GPR13 is reduced. Others have shown that when CX3CR1 is depleted by 
Diphtheria toxin treatment in CD11b-positive macrophages, 3 days following spinal 
nerve transection, no hypersensitivity was noted.  By one week post-nerve injury, 
macrophages repopulated with no pain behavior evident90. When these same mice 
undergo the same nerve injury, neuropathic pain developed, suggesting that repopulated 




In conclusion, the peripheral nerve response to injury involves complex responses 
from multiple cell types and it is for this reason we sought to profile mRNA expression 
for a specific set of genes involved in neuroinflammation by using mRNA derived from 
the site of injury. Our examination focused on the expression of genes involved in pain 
response modulation including those associated with inflammation, neurotransmitters 
signaling, neurotrophins, purinergic receptors, cytokines, and chemokines as well as 
products associated with the conduction of pain including ion channels, sodium channels, 
potassium channels, signal transduction/transcription, and synaptic transmission. We find 
differential expression of mRNAs in several of these categories in the pain-state as well 
as genes that are subsequently responsive to CXB-NE nanoemulsion drug therapy. 
Furthermore, analyzing gene expression in the sciatic nerve offers insight into how 
mRNA expression distal to the neuronal cell bodies may be of significant importance in 
establishing and maintaining chronic pain.  
3.6 Supplemental Data 
 
Table 5. Gene list of RT2 Profiler Array: Neuropathic and Inflammatory Rat Pain 
(Qiagen). These genes have been implicated in the transduction, maintenance, and 
modulation of pain responses after tissue damage. 
Ace Cd200 Gch1 Il2 Mapk8 Pla2g1b Scn11a 
Adora1 Cd4 Gdnf Il6 Ngf Pnoc Scn3a 
Adrb2 Chrna4 Grin1 Itgam Ntrk1 Prok2 Scn9a 
Alox5 Cnr1 Grin2b Itgb2 Oprd1 Ptger1 Slc6a2 
Bdkrb1 Cnr2 Grm1 Kcnip3 Oprk1 Ptger3 Tac1 
Bdnf Comt Grm5 Kcnj6 Oprm1 Ptger4 Tacr2 
Cacna1b Csf1 Htr1a Kcnq2 P2rx3 Ptges Tlr2 
Calca Cx3cr1 Htr2a Kcnq3 P2rx4 Ptges2 Tlr4 
Cck Dbh Il10 Maob P2rx7 Ptges3 Tnf 
Cckbr Edn1 Il18 Mapk1 P2ry1 Ptgs1 Trpa1 
Ccl12 Ednra Il1a Mapk14 Pdyn Ptgs2 Trpv1 
Ccr2 Faah Il1b Mapk3 Penk Scn10a Trpv3 
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Figure 13. Normalization of genes to the housekeeping gene, Rplp1.  Average CT value ranged 
from 18.5 to 20.1 in all samples. One-way ANOVA was not statistically significant amongst sham 
control, CCI drug-free (vehicle)-loaded nanoemulsion (DF-NE), or CCI celecoxib-loaded 
nanoemulsion (CXB-NE). P > 0.100. 
 
Figure 14. Gene expression amongst controls. Student’s t-test illustrated no 
statistically significant difference in the naïve and sham controls.  All samples failed 
to express Actb (a neuronal marker) or the inflammatory mediator IL-18. P > 0.100. 
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Chapter 4. Targeted COX-2 inhibiting nanomedicine results in pain-relief and 
differential expression of RNA in the dorsal root ganglia of injured male rats 
 
Submitted for publication in Molecular Pain – in press. 
 
4.1 Contributions Statement   
Andrea Stevens did all work in this chapter except where noted below: 
Muzamil Saleem, Graduate Student in Dr. John A. Pollock’s laboratory, dissected the 
dorsal root ganglia tissue from each animal.  
Brooke Deal, Graduate Student in Dr. John A. Pollock’s laboratory, constructed the heat 
map. 
Jelena M. Janjic, Associate Professor in Graduate School of Pharmacy at Duquesne 
University and co-founder of Duquesne University’s Chronic Pain Research Consortium, 
together with Dr. Pollock jointly designed the experimental approach for evaluating 
nanoemulsions in the CCI rat model for effects on neuropathic pain.  Dr. Janjic conceived 
and designed the overall macrophage-targeted drug delivery approach with 
nanoemulsions, the nanoemulsion composition and processes for fabrication. 
John A. Pollock, Professor of Biology and Principle Investigator, jointly designed the 
approach to assess the RNA transcriptome (with Andrea Stevens); all experiments were 
performed by Andrea Stevens under the guidance of John A. Pollock.   
The University of Pittsburgh Genomics Research Core (Dr. Jeannette Lamb) and 
Genomics Analysis Core (Dr. Uma Chandran) performed the RNA sequencing and 
carried out the initial data analysis. Both provided substantial guidance in the technical 
aspects of the project. 
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Original draft preparation by Andrea Stevens, additional writing and review was by all 
authors. 
4.2 Introduction 
Peripheral neuropathy is characterized as damage or injury to the peripheral 
nervous system resulting in spontaneous pain, allodynia, and mechanical and thermal 
hyperalgesia. Peripheral neuropathy is characterized as damage or injury to the peripheral 
nervous system resulting in spontaneous pain, allodynia, and mechanical and thermal 
hyperalgesia. A key mechanism underlying peripheral neuropathy is neuroinflammation, 
which is thought to be more efficient at driving chronic pain than systemic inflammation1 
as it involves the induction of the innate immune response as well as activation of the 
nervous system. Interactions between injured neurons, glia and infiltrating immune cells 
result in the production of effector molecules known as inflammatory mediators, all of 
which contribute to the hypersensitive state. It is previously known that the release of 
inflammatory mediators contributes to the induction and maintenance of neuropathic pain 
leading to the alteration of neuronal function both at the site of injury as well as at the site 
of neuronal cell bodies in the dorsal root ganglia (DRG) 5, 20, 46,91. Sensitization of the 
injured nerve and its associated neuronal cell bodies in the DRG may lead to long-term 
changes in gene expression in these cells, as suggested by RNA transcriptome studies156-
158. 
We have utilized a neuropathic pain model in male rats known as chronic 
constriction injury (CCI) of the sciatic nerve13, 14, 17, 18, 20, 46, 48, 49 159. Within hours of CCI, 
activation of the inflammatory response occurs, resulting in cellular and molecular 
expression changes at and near the site of injury20,160. The production of inflammatory 
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mediators along with activation of immune-like glial and immune-cells leads to shifts in 
cellular phenotypes, which further results in changes in gene expression that signals 
hypersensitivity and chronic pain in CCI animals94,160-162. We have previously reported on 
gene expression changes that occur at the site of injury at the sciatic nerve for mRNAs 
involved in neuroinflammation as well as in the associated dorsal root ganglia47,49. For 
example, we have previously shown that CCI associated hypersensitivity is associated 
with GAP43, NPY and TRPV1 mRNA expression changes in the DRG and furthermore, 
that TRPV1 protein expression changes in specific CCI DRG cell bodies of neurons that 
innervate the affected foot (identified by DiD retrograde labeling)47. In other studies, 
qPCR of mRNA expression in the injured sciatic nerve for 84 neuroinflammatory genes 
revealed several distinct differences between naïve, CCI and CCI treated with COX-2 
inhibition49.  Changes in the expression of mRNAs for cytokines and chemokines is 
consistent with the inflammation and corresponding infiltration of macrophages at the 
site of injury. Furthermore, the expression of transcripts for integrins involved with 
selective macrophage adhesion, as well as changes in neuronal and glia expression 
profiles was observed in the sciatic nerve dependent on the pain or pain-relieved state49. 
Administration of a macrophage-targeted COX-2 inhibiting nanoemulsion (CXB-NE) 
revealed that by targeting the production of PGE2 at the site of injury, pain relief is 
associated with a partial reversal of the gene expression profiles in the sciatic nerve when 
compared to tissue in a pain state49. Here we hypothesize that ultimately, the 
inflammatory milieu and tissue response at the site of injury is communicated to the DRG 
where changes in expression profiles are of particular importance given that these cells 
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are a component of primary sensory neurons, acting as the bridge between the peripheral 
and central nervous system.   
RNA sequencing allows for the exploration of the molecular and biological 
mechanisms of neuropathic pain through the analyses of whole transcriptome changes 
after nerve injury. Using RNA sequencing, several studies have previously examined 
pain-associated changes in expressed RNA in the DRG 77,78, 79, 165, 166. Here we report 
studying changes in the RNA transcriptome in the DRG when the CCI animal is 
experiencing significant pain as compared to a naïve animal and separately for animals 
that are treated with an anti-inflammatory nanoemulsion (COX-2 inhibiting Celecoxib-
loaded nanoemulsion). The nanoemulsion pain-relieving therapy selectively targets the 
cyclooxygenase-2 (COX-2) in macrophages, which is normally produced by these 
infiltrating cells and other activated cells at the site of injury, triggering pain29. The non-
steroidal anti-inflammatory drug (NSAID) Celecoxib (CXB) can be used to treat pain 
through the reduction of PGE2 following selective inhibition of COX-2. We have 
previously shown that localized delivery of a single micro-dose (0.24 mg/kg) of 
Celecoxib in nanoemulsion, which is incorporated in circulating macrophages/monocytes 
that then naturally accumulate at the site of injury provides up to 6 days of pain relief 46, 
48, 49,167. An important feature is that the nanomedicine delivers drug to the affected 
injured nerve46, 48, 49. This creates a unique opportunity to assess drug effects on cellular 
expression of RNAs when the drug is present at the distal injury and virtually no other 
parts of the peripheral nervous system.  With this approach, we have been able to reveal 
transcriptome changes in the DRG associated with CXB-NE.  Results show that DRG 
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RNAs in CCI treated males exhibit differential expression in association with changes in 
neurons, activated glial cells and multiple immune cells. 
 
4.3 Methods (See Chapter 2 and Appendix A for detailed methodology) 
4.3.1 Blinding statement  
 In order to avoid bias, I was blinded to the tissue collected, wherein another 
investigator collected all tissues and labeled them.  Tissue identities were not revealed 
until differential expression analysis 
4.3.2 Statistics  
Both raw P values and adjusted P values (also known as False Discovery Rate; 
FDR) were collected in this study using One-way ANOVA with Tukey’s post-hoc testing 
(GraphPad Prism v8). The traditional ‘raw P values’ included  ≤0.05 and ≤0.001 and the 
more stringent False Discovery Rate (‘FDR’) value ranged between ≤0.05 to 0.50. The 
FDR value’s interpretation is that with a raw P value of ≤0.05, 5% of 100 of those are 
false positives. Although the traditional raw P values can still be reliably utilized, with 
the FDR, we can say with confidence that these values are not false positives and 
increases the statistical likelihood. 
 
4.4 Results 
4.4.1 Mechanical allodynia in CCI rats and relief from hypersensitivity with a 
microdose of celecoxib nanoemulsion 
Consistent with previous studies, male rats experiencing sciatic nerve CCI 13, 46, 47, 
49 exhibit peripheral neuropathy in the ipsilateral hindpaw, which can be demonstrated 
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with footpad stimulation by von Frey monofilaments of increasing diameter. Behavioral 
testing of animals in this specific study illustrates a behavioral baseline (before animals 
receive surgery) of no significant difference in pain-like behavior among the populations 
in this study (Figure 6). Mechanical allodynia testing was not conducted on the day of 
surgery (day 1), but was continued on days 2-12 following CCI surgery.  All CCI animals 
used in this study exhibit behavior indicative of increasing hypersensitivity up to day 8 
(Figure 15), at which time the population was divided into naïve (no injection treatment), 
those that receive intravenous injection of celecoxib-loaded nanoemulsion (CXB-NE) 
and those that receive an intravenous injection of drug-free nanoemulsion (DF-NE, 
vehicle).  By day 10 (2 days post injection) animals receiving CXB-NE experience a 
statistically significant decrease in allodynia compared to those receiving vehicle (DF-
NE) (Figure 15).  There is no statistically significant difference between CCI CXB-NE 
behavior and naïve rats on days 11 and 12 indicating that the CCI animals were 
experiencing complete pain relief, whereas the CCI DF-NE animals continue to reflect 







FIGURE 15: Pain relief behavioral testing of the animals used in this study and 
timeline of events following treatment. Celecoxib-loaded nanoemulsion (CXB-
NE) reduces pain-like behavior in CCI animals within one day of administration 
compared to those receiving drug-free nanoemulsion as a vehicle (DF-NE). By 
day 12, injured rats given CXB-NE return to baseline behavior, whereas rats 
treated with CCI DF-NE continue to exhibit hypersensitivity (displayed as 
****). Data are expressed as a mean +/- SD.  Significance was determined by 
two-way ANOVA and post-hoc Tukey’s multiple comparison test (P <0.0001). 
Animals underwent mechanical allodynia on the ipsilateral hindpaw two days 
prior to surgery (days -2 and -1), a rest day on day 0 (day of CCI surgery) and 
day 1, and continued von Frey testing until euthanasia (day 12). Tail vein 
injection of nanoemulsion occurred as pain-like behavior plateaus on day 8. All 
animals were euthanized on day 12. Naïve n=3, CCI DF-NE n = 3, CCI CXB-
NE n=4.  
 
4.4.2 RNAseq Analysis 
To identify transcriptional profiles of RNA in DRG experiencing peripheral nerve 
injury, high throughput RNA sequencing was performed on total RNA extracted from 
DRG recovered from animals on day12 post CCI surgery. Male rats were administered a 
single dose of nanoemulsion (0.24 mg/kg) intravenously on day 8 post-surgery, a time 
when pain-like behavior approaches a maximum. Total RNA was isolated from L4 and 
L5 ipsilateral dorsal root ganglia (and combined) for uninjured naïve rats as well as 
injured CCI (DF-NE) and CCI CXB-NE drug-treated rats. With alignment to the Rattus 
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norvegicus reference genome, overall, the RNA sequencing of the naïve animal DRG 
produced 18.8 million raw sequences of which 12.7 million sequences mapped to the 
reference genome representing 21,152 transcripts from 14,717 genes (Table 6). The 
sequencing from CCI DF-NE animals represented 20.2 million raw sequences, 13.4 
million mapped to the genome corresponding to 21,218 transcripts for 14,753 genes 
(Table 6).  The analysis of the RNA from CCI CXB-NE DRG found 26.1 million raw 
sequences, 18.8 million of which mapped to the rat genome, corresponding to 22,541 
transcripts for 15,642 genes (Table 6).   
The analysis shows that between 30-40% of the RNAs detected correspond to 
exonic elements that code for mRNAs that can be translated into protein (Figure 16). 
Non-coding base pairs comprising intronic and intergenic elements consists of the 
majority of the represented sequence elements that were detected.  Intronic elements were 
expressed evenly in naïve and CCI DF-NE at 14%. A higher number of intronic 
sequences were detected for CCI CXB-NE at 21% overall (Figure 16).  Intergenic 
elements dominated the detected RNAs; naïve 48%, CCI DF-NE 49%, and CCI CXB-NE 





















M, Millions; Mapped pairs is the total number of pairs for which both ends map; Transcripts/Genes 









FIGURE 16: Distribution of gene elements. The mapped percentage of expressed 
exonic, intronic, and intergenic elements in naïve, CCI DF-NE, and CCI CXB-NE 
conditions. There is a significantly higher percentage of intronic reads in CCI CXB-NE 
compared to naïve and CCI DF-NE and a significantly lower percentage of intergenic 










Raw Sequences 18.8 x 106 ± 1.2 
x 106 
20.2 x 106 ± 2.9 
x 106 
26.1 x 106 ± 1.1 
x 106 
Mapped Sequences 12.7 x 106 ± 8.4 
x 105 
13.4 x 106 ± 2.2 
x 106 
18.8 x 106 ± 8.1 
x 105 
Transcripts Detected 21,152 ± 114 21,218 ± 524 22,541 ± 167 
Genes Detected 14,717 ± 90 14,753 ± 375 15,642 ± 118 
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A comparison between RNAs detected in DRGs from vehicle (DF-NE), versus 
COX-2 inhibited (CXB-NE), and naïve shows that 8,948 distinct genes are expressed in 
all three conditions. Gene biotype analysis was performed for those RNAs that were 
differentially expressed showing that the majority of transcriptional changes were 
observed in protein-coding genes (94%). The remaining differentially expressed RNAs 
are considered non-coding, being composed of 111 (1.2%) RNAs of known long non-
coding genes (lncRNAs), and as microRNAs (miRNAs; 0.07%). An additional 322 RNAs 
account for the remaining (2.79%) found within the samples but are not shown.  
 
4.4.3 Chronic constriction injury of the sciatic nerve leads to differential expression of 
RNAs in the DRG 
Table 7 shows the number of differentially expressed RNAs out of the 8,948 
RNAs that were analyzed for statistically significant differences in the comparisons of 
control animals (naïve) versus CCI DF-NE (drug-free nanoemulsion) treated rats, control 
versus drug-loaded nanoemulsion (CXB-NE) treated CCI rats, and between the treated 
and untreated pain states. A comprehensive table of all statistical values studied are in 
Table 7, including the traditional ‘raw P values’ of ≤0.05 and ≤0.001 and the more 
stringent False Discovery Rate (‘FDR’) value ranging between ≤0.05 to 0.50. The FDR 
value is the adjusted P value, and its interpretation is that with a raw P value of ≤0.05, 5% 
of 100 of those are false positives. Although the traditional raw P values can still be 
reliably utilized, with the FDR, we can say with confidence that these values are not false 
positives.  When compared to naïve-unoperated controls (pain free), CCI DF-NE (in 
pain) exhibited 183 total RNAs that were differentially expressed (raw P value ≤0.05) 
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and 16 with a raw P value ≤0.001.   When the analysis calculates the adjusted P value 
(FDR ≤0.05) zero genes were revealed as significant; however, when the FDR value is 
increased to ≤0.50 and a raw P value ≤0.001, 16 genes are differentially expressed; 9 
upregulated and 7 downregulated. Interestingly, these are the same genes within both 
statistical categorizations.  When comparing naïve (unoperated, pain free) to CCI CXB-
NE animals, 584 total RNAs are differentially expressed with a statistically significant 
raw P value <0.05 and 78 RNAs with a statistically significant FDR value (≤0.05). When 
comparing untreated injured animals, CCI DF-NE (pain) to CCI CXB-NE (COX-2 
inhibiting nanoemulsion treated pain relieved) 675 genes differentially expressed were 
shown to be statistically significant (raw P value <0.05).  Of those RNAs, 487 were 
upregulated in the pain relieved state (CCI CXB-NE), while 188 were downregulated (in 
CCI CXB-NE) (Table 7). When considering the adjusted P value (FDR) ≤0.05 for the 
comparison of CCI DF-NE (pain) to CCI CXB-NE (COX-2 inhibiting nanoemulsion 
treated pain relieved) 115 genes were found to be differentially expressed (Table 7). Of 
those 115 genes, 98 were upregulated in pain relief (CCI CXB-NE) and 17 were down 
regulated (in CCI CXB-NE) (Table 7). All further differential expression analyses in this 
work focuses on transcriptional differences amongst the pain state animals; all other data 
can be found in the Appendix B (Tables 14-20) section. Additionally, data reported in 
Appendix B includes all data with a significant P value (≤0.05). 
Comparison of detected RNAs from CCI DF-NE (pain) to CCI CXB-NE (pain-
relieved COX-2 inhibited) revealed significant changes in a total of 115 genes, 91 of 
which are considered protein-coding genes, 82 exhibiting elevated expression while pain 
is relieved, with 9 genes down regulated, and 24 representing non-coding transcripts; 57 
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of these genes are also shared with the naïve condition and their comparative expression 
levels visualized in Figure 17. 
Table 7: Numbers of RNAs differentially expressed utilizing multiple statistical values. Upregulated and 
downregulated values represent the latter condition compared (CCI DF-NE genes up- and down-regulated 
when compared to naïve, CCI CXB-NE genes up- and down-regulated when compared to naïve; and RNAs 





Naïve vs. CCI 
CXB-NE 
CCI DF-NE vs. 
CCI CXB-NE 
Raw P value Data       
Differentially Expressed (P≤0.05) 183 584 675 
Upregulated Genes 110 514 487 
Downregulated Genes  73 70 188 
FDR Data     
Differentially Expressed (FDR≤0.05) 0 78 115 
Upregulated Genes 0 72 98 
Downregulated Genes  0 6 17 
FDR Data     
Differentially Expressed (FDR≤0.10) 0 107 164 
Upregulated Genes 0 97 141 
Downregulated Genes  0 10 23 
FDR Data     
Differentially Expressed (FDR≤0.50) 16 316 550 
Upregulated Genes 9 287 487 
Downregulated Genes  7 29 63 
Raw P value Data    
Differentially Expressed (P≤0.001) 16 97 136 
Upregulated Genes 9 88 116 



















Figure 17. Heatmap showing log2 count per million (CPM) of the 57 genes shared across 
all three conditions with an adjusted P value (FDR) ≤ 0.05. 
 
 
































































Table 8 illustrates the detailed information of the 25 up-regulated protein-coding 
genes with the greatest fold-change in expression along with their associated molecular 
function (NCBI database). During COX-2 inhibition (CCI CXB-NE), Prosaposin-like 1 
(Psalp1) shows the highest expression change of 42-fold (essentially going from 
undetectable to expressed at a high level), with other notable genes including Leucine 
rich repeat transmembrane neuronal 1 (LRRTM1), transient receptor potential cation 
channel, subfamily V3 (TrpV3) and potassium voltage-gated channel subfamily J, 
member 9 (Kcnj9) exhibiting an increased expression after administration of the anti-
inflammatory Celecoxib-loaded nanoemulsion (Figure 17).  Table 9 illustrates those 
significant down regulated protein-coding genes in CCI CXB-NE, having a raw P value 
<0.05, with their protein function as reported by NCBI. Of the 17 down-regulated 
transcripts (FDR ≤0.05) in the pain relief state (CCI CXB-NE) compared to the pain-state 
(CCI DF-NE), 9 of which are protein-coding (Table 9). 
Of these differentially expressed genes in pain-state versus pain-relieved animals, 
4 are previously annotated long non-coding RNAs (lncRNAs), all of which experience an 
increased expression after CXB-NE (Table 10).  While these lncRNAs are annotated in 






Table 8: Top 25 upregulated protein-coding genes differentially expressed between CCI 
DF-NE and CCI CXB-NE rats with an FDR <0.05. 
 























function 1A histone 
chaperone 















Nudix hydrolase 16 
like 1 
 






type finger 10 
 
March10 27.061 0.04993 ENSRNOG00000
007084 
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Myosin heavy chain 
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BAX inhibitor motif 
containing 1 
 

















Tissue inhibitor of 
metalloproteinase 4 
 






























Table 9: Top downregulated protein-coding genes differentially expressed between CCI 



























family 10 member 1 
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transcription factor 2 




























U2 small nuclear RNA 
auxiliary factor 1 















Table 10: Differentially expressed annotated lncRNAs between CCI DF-NE and CCI CXB-NE rats with 











4.4.4 Functional enrichment analysis  
To further examine the mechanisms of differentially expressed RNAs within the 
pain states, Gene Ontology (GO, http://www.pantherdb.org) annotation and functional 
enrichment analyses were performed168. Gene Ontology relies on grouping known genes 
into categories of common function. The number of genes within each GO category 
encompasses all genes reported with significant enrichment (FDR ≤0.5) and that 
represent functional pathways already annotated (Table 11). This analysis shows that 
mRNAs exhibiting differential expression in this analysis are members of 14 functional 
pathways. We find there are up to ten differentially expressed mRNAs in the CCI pain 
state versus pain relief that are evident in these 14 distinct pathways (Table 11, Appendix 
B Table 21). Gene Ontology revealed the most significantly enriched ‘biological 
processes’ were the collection of “gene expression” (classified per its Gene Ontology 



















ER membrane protein 
complex subunit 9 























ENSEBML Gene ID 
AABR07033570.1 50.95 .0001 ENSRNOG00000056730 
AABR07033249.1 27.06 0.049 ENSRNOG00000055160 
AABR07062800.1 15.77 0.0046 ENSRNOG00000054861 
Rn60_1_2212.2 4.97 4.15E-12 ENSRNOG00000062127 
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class as GO:0010467) and response to drug (GO:0042493) (Appendix B Table 21). The 
most significantly enriched ‘molecular functions’ include molecular transducer activity 
(GO:0060089) and signaling receptor activity (GO:0038023) (Appendix B Table 21). 
The more specific, GO Slim analysis of molecular function reveals G-protein coupled 
receptor activity (GO:0004930) and transmembrane signaling receptor activity 
(GO:0004888), both of which are noted in GO molecular function as well. Twenty 
statistically enriched cellular components are shown in the pain state when CXB-NE and 
DF-NE animals are compared. Notable cellular components include membrane-bounded 
organelle (GO:0043227), intracellular membrane-bounded organelle (GO:0043231), and 
cytoplasmic part (GO:0044444) (Appendix B Table 21).  
KEGG signaling pathway analysis comparing 675 differentially expressed genes 
(raw P value 0.05) amongst CCI DF-NE and CCI CXB-NE conditions displays a single 
statistically significant KEGG pathway of Calcium signaling (KEGG:04020). When drug 
is present (CCI CXB-NE versus naïve) between the 584 differentially expressed genes 
(raw P value 0.05), cell cycle (KEGG:04110) show KEGG pathway expression, 
however  no significant KEGG signaling pathways between CCI DF-NE and naïve 
conditions are noted. Reactome pathway (www.reactome.org) analysis169 shows that 
when COX-2 is inhibited in macrophages, there is a statistically significant activation of 
two pertinent Reactome pathways: neutrophil degranulation (R-RNO-6798695) and the 
innate immune system (R-RNO-168249). Furthermore, PML-RAR alpha-regulated 
adapter molecule 1, Pram1, is known to be involved in neutrophil degranulation and has a 
fold change of 8.73 in the COX-2 inhibiting Celecoxib-loaded nanoemulsion (CXB-NE) 
pain relieved state. Expression changes in Importin 7 (Ipo7) and Strawberry Notch 
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Homology 2 (Sbno2) are two genes involved in the activation of the innate immune 
system. Sbno2 is reduced in expression when CXB-NE is present (fold change 0.70) and 
Ipo7 is increased (6.9 fold change).   
Table 11. Gene Ontology (GO) Panther functional pathway analysis. The number of genes within the 
previously annotated functional pathways with significant enrichment (FDR ≤0.5. Includes genes 
differentially expressed between CCI DF-NE and CCI CXB-NE animals. Displays genes with an FDR 




4.4.5 Genes previously implicated in neuroinflammation 
 
Several genes that have been previously reported to exhibit differential expression 
in neuroinflammation and/or the neuropathic pain were independently revealed in our 
analysis as summarized in Table 12 and Table 13.  Table 12 illustrates mechanism-
specific genes expressed in the pain state compared to pain relief after injection of COX-
Functional Pathway  Genes Involved 
5HT2 type receptor mediated signaling 
pathway (P04374) 
Gna11, Slca4, Plcd3, Cacna1c, Htr2b 
Angiogenesis (P00005) Pla2g4b, Fos, Pld2, Apc, Angpt2, Sphk2, Cryab 
Blood coagulation (P00011) F2rl2 
Cytoskeletal regulation by Rho GTPase 
(P00016) 
Myh6 
FAS signaling pathway (P00020) Parp2 
Gonadotropin-releasing hormone receptor 
pathway (P06664) 
Gna11, Ptger1, Fos, Cacna1c, Itpr2 
Heterotrimeric G-protein signaling pathway 
(P00026, P00027) 
Kcnj9 
Huntington disease (P00029) Rhog, Fos, Htt, Grin3b, Dync1h1, Optn, Arf6 
Inflammation mediated by chemokine and 
cytokine signaling pathway (P00031) 
Myh6, Pla2g4b, Gna11, Rhog, Myh7b, Camk2g, 
Adcy5, Ifngr1, Itpr2 
Integrin signaling pathway (P00034) Parva, Arhgap26, Lama5, Actn3, Col10a1, Arf6, 
Parva, Lama3, Col5a3 
Muscarinic acetylcholine receptor 2 and 4 
signaling pathway (P00043) 
Kcnj9 
Oxidative stress response (P00046) Pla2g4b 
Nicotinic acetylcholine receptor signaling 
pathway (P00044) 
Myh6, Myo7b, Myo19, Myo18b, Myh7b, 
Chrnb1, Cacna1c 
TCA cycle (P00051) Aco2 
VEGF signaling pathway (P00056) Pla2g4b 
Wnt signaling pathway (P00057) Arr3, Myh6, Gna11, Wnt4, Myh7b, Apc, 
Pppr2r5b, Myh6b, Cdh15, Itpr2, Arr3, Smarcd3 
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2 inhibiting CXB-NE, with upregulation and downregulation noted with arrow symbols. 
Table 13 shows previously identified cell-specific expression with specific changes 
following CXB-NE. Based on gene ontology analysis using the Gene Expression 
Database34, genes with overlapping expression in the pain and immune responses include; 
the purinergic ligand-gated calcium channel P2rx4, the G-protein coupled PGE2 receptor, 
Ptger1, and IL-16, a pro-inflammatory cytokine that is chemotactic for CD4+ T-
lymphocytes. Genes that normally exhibit neuronal expression and that are involved with 
the  overall neuroinflammatory response include the sodium channels Scn8a/Nav1.6 and 
Scn11a/Nav1.9; the calcium channels Trpv1, Trpv3; and the NMDA receptor 
Grin3b/NMDAR3b. Significant expression changes occur when celecoxib (CXB) is 
administered in the pain-state and include mRNAs associated with axonal growth cone 
(Flrt3), growth cone (LRRTM1), axon guidance (Flrt3), regulation of axon guidance 
(Mycbp2), response to axon injury (Flrt3), and axonogenesis (Map1a, Dst). Molecular 
expression of genes involved in the immune response are noted including the β-arrestin 2 
(Arrb2). Transforming growth factor β receptor signaling pathway activation including 
importin 7 (Ipo7) involved with the innate immune response, strawberry notch 2 (Sbno2) 
involved with macrophage activation, and PML-RAR alpha regulated adaptor molecule 1 
(Pram1) a component of integrin-mediated signaling as well as T cell receptor signaling, 
regulation of neutrophil degranulation, and lysine (K)-specific demethylase 5D (Kdm5d), 
which is involved with T cell antigen processing and presentation.  SH2B adaptor protein 
3 (Sh2b3) a component of the cellular response to chemokines and negative regulation of 
chemokine-mediated signaling pathways and Fanconi anemia complementation group C 
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(Fancc) involved in myeloid cell homeostasis. All differentially expressed gene 





Table 12: Differentially expressed genes in CCI DF-NE versus CCI CXB-NE involved in underlying 
neuroinflammatory pain mechanisms categorized using molecular functions. Increased and decreased 



























































































































































































































































































































































Table 13: Cell-specific expression of differentially expressed genes in the pain state compared to pain relief. 










































































































































































 None  Arr3 None  Omg 
Syne2 











































































































































None None None Cryab Pla2g
4b 
None 





4.4.6 Validation of genes by qPCR  
Quantitative reverse transcription PCR was conducted on RNA purified from 
DRG amplified with primers for TrpV3, Scn8a, Pram1, IL-16, Ipo7, Flrt3, and Ifngr 
(Figure 18). All of these genes exhibited elevated RNA expression in the CCI DF-NE 
pain-state as compared to naïve when using RNA sequencing. All of these mRNAs when 
individually assessed by qPCR also exhibited elevated expression in the CCI CXB-NE 
pain-treated state compared to when the animals are in a pain state (CCI DF-NE).  These 
results confirm the observation that there is a shift in expression for these transcripts 
when CXB-NE is present. 
 
 
Figure 18. Individual qPCR analysis of distinct genes showing differentially 
expressed in the pain (CCI DF-NE) compared to the pain-relieved (CCI CXB-NE) 
state.  CCI animals given CXB-NE exhibit increased expression of 7 known 










4.5 Discussion  
RNA sequencing allows for the exploration of an aspect of the molecular and 
biological mechanisms underlying neuropathic pain through the analyses of 
transcriptome changes. Identifying gene expression changes in the pain state (CCI DF-
NE) is important in defining the mechanism of neuropathic pain and the sustained 
chronic pain response that ensues long after injury has occurred. Up until recently, 
relevant gene expression studies have been limited to individual genes and subset of 
genes via quantitative PCR and microarrays47, 49, 160.  Although these techniques are vital 
in gene expression studies, they can only be utilized to identify known RNA transcripts. 
RNA sequencing differs in that it allows for the identification of expressed RNAs not 
previously known.  Thus, researchers have begun to reveal RNA transcriptome changes 
in the affected tissues underpinning pain in small animal models 157,158, 163, 164, 166. 
Mounting evidence indicates that differential expression of transcripts in the DRG coding 
for ligand-gated ion channels, cell signaling molecules, G-protein coupled receptors, and 
neuroimmune-specific precursors are all involved in the establishment of the perceived 
pain158,164, 165. We sought to further this analysis by assessing whole transcriptome 
changes in the DRG for animals experiencing pain relief from a state of modelled 
neuropathic pain as a result of treatment with the COX-2 inhibiting NSAID, celecoxib 
(CXB) packaged in nanoemulsion.  The effective dose of celecoxib is a  micro-dose, 
delivering COX-2 inhibiting CXB-NE to the site of injury.  We reveal a novel drug effect 
on the differential expression of RNAs associated with neurons, activated glial cells, and 
multiple immune cells in the proximal dorsal root ganglion. Additionally, we use 
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PANTHER Gene Ontology and functional enrichment analyses to reveal 14 distinct 
pathways implicated when CXB-NE is given to CCI animals.  Reactome pathway 
analysis indicates an altered neuroinflammatory response with changes in neutrophil 
granulation and the innate immune system within the cell bodies of injured rats.  
Moreover, we use qPCR to explore a subset of genes that show elevated expression in 
CCI rats experiencing a state of pain-relief following administration with CXB-NE, 
compared to those in a pain state (drug-free nanoemulsion).  This subset of genes has 
been previously reported in the literature to be involved in neuroinflammation 20,49,79, 
165,80,240. RNAs revealed in this current study are inclusive of both protein-coding 
(mRNAs) and non-protein-coding, including recently annotated long non-coding RNAs 
(lncRNAs).  Overall, the impact of a precise drug inhibition of COX-2 and the 
corresponding reduction in PGE2 production at the site of injury is to broadly influence 
RNA expression in multiple cell types of the corresponding DRG. 
 The main achievement of this study is the demonstration that treatment of 
neuropathic pain in animals achieved by targeted inhibition of COX-2 in macrophages 
leads to changes in gene expression profiles throughout the affected peripheral nervous 
system; not just confined to the site of injury49 or within infiltrating macrophages. For 
context, previous studies using systemically, intrathecally, or subcutaneously delivered 
celecoxib demonstrated a decrease in PGE2 and moderate attenuation of allodynia in CCI 
animals241, 242, whereas upon intraneural injection hypersensitivity persisted as well as 
PGE2 levels48.  Our studies use a theranostic nanoemulsion, which an anti-inflammatory 
NSAID component (Celecoxib) utilized for treatment and a near infrared fluorescent dye 
(NIRF) to localize the nanoemulsion in vivo 46,48,49. Nanoemulsion is readily cleared from 
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the bloodstream and introduced to the DRG by infiltrating macrophages48, 73, 196, 243. We 
hypothesize that the observed gene expression changes in the DRG is due to targeted 
COX-2 in infiltrating macrophages upon phagocytosis of the nanoemulsion from the 
bloodstream46,48,49.  In accord with previous studies, a single dose (~0.24 mg/kg) of 
Celecoxib-loaded nanoemulsion (CXB-NE) one week after CCI surgery leads to in a 
change in the number of infiltrating macrophages, revealing on day 12 while the DRG 
has infiltrated macrophages, the density is 40% of what is seen in the injured sciatic 
nerve46. Also, while 63% of the macrophages in the sciatic nerve have nanoemulsion, 
only 19% of the macrophages in the DRG carry nanoemulsion46. From a behavioral 
standpoint, in CCI CXB-NE animals, there is a reduction in hypersensitivity within a day 
of intravenous injection and a near reversal in hypersensitivity by day 12, at which time 
tissue collection occurred46,48,49. Furthermore, our group (Saleem et al 2019) 46 have 
shown that peak pain-relief occurs on the third and fourth day after CXB-NE treatment 
and persists up to 6 days after administration46. Although gene expression changes were 
examined on day 12, it is likely that different subset of genes will be expressed beyond 
this time point.  Saleem et al.46 also demonstrated shifts from M1 to M2 phenotypes 
within the injured nerve when CXB-NE is administered compared to CCI animals 
receiving drug-free nanoemulsion (DF-NE), revealing an increase in the number of M1 
macrophages in CCI DF-NE animals on day 12 46. Alternatively, the number of M2 
macrophages is significantly increased in injured animals receiving CXB-NE on day 12, 
with a parallel production on day 18 in both pain-treated and untreated pain states5. At 
day 12, there are nearly twice as many infiltrating macrophages in the injured sciatic 
nerve than the corresponding DRG; interestingly, about 60% of the sciatic nerve 
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macrophages have nanoemulsion, whereas in the DRG only about 20% carry 
nanoemulsion46. When CXB is present, the number of macrophages at day 12 in the in 
sciatic nerve is nearly halved, but is unchanged in the DRG46. By day 18, the number of 
macrophages in the DRG increases about 3-fold, while it remains unchanged in the 
injured nerve46. Given that analgesia persists until around day 15, this may indicate the 
induction and persistence of gene expression that influences the milieu of cells at the 
DRG long term.    
Clearly transcriptional changes are not restricted to changes in expression of 
genes associated with the production of PGE2 in macrophages, instead transcriptional 
changes are evident for other neuroinflammation-associated genes and genes expressed in 
other cell types. The 25 genes with the greatest increase in expression are protein-coding 
genes associated with CCI CXB-NE pain relief (compared to CCI DF-NE) are illustrated 
in Table 8, however, the biggest differences may not be the most important in terms of 
underlying biology.  Tables 12 and 13 refer to genes previously implicated in 
neuropathic pain and neuroinflammation, which display varying degrees of altered 
expression in this study. Genes known to be involved in neuroinflammation and found to 
be responsive to drug therapy in this study are listed in Tables 12 and 13.  Among the 
differentially expressed RNAs, Phospholipase A2 Pla2g4b (involved in the hydrolysis of 
phospholipids in the membrane), G-protein coupled Prostaglandin E receptor type 1 
Ptger1 and Prostaglandin D2 Synthase Ptgds are involved in the production of PGE2 after 
breakdown of the cell membrane.  We also find differences in Coactosin-like (COTL1), 
which binds to F-actin and interacts with 5-lipoxygenase in leukotriene biosynthesis. All 
of these are associated with the metabolism of arachidonic acid and eicosanoids, which 
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are associated with COX-2 inhibition; and they show differential expression when CXB-
NE is present in CCI animals.   
We also know that on day 12, day of tissue collection, CCI animals are known to 
be undergoing peripheral nerve regeneration46,76. Our data shows that genes involved in 
this process are affected when drug-loaded nanoemulsion is applied to the pain state, 
possibly leading to an increase in factors contributing to nerve regeneration. Fibronectin 
leucine rich transmembrane protein 3 Flrt3, and leucine rich repeat transmembrane 
neuronal proteins LRRTM1, LRRTM2, and LRRTM3 are all differentially expressed and 
are known to be involved in axon outgrowth and synapse formation170.  
One way to think of these observations is in terms of a potential shift in cell fate, 
which may be occurring among several cell types during the chronic inflammatory state. 
The transition to chronic pain relies on significant changes in gene expression.  Similarly, 
when COX-2 is inhibited in macrophages during the neuroinflammatory response, the 
shifts in RNA expression can represent realignment of cellular function representing 
pain-relief and possibly shifts in cell fate as was seen in the macrophage transition from 
M1 to M2 in the sciatic nerve in response to CXB-NE46.  Transcriptional and protein 
changes are noted in both the damaged sciatic nerve and the dorsal root ganglia46,47, 49, 244.  
We have previously shown that intravenous injection of CXB-NE one week post injury, 
results in differences in macrophage expression at the injured sciatic nerve and in the 
lumbar DRGs46 as well differential expression of a subset of mRNAs in the sciatic nerve 
compared to the DRGs49. Here we show when COX-2 is inhibited, there is an increased 
expression in inflammatory molecules (pro-inflammatory cytokines IL-12, Il12rb2, IL-
16) and other RNAs known to be involved with cells associated with the neuro-
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inflammatory response including Unc13d involved in intracellular trafficking and 
exocytosis, also Pram1 an adaptor protein involved with T-cell receptors mediated 
signaling, Sh2b3 an adaptor protein involved with regulating signaling pathways and 
Ipo7 a nuclear transport protein.  In addition, there is a down-regulation in ion channels 
in CCI DF-NE (Scn8a, Scn11a, Scn3b, Clcn7, Kcnj9, Kcnt1, Kcnmb1, Kcne3, Kcnh6, 
Kcnab1, Trpv1, Trpv3, Cacna1c, and Cacna1d) ranging from a fold change of 2.5 to 20.7, 
when the raw P value is ≤0.05. Given these changes, it appears that select RNAs 
associated with neuronal expression in the DRG shift from a normal sensory neuron to a 
hypersensitive pain-responding neuron after chronic constriction injury. Even after a 
pain-relieving behavioral change is evident after CXB-NE is given, RNAs typically 
associated with inflammation continue to exhibit increased expression on day 12.  In 
comparison, to the injured sciatic nerve, when given CXB-NE, neuroinflammatory-
associated RNAs show downregulation, with a decreased expression of Scn9a and TrpV3 
and an increase expression in Cacna1b49. Interestingly a comparable RNA sequencing 
studying examining sex differences at the DRG after CCI revealed a modest upregulation 
of Scn9a79.  It is important to note that gene expression differences exist in the DRG and 
sciatic nerve after CCI.  We have shown previously that IL-6, IL-1, Scn9a/Nav1.7, 
Grin2b/NMDAR2b, Itgam/Cd11b, Moab, Tac1, and Trpv3 are all downregulated in the 
injured sciatic nerve after CXB-NE administration, whereas Cacna1b is upregulated49. 
Similarly, some genes and their homologs exhibit differential expression in the DRG 
under nanoemulsion treatment.  For example, in the DRG, there is an increased 
expression of the Calcium channel Cacna1b and sodium voltage gated channels Nav1.6 
and Nav1.8 after treatment with CXB-NE. A recent study in mice explored how DRG 
 
 102 
macrophage activation may influence sensory neurons and found a significant 
upregulation of IL-1 only in CD11b macrophages, with no evidence of IL-1  
expression in satellite cells or sensory neurons244.  In addition, there is a shift in RNA 
expression typically associated with Schwann cells, macrophages, and mast cells in their 
inflammatory functions. RNA expression changes in cell adhesion molecules (Flrt3, 
Elmo3, Card14, Dst, Parva, Myo7b, Myo19, Itgb1bp1, Thsb3) is also seen, suggesting 
the extracellular milieu for the cells in the DRG, including the primary sensory neurons, 
is changing. An increase in expression of Flrt3 in the DRG has been noted in previous 
RNA sequencing studies79. Furthermore, Mast cells may be in a degranulating state in the 
pain-relieved state, as indicated by an increase in Pram1 and Unc13d expression. We 
have previously shown a decrease in Mcpt1 mast cell degranulation at the site of injury 
when COX2 is inhibited by nanoemulsion CXB-NE 46,49. 
This study shows decreased expression of TrpV3 RNA in the DRG while in the 
pain state (DF-NE) as compared to animals with COX2 inhibited by CXB-NE that are 
experiencing pain relief. Interestingly, we have previously shown the opposite effect in 
the sciatic nerve where a significant decrease in TrpV3 gene expression is evident in CCI 
CXB-NE animals49. One interpretation is that TrpV3 expression at the injured sciatic 
nerve is prominent due to its activation by arachidonic acid metabolites in inflammatory 
conditions. A 2006 study by Zhu and colleagues114 shows that TrpV3 is potentiated by 
unsaturated fatty acids such as the activation of arachidonic acid, which is targeted 
specifically by CXB. Furthermore, a study by Freichel (2012)171 and colleagues 
demonstrated that activated mast cells exhibit increased expression of Trp proteins, 
associated with pain and degranulation.  
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Neuro-immune cross-talk may be associated with the increased expression of 
F2rl2 a 7-Transmembrane G-Protein coupled receptor, Pram1, which is associated with 
T-cell receptor mediated signaling, and Ipo7 a nuclear transport protein.  These 
observations are consistent with the REACTOME analysis, displaying activation of 
neutrophil degranulation (R-RNO-6798695) and activation of innate immune system (R-
RNO-268249) pathways. Neuroimmune signaling further mediated by the purinergic 
receptor P2rx4 (expressed by neurons and immune cells) may lead to the increase in 
neutrophil and M1 macrophage infiltration after nerve injury as seen when given a 
systemic COX-2 inhibitor245. Although we have previously reported in vitro and in vivo 
specificity of the nanoemulsion to monocytes72, activation of the innate immune system 
may lead to an increased neutrophil response after CCI. Within injured sciatic nerve 
tissues, we have previously identified pain and CXB-NE pain-relief shifts in M1 and M2 
macrophage phenotype and mast cell degranulation activity using the same experimental 
conditions at day 12 46. Considering all of the RNA expression data from both the injured 
sciatic nerve15 and associated DRG cell bodies reported here, we observe that due to the 
CCI damage of the associated axons and surrounding cells in the sciatic nerve, RNA 
expression changes are apparent at not only the injured sciatic nerve 46,48,49, but also in the 
cells of the DRG. 
In addition to differential expression of protein-coding RNAs expressed in the 
DRG, non-coding RNA expression changes was investigated.  The role of non-coding 
RNAs remains an important aspect of pain research as these RNAs, actively participate in 
processes that coordinate gene expression172.  One class of non-coding RNAs are long 
non-coding RNAs (lncRNAs), which are greater than 200 nucleotides in length, highly 
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abundant and multi-functional. lncRNAs have the capacity to regulate gene expression173. 
Interestingly, we have identified 4 lncRNAs that are differentially expressed when 
celecoxib-loaded nanoemulsion is administered (Table 10). Each of these lncRNAs 
exhibit significant expression changes ranging from a nearly 5-fold increase to a 50-fold 
increase in CCI- CXB-NE (Table 10) and have only been recently annotated in 
ENSEMBL.  
In summary, peripheral nerve injury resulting in behavioral hypersensitivity 
causes changes in RNA expression at the site of injury49, as well as differential RNA 
expression evident in the corresponding cell bodies of the dorsal root ganglia.  We also 
demonstrate that introducing CXB-NE not only reduces hypersensitivity46,48,49, and 
reduces inflammation at the site of injury46,48,49, the drug therapy is associated with 
widespread changes in the transcriptome of various cell types at the site of injury and the 
cells of the corresponding dorsal root ganglia.  Even though celecoxib specifically 
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5.1.1 Neuropathic injury involves a dynamic inflammatory response involving the 
neuro-immune triad 
I have hypothesized that neuropathic conditions will elicit RNA expression changes 
representative of neuroinflammation, the pain response, and the underlying neuroimmune 
cross-talk. Specifically, these expression changes would be apparent at the site of injury 
within the inflamed sciatic nerve and its’ connection to the central nervous system, the 
cell bodies of the dorsal root ganglia (DRG) as well as within other aspects of the neuro-
immune triad, including neurons, glial cells and immune cells such as macrophages and 
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Schwann cells.  We have demonstrated that altered RNA expression profiles, inclusive of 
protein-coding and non-coding molecules, occurs in both site of the injured nerve as well 
as in the DRG.  Although we cannot say for certain whether these specific RNAs are 
found within a given cell type within the sciatic nerve or DRG tissue, we can speculate 
on their expression based on associations established in the literature. More studies are 
required to determine which cell type is expressing each given RNA and is discussed in 
the Future Studies subsection.   
It is previously known that neuropathic injury involves a dynamic inflammatory 
response mediated by multiple cell types both at the site of injury (in the sciatic nerve) 
and in the DRG19,27. There is an increased dialogue between immune cells, neurons, and 
glia that results in behavioral hypersensitivity interpreted as pain. The resultant 
neuroimmune cross-talk at and near the site of injury perpetuates its effects in two ways.  
Firstly, the sutured chronic injury of the nerve leads to a change in the microenvironment 
causing a local neuroinflammation19. Neuroinflammation consists of both phenotypic and 
structural changes to resident immune, glial and neuronal cells as well as the activation of 
infiltrating immune cells91.  Each cell type is able to influence the neuroinflammatory 
response through the production and release of inflammatory mediators such as 
cytokines, chemokines, neurotrophic factors, Substance P, and prostanoids and the 
increased expression of ion channels and cell surface receptors91.  Second, there is 
subsequent healing and axonal regeneration of the injured peripheral nerve fibers12,174.  
This overall process is initially marked by a degeneration phase, known as Wallerian 
degeneration, within 3-5 days of injury174, promptly followed by an extensive period of 
regeneration.  During each of these phases, both immune and glial cells undergo 
 
 107 
phenotypic shifts assisting in the initial degradation and phagocytosis of debris at and 
surrounding the site of injury followed by neuroimmune signaling of pro- and anti-
inflammatory mediators12. One of the major goals of our study is to explore the 
underlying neuroimmune response, in terms of RNA expression changes, following nerve 
injury caused by chronic constriction (CCI). 
Differential expression of RNA within the injured sciatic nerve as well as in the cell 
bodies of the DRG is evident 12 days after injury. Assessment of the differential 
expression of mRNAs in CCI sciatic nerves was performed by quantitative PCR for 
several genes previously identified as associated with neuroinflammation.  We found 
many that mRNAs exhibited differential expression associated with CCI pain as well as 
pain relieved states. The injured sciatic nerve exhibited an increased expression of 
macrophage-related genes in the pain state (CCI DF-NE) compared to the sham control 
and pain relieved animals (CCI CXB-NE) (as discussed later in Section 5.1.2). Other 
immune-cell related genes exhibit differential expression when compared to the sham 
control and between the CCI conditions including T cell marker Cd4, cytokines IL-6, IL-
18 and IL-1β.  Chemokine receptor Cx3cr1, Toll-like receptor 2 Tlr2, and Tumor necrosis 
factor Tnf1. 
Helper T cell marker Cd4 gene exhibited an elevated expression in the injured nerve 
(fold change 8.3) as compared to the un-injured control.  When pain is relieved, Cd4 
mRNA expression was still elevated, though reduced slightly (fold change of 7.3) relative 
to un-injured control state. Although not a statistically significant difference in 
expression, there is a downregulation of Cd4 in CXB-NE pain-relieved animals, possibly 
indicating that fewer T cells were present at the site of injury after the attenuation of 
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COX-2 in macrophages.  This may be a significant finding as a number of studies have 
implied a role of helper T cells in the pathogenesis of pain35-37, with a more significant 
interplay in the neuroimmune triad in female animals167, 193 (see Section 5.2 for future 
studies).  
Differences in RNA expression are noted between CCI DF-NE and sham controls, 
illustrating that numerous genes alter their expression in response to the 
neuroinflammation caused by CCI.  Notable changes include the pro-inflammatory 
cytokines associated with multiple cell types (neurons, macrophages, Schwann cells) 
including IL-6, IL-18 and IL-1.  IL-1β, a pain-induced cytokine, exhibits a significant 
(18 fold) increase compared to the sham control. IL-1β is a tightly regulated cytokine 
produced predominantly by myeloid cells218.  It is synthesized as an inactive precursor 
molecule that must be cleaved to initiate biological activity involved in the immune 
response130. Pattern recognition receptors interact with damage-associated molecular 
patterns (DAMPs) secreted in response to tissue injury, leading to the cleavage of IL-1β 
to its active form130. Okamoto and colleagues128 examined cytokine mRNA expression in 
the sciatic nerve at several time points following nerve injury. They found that at day 14, 
IL-1β was upregulated (30 - fold increase) in expression in the CCI pain state.  Although 
the relative expression is much higher in the Okamoto128 study than what is observed 
here, we nonetheless found that IL-1β exhibited elevated differential expression. The 
differences between our procedure and that of Okamoto and co-workers can account for 
the differences in observed expression levels, where methods of RNA isolation and 
extraction as well as experimental parameters for the qPCR reaction can account for the 
observed differences in the results.   
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Both IL-1β and IL-18 are involved in inflammasome signaling upon activation of the 
innate immune response. This response is mediated by pattern recognition receptors that 
are able to recognize danger-associated molecular patterns (DAMPs) upon nerve 
injury134, inducing gene transcription and translation of IL-1β and IL-18 inactive 
precursors (pro- IL-1β and IL-18)236.  When DAMPs are recognized, IL-1β and IL-18 are 
produced by inflammasomes219,234. As noted earlier, this study shows that both of these 
genes exhibit an elevated RNA expression after nerve injury.  Vasudeva et al.20 
established an increase in protein expression after CCI of both IL-18 and IL-1. Their 
work also demonstrated, using Bayesian network analysis, that IL-18 acts as a central 
node involved in inflammatory signaling in the CCI pain response. This represents a 
unique activation of the inflammasome. The inflammasomes are a group of multimeric 
protein complexes that are triggered by a range of substances during tissue damage93.  
Inflammasomes were first described in 2002239 as a cytosolic caspase-activating protein 
complex in macrophages, but now are known to be found in multiple cell types including 
neutrophils, mast cells, and T cells236. It is currently known that inflammasome 
activation, in turn, leads to the activation and proteolytic cleavage of IL-18 and IL-1β 219. 
While our research illustrates that genes involved in inflammasome activation and 
signaling are being expressed nearly two weeks after nerve injury, these results do not 
directly address whether or when the inflammasome is activated.  However, this may be 
indicative of inflammasome signaling being a pertinent player involved in the ongoing 
maintenance or persistence of pain.  
An extensive cross-talk is thought to be occurring between the nervous and immune 
systems, in which specifically activated nociceptors and immune- and immune-like glial 
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cells engage in multi-directional signaling, possibly leading to the persistence of pain137. 
Signaling occurs through the local and persistent production and release of a milieu of 
inflammatory mediators by neurons, macrophages, monocytes, neutrophils, mast cells, 
Schwann cells, and satellite glial cells. Our results show that mRNA expression in the 
injured sciatic nerve is altered for mRNAs typically associated with neurons, including 
Actin- Actb, receptors for inflammatory mediators Calca, Ntrk1, Comt, endothelin 
receptor Ednra, glutamatergic receptors Grm1 and Grm5, ion channels Kcnj6, Kcnq, 
Scn9a/Nav1.7, TrpV3, and Cacna1b/Cav2.2. In addition, a subset of genes previously 
associated with multiple cell types and neuroinflammation showed marked expression 
differences when drug therapy is present, including the inflammatory mediators Glial cell 
derived neurotrophic factor GDNF (associated with Schwann cells and neurons), 
cytokines IL-18, IL-1, IL-6 (associated with circulated monocytes, macrophages, 
Schwann cells, and neurons) , monoamine oxidase B Maob, and tumor necrosis factor 
Tnf as well as their associated receptors (Chemokine C-X3-C motif receptor Cx3cr1)49. 
Our RNAseq study further demonstrates an altered expression of RNAs previously 
associated with neuroinflammation (Trpv1, TrpV3, Scn8a, Scn11a, Kcnj9, Cacna1c, IL-
12, IL-16) as well as nerve regeneration (Flrt3, LRRTM1, LRRTM2, LRRTM3)49.   
Cx3cr1 is a single ligand, membrane-tethered chemokine CX3CL1 (fractalkine)53. All 
circulating monocytes express the fractalkine receptor and it is known to exhibit elevated 
expression in the pain state220, particularly in the dorsal root ganglia and spinal cord as 
well as in macrophages in the periphery following injury221. The Cx3cr1 gene exhibits no 
significant difference in expression in sham relative to CCI CXB-NE but is significantly 
downregulated when CXB-NE is present.  A fold change in pain-relieved animals 
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decreases nearly 5-fold compared to pain state animals (CCI DF-NE).  This data suggests 
that by inhibiting COX-2 in macrophages, there is a subsequent decrease in fractalkaline 
signaling and a reduced production of its receptor Cx3cr1 in the periphery.   
Ensheathing Schwann cells (as well as neurons and macrophages) at the site of 
injury are known to actively secrete IL-6127.  We found that IL-6 mRNA expression is 
elevated post-CCI in the drug-free ipsilateral sciatic nerve.  However, IL-6 is recognized 
as a marker in nerve regeneration122. With a significant downregulation of IL-6 when 
COX-2 inhibiting nanoemulsion is present in macrophages at the sciatic nerve, we would 
assume less nerve regeneration is occurring when drug is present.  However, it is clear 
that IL-6 is not the only inflammatory mediator produced that is involved in regulating 
axonal regeneration.  
In terms of the role of neurons in the neuro-immune triad, we have also successfully 
demonstrated that neuronal injury in the periphery leads to changes in gene expression at 
the site of injury and in the corresponding ganglia, which may be distinct. Peripheral 
sensory axons of the sciatic nerve have their cell bodies in the DRG, but it is at the distal 
axon, centimeters away from the DRG cell-bodies, which are injured and thus the source 
of noxious stimulation. Knowing that pain signals begin as noxious stimuli detected by 
nociceptors in peripheral nerve fibers of DRG primary sensory neurons, which are then 
transmitted to the central nervous system, DRGs act as a bridge between pain sensation in 
the periphery to response in the spinal cord and brain that are interpreted as pain. It 
appears that depending on whether the RNA is being produced to function within the cell 
bodies or is being transported to the distal nerve fibers for various functions, RNA 
expression may be different.  This observation is supported with the results on the 
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production of the voltage transient receptor potential 3 (TrpV3) mRNA in both the sciatic 
nerve and DRG.  TrpV3 is downregulated in both neuronal tissues after administration of 
CXB-NE, suggesting it may be actively transported from the nucleus of the DRG to the 
distal axons in similar levels in response to nerve injury.  Another gene typically 
associated with neurons includes the tachykinin pain molecule precursor gene, Tac1. 
Tac1 leads to the generation of substance P, neurokinin A, neuropeptide δ, and 
neuropeptide γ 143,144 which are mainly expressed in neuronal tissues in the central 
nervous system and in primary afferent neurons in the peripheral nervous system144. 
However, it has also been shown that substance P and neurokinin A are expressed in non-
neuronal cells including macrophages and circulating monocytes144. This suggests an 
interplay between the inflamed sciatic nerve tissue and the COX-2 inhibited macrophages 
after CXB-NE administration.  
Another facet of the study RNA profiles within the injured nerve tissue would include 
the differentiation of sensory and motor neurons within the studied samples.  As stated 
earlier, the sciatic nerve contains a mixed population of motor and sensory axons, 
whereas the corresponding cell bodies of the DRG are purely sensory.  The 
corresponding motor components are found within the ventral nerve root.  Vasudeva et 
al. conducted a study on CCI used DiD retrograde labeling from the footpad to the 
nervous system to identify the presence of anatomical structures within the labeled 
neuronal pathway to the lumbar level 5 (L5) DRG47. RNA sequencing of the ventral 
nerve root could be conducted in order to determine the role of motor sensation and 
RNAs associated with motor movement and muscle within the CCI NSAID-loaded 
nanoemulsion model used in the second aim of my study.   
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Differences in expression of RNAs associated with the DRG and the injured sciatic 
nerve can be accounted for, mainly due to their anatomical and functional differences.  
The injured sciatic nerve contains axons and supporting cells that together are involved in 
propagation of action potential and signaling, whereas the primary sensory neurons 
contain the nuclei, where transcription is actively occurring. In both the DRG and the 
sciatic nerve the distinct cells have a wealth of cell surface receptors and signaling 
mechanisms that help to interpret cell-cell communication in the local environment. The 
cell bodies extending axons into the sciatic nerve are located in the L4-L6 DRGs, with 
most innervation being in L4 and L5 DRG.  Once these primary sensory neurons are 
activated by axonal injury at the sciatic nerve, they are likely to modify their RNA 
production in response to nerve injury.  Studies have shown that after multiple axonal 
injuries in the periphery, the DRG become primed and thus are likely to regenerate distal 
axons more rapidly in response to subsequent lesions181-183. In addition to this response, 
retrograde signaling sent from the site of injury to the cell body occurs184 may help to 
initiate transcriptional changes in the nucleus that increase production of molecules 
involved in neuronal regeneration185, 186.  Simultaneously, this retrograde signaling also 
contributes to the altered gene expression of the surrounding cells and milieu of 
inflammatory mediators around the injured neurons10,183,186, 187. Taken together, our 
studies revealed altered RNA expression in the injured sciatic nerve as well as the 
corresponding DRGs with differential expression appearing to be evident in multiple cell 
types in both locations. 
CXB-NE tends to exert its effects in a different manner in the affected DRGs, than at 
the site of injury in the sciatic nerve.  For example, the receptor to cytokine interleukin 
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12, IL-12rb2, as well as IL-16, are both upregulated in the DRG after administration of 
COX-2 inhibiting nanoemulsion. Furthermore, IL-12 is produced by antigen-presenting 
cells such as macrophages and can exert an effect on T cells, such as stimulating 
production of IFN- 178.  Additionally, IL-16 production is associated with mast cell 
activation following prostaglandin synthesis179. Saleem et al.46 has shown the presence of 
degranulating mast cells at the DRG in CXB-NE treated rats.  In the inflamed sciatic 
nerve, however, we have showen there is a differential expression of IL-18, also highly 
involved in the production of IFN-20. Interestingly, IL-18 RNA expression was not 
detected in the DRG 12 days post-surgery.  
 By dampening the neuroimmune cross-talk provoked by production of 
inflammatory mediators, we have demonstrated COX-2 attenuation in tissue-
differentiated macrophages not only leads to a decrease in PGE2 production46, 48 but also 
leads to changes in RNA expression of genes both known to be implicated in 
neuroinflammation as well as other novel ones. Interestingly, although our study only 
targeted COX-2 production in macrophages, gene expression changes associated with 
other cell types were modulated when drug therapy is present.  Furthermore, injured 
animals exhibited differential expression of multiple RNAs within the injured sciatic 






5.1.2 COX-2 inhibiting nanomedicine modulates RNA expression that has been 
altered by nerve injury in macrophages and other cells involved in 
neuroinflammation 
Overall, under neuropathic conditions, we know that CXB-NE is altering the activity 
of COX-2 and the production of PGE2 in macrophages.  We anticipated that RNA 
expression changes may too be occurring in these targeted cells.  However, our data 
reveals that the impact of this pain-relieving therapeutic extends beyond the macrophages 
to influence changes in RNA expression in other cell types. Furthermore, while pain is 
known to alter gene expression within the neurons in the dorsal root ganglia (DRG), there 
is an observed similar effect at the site of injury, involving multiple cell types based on 
previous studies of RNA expression corresponding to a given cell type.  
We know that macrophages are recruited to the site of injury within three days after 
surgery where they begin to phagocytose myelin debris and biproducts of damage formed 
as a result of nerve injury56,176. Previous studies by our laboratory have established that 
there is a reduction in number of infiltrating macrophages in CCI CXB-NE animals 
associated with a reduction of COX-2 activity and the subsequent production of PGE246, 
48, and thus it is expected that RNA expression changes may too be occurring in these 
targeted cells as well.  In fact, we have found that in the damaged sciatic nerve, several 
macrophage-associated genes as well as genes responsible for coding pro-inflammatory 
cytokines exhibit altered RNA expression. A study by Bausbaum et al. (2020)250 utilized 
a spinal nerve ligation (SNL) model and fluorescence-activated cell sorting to distinguish 
CX3CR1-positive macrophages within the injured DRG and found that the CX3CR1-
positive cell population in the L4 and L5 DRG was increased by nearly 3 fold compared 
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to the unoperated, contralateral side 4 days after injury.  Based on this study, Bausbaum 
and colleagues250 were able to conclude from DRG macrophages are a major contributor 
to the initiation and maintenance of pain, and via other cell-sorting and transgenic mouse 
line experimental techniques, that macrophages outside of the DRG may not be as 
important as once thought250. However, data generated within my laboratory has shown 
that on day 12, while the DRG has infiltrating macrophages, the density is 40% of what is 
seen at the injured sciatic nerve46.  When CXB-NE is present, the number of 
macrophages at day 12 in the sciatic nerve is nearly halved, but unchanged in the DRG46.  
This may indicate that the gene expression profiles associated with an increase in 
neuroinflammation are occurring moreover at the site of injury than the corresponding 
DRGs 12 days post-injury.  Overall, mRNAs associated with neuroinflammation 
demonstrated a reduction at the injured sciatic nerve when CXB-NE was administered 
compared to DF-NE in CCI animals.  On day 12 in the DRG, RNA expression profiles 
associated with neuroinflammation demonstrated a partial reversal in expression with 
some prominent neuroinflammatory genes showing an upregulation in pain-treated (CCI 
CXB-NE) animals compared to those without treatment (CCI DF-NE).  This could 
possibly be attributed to an ongoing effect of the CXB-NE on long-term gene expression 
changes.  Coinciding with behavioral data, in which analgesia persists until day 15 46, this 
may indicate the induction and persistence of gene expression that influences the milieu 
of cells at the DRG are long-term and may be occurring later. After all, even after 
administration of a pain-relieving drug (CXB-NE) is evident, RNAs typically associated 
with inflammation continue to exhibit increased expression on day 12 in the DRG.  In 
order to explore this phenomenon further, an increased time point study is required where 
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tissues are dissected later than 12 days and the same RNA expression profiles are 
assessed.    
Itgam/Cd11b and Itgb2/Cd18 form the integrin MAC-1 complex, which is 
responsible for the recruitment and adhesion of leukocytes to the site of injury55,121. 
Similarly, Mcp5 serves to recruit circulating monocytes to the site of injury comparable 
to Mcp1, a better studied homolog122, 223. Each of these genes produce proteins that are 
involved in macrophage recruitment to the site of injury and showed a decrease in RNA 
expression when directed COX-2 inhibition occurred in macrophages 4 days after 
intravenous injection of CXB-NE. This may signify that by inhibiting COX-2 and a 
subsequent decrease in PGE2 production at the site of injury in macrophages, there is an 
attenuation of the recruitment of signaling for new infiltrating macrophages. In the sciatic 
nerve, other mRNAs typically associated with macrophages and circulating monocytes 
exhibited increased expression when compared to the sham control but not a major 
difference between the pain and pain relieved state.  These genes include Adrb2 
(adrenergic beta-2 receptor), Ccr2 (chemokine C-C receptor 2), Cnr2 (cannabinoid 
receptor 2), and Ptgs2 (prostaglandin E synthase 2).  Given this attenuation in COX-2 
activity in macrophages, our data suggests that by inhibiting this enzyme and its 
biproducts, there is a subsequent change in macrophage signaling, including integrins and 
cytokines that can potentially affect surrounding cells.  
Gene profiles of macrophage-related genes also exhibit differential expression after 
injury following CXB-NE. M1, pro-inflammatory, macrophages are induced by 
interferon gamma, IFN-, amongst other activators176.  At day 18 in the DRG, there is an 
increase in the number of M1 macrophages in CCI CXB-NE relative to CCI DF-NE by 
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56% compared to day 12 46. As we know, activated M1 macrophages mainly secrete pro-
inflammatory cytokines, which promote debris removal, and may assist in the healing 
process176. Furthermore, it is thought that anti-inflammatory and axonal healing 
promoting-M2 macrophages infiltrate the site of injury after M1 macrophages have 
fulfilled their phagocytic, pro-inflammatory role176. Our study showed a distinct increase 
in expression of the interferon gamma receptor (Ifgnr) RNA within the DRG after 
animals experienced pain-relief (CXB-NE). This is consistent with other studies as IFN- 
has been shown to directly polarize macrophages toward an M2 phenotype176.  M2 
Macrophages are also known to promote angiogenesis177, which provides nutrition for the 
repair of the nerve tissue, an important step in nerve healing176.  It is possible that an 
increase in Ifgnr mRNA in the cell bodies of the DRG is involved in the repair process 
associated with the polarization of macrophages both in the DRG as well as near the site 
of injury in the sciatic nerve.  
Additionally, a heightened increase of monocyte chemoattractant protein 1 and 5 
(Mcp1 and Mcp5) are noted in both the sciatic nerve and DRGs after chronic constriction 
injury (Figure 18). Mcp1 is a mediator in the immune response, it is involved in binding 
to the surface of circulating monocytes helping to recruit them to the site of injury122.  

















Figure 19. Differential expression of Mcp1 mRNA in the sciatic nerve 
and DRG on day 12 post-surgery. qPCR was performed on Mcp1 
mRNA from (A) L4-L5 DRG and (B) injured sciatic nerve. In the 
injured sciatic nerve tissue, there is significant expression differences in 
the naïve control and CCI animals. In the DRG, there is no statistical 
difference in Mcp1 of CCI CXB-NE and naive animals, but there is 
between CCI CXB-NE and CCI DF-NE as well as sham and CCI DF-
NE. Note that although two different controls are reported (sham and 
naïve) they are statistically the same. One-way ANOVA and Tukey’s 
multiple comparison was performed between conditions.  **** P < 
0.0001. 
 
molecule in the pain response in animals.  As noted in Table 2, mRNA expression 
differences exist in the different neuronal tissue.  In the DRG, there is a large increased 
expression of Mcp1 mRNA in the CXB-NE pain-relieved animals compared to pain state 
animals (Figure 19).  In the corresponding sciatic nerve, there is a slight increase in 
Mcp1 in the CCI CXB-NE pain-relieved animal. Surprisingly, the CCI animals treated 
with DF-NE, which are still exhibiting pain-like behavior, have a slightly elevated 
expression of Mcp1 in the DRG, whereas at the corresponding site of injury, the Mcp1 
expression in the sciatic never is very high, even higher than that observed in the pain-
relieved sciatic nerve (Figure 19). Although, Mcp1 is known to be expressed during CCI 




in the axon terminals223, Celecoxib-loaded nanoemulsion seems to have a differential 
effect on these two anatomical areas as observe with these two different techniques.  This 
is expected as the dorsal root ganglia contain the cell body where RNA is being actively 
transcribed, whereas the axons may contain differing amounts of RNA, depending on the 
needs of the distal nerve fibers.  
Of note, Mcp1 mRNA expression levels were compared to different negative controls 
– whereby naïve tissue was utilized in the DRG studies and sham tissue in the sciatic 
nerve studies.  This is consistent throughout Specific Aim 1 (Chapter 3) and Specific Aim 
2 (Chapter 4), in which main analyses of RNA expression in the sciatic nerve was 
compared to sham negative controls (Chapter 3) and RNA expression in the DRGs were 
compared to naïve negative controls (Chapter 4).  As noted in the supplemental section of 
Chapter 3, multiple negative controls were initially used (included naïve and sham) in the 
study but because of cost-restrictions, only sham data was further analyzed. Only 
ipsilateral tissues were assessed throughout the study for the purposes of consistency and 
to keep costs as low as possible not all possible negative controls were considered.  Naïve 
controls were utilized of ipsilateral sciatic nerve and DRG tissues, in which the animals 
received no surgery or nanoemulsion.  Gene expression in naïve controls in the sciatic 
nerve were comparable to sham (Figure 14) negative controls(in which these animals’ 
sciatic nerves are exposed during surgery, but no sutures are placed on the nerve to create 
CCI), thus only sham controls were utilized in running the RT2 PCR Arrays, as they were 
expensive. For individual qPCR analysis of sciatic nerve tissues, only sham controls were 
included to keep the analyses consistent between individual genes and those within the 
RT2 arrays. In terms of behavior, both naïve and sham animals exhibited similar behavior 
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patterns, with the exception that sham animals experienced pain 1-3 days after surgery 
(Figure 15), most likely due to post-operative pain.  When compared in terms of mRNA 
expression within the injured sciatic nerve, no statistically significant mRNA difference 
was revealed on day 12 between naïve or sham negative controls in a subset of genes 
including the neuroinflammatory genes (IL-18, IL-1, IL-10 MCP-1, MCP-5; Figure 
14). As for the DRG, no statistically significant difference was noted between the two 
negative controls in a smaller sample size on day 12 for a subset of housekeeping 
(Gaphd, Rplp1) and neuroinflammatory genes (IL-18, IL-1, MCP-1, MCP-5) and naïve 
negative controls to limit time and cost involved in animal surgeries.  
In terms of CCI-induced gene expression changes (without administration of any 
nanoemulsion), differential expression of RNA within the injured axons of sciatic nerve 
as well as the cell bodies 12 days after injury were noted when compared to CCI animals 
receiving any form of nanoemulsion. CCI animals administered drug-free nanoemulsion 
(DF-NE) were expected to exhibit similar gene expression profiles to CCI only animals 
(those receiving no nanoemulsion), as they exhibit the same mechanical allodynia 
behavioral patterns (Figure 6) and are assumed to be comparable in terms of underlying 
molecular physiology of CCI only animals.  We found this for the most part to be true, 
however, animals given no nanoemulsion at all (CCI only) exhibited much higher 
increases in several neuroinflammatory-related genes than CCI DF-NE animals in the 
sciatic nerve (Table 14), with a particular increase in expression of Cd18, Mcp5, and 
Cx3cr1 in the CCI only (no nanoemulsion) animals.  This is of interest, and will require 
further exploration, as each of these are macrophage-associated genes and it may be 
possible that the nanoemulsion itself, although inert, could be activating the immune 
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response as it phagocytosed by circulating monocytes46-49,71-73. Inclusion of these controls 
were not used in the publications (Chapters 3 and 4) as they require a much further 
investigation and are considered outside of the scope of the goals of the studies. 
 
Table 14.  Fold change of mRNA expression compared for each of the CCI conditions normalized 
to the pain-free sham animals.  The mRNA expression in the two hypersensitive conditions is 
distinct. Relative comparison of mRNA between the experimental group and sham control is 
shown based on the fold change using the Livak method (p 0.05). 











Cd18 31.9 11.5 6.8 
Cd11b 11 9.5 4.0 
Mcp5 41.3 11.9 4.3 
Mcp1 12.4 8.2 2.9 
IL-10 0.9 1.4 1.1 
IL-1ß 11.2 18.4 7.1 
Cx3cr1 19.1 5.4 3.5 
 
Surprisingly, RNA expression changes involved in the production of prostaglandins, 
specifically PGE2, were limited in both the injured sciatic nerve and DRG tissues.  Of the 
8 of the 84 genes differentially expressed in sciatic nerve tissue comparing CCI CXB-NE 
to CCI DF-NE animals, these include mRNAs associated with neurons (Tac1, Grin2b, 
Maob, Scn9a), pain (Tac1), macrophages (Cd11b), and inflammatory mediators (IL-6),  
but do not show any statistically significant difference in mRNAs associated with COX-2 
or the subsequent cascade involved in PGE2 production.  For instance, beyond the RT2 
PCR array containing 84 known neuropathic and inflammatory genes, Ptgs2 
(prostaglandin E synthase 2) and Ptgds (prostaglandin D2 synthase), Ptger2 
(prostaglandin E receptor 2) were each individually assessed in both CCI conditions as 
well as naïve and sham animals, with no significant differences seen in expression. 
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Within the DRG tissues, there was, however, a decrease in Ptgds when Celecoxib-loaded 
nanoemulsion (CXB-NE) was administered to CCI rats.   
Beyond neuron or macrophage differences in expression, our studies have 
demonstrated that other cell types’ transcripts are likely affected following CXB-NE 
therapy. Our data has shown that the impact of drug reaches beyond the macrophages to 
influence changes in gene expression in a way that would include cells other than the 
macrophages carrying the nanoemulsion; these changes in RNA expression are evident at 
both the site of injury and the DRGs. RNA sequencing analysis of the DRG 
transcriptome has revealed the activation of two prominent immune-related Reactome 
pathways: neutrophil degranulation involving PML-RAR alpha-regulated adapter 
molecule 1 Pram1, and the innate immune system, which involves Importin 7 (Ipo7) and 
Strawberry Notch Homology 2 (Sbno2).  Pram1 is expressed by granulating myeloid 
cells and may be associated with increased expression of multiple myeloid cell types in 
the DRG and at the site of injury. Importins mediate the nuclear import and export of 
activated signaling proteins involved in axonal regeneration175. Although not much is 
known regarding Ipo7 or its role in chronic constriction injury or its linkage to COX-2 
inhibition, its related to importin-beta, a well understood importin that has been localized 
to injured sciatic nerve and DRGs after nerve injury175.  The transcription factor Sbno2 
contributes to the anti-inflammatory effects associated with M2 macrophages180. Pram1 
and Ipo7 expression are increased when CXB-NE is present, whereas Sbno2 is reduced in 
expression when CXB-NE is present. This suggests a potential difference in the 
neuroimmune crosstalk relative to expression changes occurring at the actual site of 
injury within the sciatic nerve.   
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5.1.3 Nanoemulsion NSAID therapeutic treatment relieves pain-like behavior, reduces 
inflammation, and reduces macrophage infiltration at the site of injury. 
Acting as a theranostic, the nanoemulsion has the ability to both deliver a 
therapeutic (in this case the non-steroidal anti-inflammatory drug, Celecoxib) as well as 
contain an imaging modality that allows us to track inflammation.  The nanoemulsion 
contains a near infrared fluorescent (NIRF) dye, DiD, that can be used for in vivo 
imaging studies.  Initial neuroimaging studies have revealed in the chronic constriction 
injury (CCI) model, that NIR fluorescence is concentrated in the area of the affected 
sciatic nerve on the ipsilateral hindleg47.  Furthermore, when the nanoemulsion carries 
another distinct imaging agent, 19F MRI, the fluorescent signal was localized on the 
ipsilateral sciatic nerve as well47.  We have confirmed that treatment with CXB-NE 
results in a decrease in inflammation at the sciatic nerve on day 11 in the same area after 
CCI46, 48,49.  This concurrent decrease in inflammation as indicated by RNA, protein, and 
NIRF signal is occurred by a reduction and near reversal of pain-like behavioral changes 
measured by von Frey mechanical allodynia testing.  A multitude of behavioral assays 
and tools can be used to assay pain-like behavior in injured rats, wherein I chose to use 
von Frey testing as it has been established in the Pollock laboratory as a reliable and 
accurate tool to assess neuropathic pain-like behavior20, 46-49.  Mechanical allodynia 
measures withdrawal responses to von Frey filaments of increasing gram force in both 
the injured (ipsilateral) and uninjured (contralateral) hindpaws. In addition, observed 
licking behaviors, lack of ipsilateral hindpaw use, and other biting or scratching at the site 
of injury were conducted and noted throughout all experiments. Other assays that can be 
explored in future experiments include the grimace scale (which uses time-lapsed 
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videography to measure rat facial expressions indicative of pain-like behavior), 
Hargreave’s testing (measures latent thermal hypersensitivity), or walking gait analysis 
(measures whole animal pain-like behavior).   
Correlating to the NIRF imaging in the live animals, histologically, there was a 
marked reduction in the number and type of macrophages present at the site of injury 
when CXB-NE treatment was employed46,48,49.  Saleem et al. also demonstrated that 63% 
of the macrophages in the sciatic nerve carry nanoemulsion on day 12, whereas only 19% 
of the macrophages in the DRG carry nanoemulsion on that day. By day 18, macrophages 
carrying nanoemulsion in CCI CXB-NE and CCI DF-NE equalizes at around 12% 46.  
With only drug-free nanomeulsion (DF-NE), there is a marked increase in CD68 positive 
macrophages at the affected sciatic nerve that coincides with injury on day 1247. Further 
analysis of CD68 macrophage infiltration at the corresponding dorsal root ganglia (DRG) 
reveals no significant change in macrophage infiltration on day 12, whereas on day 18, 
there is a substantial and nearly equivalent increase in CD68 positive macrophages in the 
DRG as there is in the sciatic nerve46.  
In past studies, we have also demonstrated that CD68 positive macrophages at the 
site of injury and the corresponding ganglia can be further distinguished based on the cell 
surface markers.  Saleem et al.46 was able to distinguish M1 (pro-inflammatory) and M2 
(anti-inflammatory) macrophages by their expression of the costimulatory protein Cluster 
of Differentiation 40 (CD40) or transferrin receptor (TFRC).  Based on these protein co-
localization studies, on day 12 within the damaged sciatic nerve, CD68 and CD40 
positive macrophages of CCI animals administered CXB-NE exhibited roughly 55% M1 
macrophages whereas DF-NE animals express a significant increase with nearly 20% 
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more46. In the same study, DF-NE expressed only 36% M2 macrophages (CD68 and 
TFRC positive cell surface markers), whereas CXB-NE animals expressed 60% 46. This 
is important as it reveals there is a shift in macrophage phenotype when injured animals 
are given the NSAID-loaded nanoemulsion. Switches in macrophage have both the 
potential to influence the production of inflammatory mediators as well as lead to 
changes in axonal regeneration178,181.  
Beyond M1 and M2 differentiation, macrophages are also pleiotropic under 
inflammatory conditions, having the ability to exert their influence in multiple ways52. As 
discussed earlier, in conjunction with our mRNA studies, we have observed a change in 
expression in the highly abundant M and 2 integrins, CD11b (ITGAM) and CD18 
(ITGB2). mRNA analysis at the injured sciatic nerve has revealed a significant increase 
in CD11b expression in the pain state compared to the pain-relieved state and a 3-fold 
increase in expression of CD18. In their protein form, together, these molecules form a 
heterodimer known as Mac-1, which is normally present in an inactive precursor in 
circulating monocytes that is known to be rapidly activated to assist in leukocyte 
adhesion, migration and accumulation at the sites of inflammation55.  In a review by 
Ristoiu et al.52, they describe the markers used for cell subtypes across the pain literature.  
They found that in the sciatic nerve, activation of CD11b- and CD68-positive 
macrophages were detected at different time points after partial spinal nerve ligation 
(PSNL), CCI and sciatic nerve crush, but they did not show a distinctive spatial 
distribution inside the nerve52. However, our studies have shown CD68 positive 
macrophages are found predominantly within the injured sciatic nerve, whereas CD11b 
positive macrophages were found primarily in the epineurium surrounding the nerve 
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fibers49. In the DRG, CD11b and CD68 macrophages invaded the tissue and either 
remain scattered between neurons or they formed perineuronal rings around medium and 
large neurons after injury52.  Moreover, these two cell surface receptor specific 
macrophage markers are known to differ in their structure and functionality. In accord 
with our findings,  CD11b macrophages are small, round shaped and distributed around 
the lesion site, whereas CD68 macrophages are large, irregular, foamy shaped and found 
amongst the damaged nerve fibers58. CD11b macrophages are known to be 
cytokine/chemokine expressing, whereas CD68 antibody is predominantly phagocytic 
(which is key for the regeneration process)58. Zhang and colleagues58 were also able to 
demonstrate temporal differences between the two macrophage subtypes. They reported 
CD11b positive macrophages existed only at early time points after injury (not beyond 
day 14), whereas CD68 macrophages persisted for at least 3 months post-injury52.  With 
our mRNA data, this suggests that CD11b positive macrophages contribute to the 
initiation of neuropathic pain by increasing cytokine/chemokine signaling and CD68 
positive macrophages contribute to the ongoing maintenance of hypersensitivity via other 
mechanisms.  It is possible that these phagocytic CD68 macrophages may be involved in 
axonal regeneration. 
5.1.4 Attenuation of COX-2 in macrophages affects peripheral nerve regeneration 
Multiple cell types are engaged during the axonal regeneration of the injured neurons 
following neuropathic injury.  Neuronal regeneration can be thought of as a transcription 
and translation dependent process where the cell bodies changes gene expression patterns 
in response to injury at the axonal level175. In addition, neutrophils are the first cell type 
recruited to the injured nerve56, followed by the recruitment of circulating monocytes (as 
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tissue macrophages), breakdown of the blood-nerve-barrier through the endothelium104 
and activation of Schwann cells, accompanied by degeneration of the  distal axon and 
ultimately expression of regeneration-associated RNAs within the cell bodies56. This is 
subsequently followed by formation of a growth cone within the injured axon56.  After 
the first 48 hours post-injury, Wallerian degeneration is marked by a phenotypic shift in 
resident and activated Schwann cells, in which they no longer serve to primarily 
myelinate the axon, but instead they dissociate and begin acting like macrophages, 
phagocytosing injured axonal debris and secreting inflammatory mediators56, 89.  as time 
proceeds, it could serve as an important indicator. Behavioral assays assessing axon 
regeneration can be utilized to explore regeneration over time.  An example being 
walking gate analysis of a rat on a treadmill belt using DigiGait technology. DigitGait 
software generates digital hindpaw prints and dynamic gait signals, representing the 
temporal record of paw placement on the belt as the injured animal walks, indicating pain 
detection based on gait249.  This technology can be used in both assessing neuropathy as 
well as recovery due to axonal regeneration249. This would be a helpful tool in detecting 
axonal regeneration as on day 12 the regenerative process is robust.  In addition, by 
blocking COX-2 activity in macrophages, there is essentially an attenuation of overall 
inflammation which may contribute to the recovery process, in which axonal regeneration 
plays a key role. Beyond day 12, further studies are required to assess the extent of axon 
regeneration occurring at the injured sciatic nerve, however, studies using the NSAID 
ketorolac, have shown histological changes to axon and myelin diameter over a period of 
42 days following sciatic nerve crush injury, revealed an increase in axonal regeneration 
and a recovery in pain-like hypersensitivity in these animals253. 
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In the DRG, a number of RNAs are differentially expressed when COX-2 is inhibited 
in infiltrating macrophages, including those known to be previously involved in axonal 
regeneration.  Neurotrophic growth factors are thought to attract cell machinery to the 
injured nerve to promote axon regeneration, assist in degrading cellular debris and the 
guiding and activation of genes to the injured stump.  The neurotrophin, nerve growth 
factor (NGF), is involved in pain signaling upon binding to Neurotrophic receptor 
tyrosine kinase A, Ntrk1/TrkA109. The NGF-TrkA complex is internalized and 
transported from peripheral axons to sensory cell bodies in the DRG109, where it may 
play a role in pain signaling. Consistent with nerve regeneration and repair involving 
administration of CXB-NE, Ntrk1/TrkA shows decreased expression in the DRG after 
drug therapy compared to CCI DF-NE.  
Certain transcription factors involved in axonal regeneration signal transduction are 
expressed when CXB-NE is present in the DRG, including c-Fos.  c-Fos is essential for 
the reprogramming of myelinating Schwann cells to non-myelinating Schwann cells33, 
which aid heavily in the regenerative process. Genes expressed involved in signaling 
include Fkbp3, , Gpr22, Arhgap2, Plce1, Arhgef11, Itpkc, Nkiras1, and Mycbp2.  The 
extracellular signaling kinase Mapk1 (mitogen-activated kinase 1) is activated by c-Fos 
and has been implicated in nerve injury in the dedifferentiation of Schwann cells as well 
as activation of MCP-133. On the other hand, Notch signaling involving decreased Rassf1 
expression after CXB-NE in the DRG and this gene is known to contribute to 
demyelination33.  Given this gene’s expression is assessed on day 12, a decrease in 
expression makes sense, as demyelination occurs during the earlier Wallerian 
degeneration phase. Preliminary immunohistochemistry staining of the general Schwann 
 
 130 
cell marker S100 (Dako, 1:100) in the distal stump has shown increased staining in CCI 
CXB-NE compared to CCI DF-NE, possibly indicating a heavier axonal regenerative 
process occurring (data not shown). In addition,  the roles of growth-associated protein 
43 (GAP-43) and F-actin protein expression on CCI animals receiving drug-free and 
celecoxib-loaded nanoemulsions has recently been examined in a pilot study238. GAP-43 
has been shown to have involvement in nerve regeneration89, whereby protein levels are 
increased in the injured sciatic nerve following administration of CXB-NE on day 8 (as 
compared to DF-NE)238.  The study by Alyssa Brauckmann also examined F-actin, a 
growth cone marker that protrudes from the distal ends of damaged axons238, 
demonstrating a significant increase between naïve/CCI DF-NE conditions and CCI-
CXBNE on day 12, with highest expression in the pain-relieved state238.  Exploration of 
potential axonal regeneration mRNAs in the injured sciatic nerve were limited to the 
genes found within the qPCR array (Qiagen) used. Only β-actin (Act-β) showed 
differential expression in the sciatic nerve.  Act-β is involved in growth cone 
formation97,153, and when CXB-NE is present, Act-β exhibits a higher level of expression 
compared to their CCI DF-NE counterparts.  This increase in actin expression may be in 
response to the activation of peripheral nerve regenerative processes154.   
Other genes that may be involved in axonal regeneration include fibronectin leucine 
rich transmembrane protein 3 Flrt3, and leucine rich repeat transmembrane neuronal 
proteins LRRTM1, LRRTM2, and LRRTM3; all of which are differentially expressed 
and are known to be involved in axon outgrowth and synapse formation170. LRRTM1, 
LRRTM2, and LRRTM3 exhibit an increase in expression when CXB-NE is present. 
Other similar genes involved in recruiting cells to the cell body microenvironment 
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involved in axonal regeneration include fibronectin leucine rich transmembrane protein 3, 
Flrt3, also shows an increase in expression after CXB-NE in the DRG. Given the 
extensive RNA changes occurring within the DRG, I propose that it is the cell bodies that 
are preparing and defining which RNA transcripts will be made and shipped to the 
injured axons within the sciatic nerve to be later translated into proteins for use by the 
targeted cells.  Use of anterograde transport allows for the translocation of RNA 
transcripts to the axon, whereby mRNAs may be translated into protein given their need 
or involvement in axonal regeneration or ncRNAs (non-coding RNAs) may act as 
regulators of protein and other RNA functions.   
Future experiments centered around the pro-healing response and possible role of 
CXB-NE in axon regeneration need to be conducted.  Including repeated and later-set 
dosing experiments in future work may reveal even stronger data on the role of selective 
COX-2 inhibition on activated macrophages and their role in axonal regeneration.  As 
pain-like behavior begins to reappear (around day 15)46, a repeated dose of 0.24 mg/kg 
could be administered and then possibly again after day 18, as this is the day established 
within previous data demonstrating distinct differences in macrophage and nanoemulsion 
infiltration at the sciatic nerve and DRGs46.  Furthermore, it would be interesting to 
administer CXB-NE beyond the established day 8 administration, to explore the 
possibility that a later administration may or may not affect expression levels of RNAs 






5.1.5 Long non-coding RNAs may be implicated in pain 
 Non-coding RNAs (ncRNAs) have the ability to influence pain pathogenesis as 
they act as transcriptional regulators with the ability to modify the expression of mRNAs 
and protein targets224. ncRNAs include the smaller microRNAs (miRNAs) which are less 
than 200 base pairs in size and long non-coding RNAs (lncRNAs), which are greater than 
200 base pairs. Each of these have been implicated in chronic pain224-227. lncRNAs 
comprise 90% of human total RNA and are uniquely expressed in all cell types, wherein 
at least 50% of lncRNAs have been reported in the nervous system228. With their ability 
to modulate gene expression of other RNA transcripts, they may have the ability to 
influence pain pathogenesis with greater strength than originally thought. In this study, of 
the 675 transcripts statistically significantly expressed in the DRG of CCI animals given 
CXB-NE relative to those given DF-NE, only a mere 26 include known ncRNAs, 
whereas 611 were mRNAs.  This is most likely because most ncRNAs have yet to be 
annotated and explored in mammalian genomes. Additionally, those 26 miRNAs and 
lncRNAs in our dataset have only been recently annotated, with little known about each 
of them in regard to their molecular function.   
miRNA undergo a complex biogenesis that was first described in 2015 by Lin and 
Gregory229. Initially, within the nucleus, a primary miRNA transcript is cleaved to a 
precursor miRNA approximately 70 base pairs in length followed by further processing 
into a 22 base pair duplex miRNA once exported out of the nucleus. One strand of the 
duplex miRNA is loaded onto the RNA-induced silencing complex (RISC) to form a 
functional mature miRNA. Mature miRNAs bind to the 3’ untranslated region of target 
genes to silence them by either translational repression or mRNA degradation224. In our 
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DRG RNA sequencing study, of interest, the miRNA miR-3074 which shows a 30 fold 
increase in expression when CXB-NE is present in CCI animals on day 12, has been 
studied in the spinal cord and shown to act primarily to inhibit cell proliferation and 
neuronal differentiation through transcriptional regulation in an oligodendrocyte 
precursor cell transplantation study in rats after spinal cord injury230. The only other 
expressed ncRNA studied in the literature to do date is miR-3065, which has shown 
involvement in breast cancer development231. Future studies should focus on those 14 
miRNAs expressed in this study and their role in neuropathic pain, as previous studies 
have shown miRNAs exhibit differential expression based on the given injury model and 
cell type in which they are expressed224.  Conflicting reports about the regulation of a 
given miRNA has been shown to differ depending on which pain model is utilized, the 
animal being studied, and tissue RNA is extracted from224, therefore miRNA profiling 
should be evaluated in a way specific to our given study.  For instance, validation studies 
using uniquely generated primers can be designed to look for specific miRNAs in a given 
DRG (or sciatic nerve).  Furthermore, in vitro studies of macrophage expression of 
miRNAs shown to be differentially expressed should be conducted. Both of these studies 
could help reveal if in fact and how much the given miRNA is expressed in the DRG 
after CCI injury and drug therapy as well as if macrophages are directly involved in 
generating these transcripts.   
Other tools available for studying miRNA expression include those that explore 
when and how a given ncRNA is regulated in its expression as these regulatory 
mechanisms may reveal the potential roles of miRNA in injury and their associated 
action of the pain-relieving therapy. Such tools include those that have the ability to 
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affect miRNA expression in vivo such as chemically modified anti-miRNA 
oligonucleotides that inhibit endogenous miRNA expression by binding to and 
sequestering the targeted miRNA and consequently rendering it useless for RISC 
complex incorporation224. However, these chemical agents proved inefficient in 
inhibiting targeted mRNA in DRG following intrathecal injection in small animal 
models224.  Another tool that can be used to study miRNA expression includes the use of 
miRNA mimics. miRNA mimics are double-stranded RNA molecules that mimic 
endogenous miRNAs on cellular uptake where the strand containing the targeted mature 
miRNA sequence (known as the active strand) is preferentially incorporated into the 
RISC complex, and the other strand (known as the inactive strand) is degraded224. By 
conjugating a fluorescent tag to the active strand, localization following uptake into 
peripheral sensory neurons can be established.  Although each of these tools can reveal 
the potential location of these molecular transcripts, it is still necessary to understand 
their function.  Function studies involving ncRNAs are important as ncRNAs have the 
ability to target and affect specific mRNAs as well as other RNA transcripts.  Most of 
these tools lie in miRNA target-prediction computer algorithms that explore the validity 
of predicted miRNA-mRNA pairs to treat cells or in vivo tissue with mimics or inhibitors 
of dysregulated mRNAS, extracted from affected tissues224. 
In addition to quantitative PCR (qPCR) to quantify the differential expression of a 
given ncRNA, other tools are commonly used.  Northern blotting was once considered 
the gold standard in ncRNA research but is limited in its use in pain studies due to 
technical limitations224. Fluorescent in situ hybridization (FISH) studies can be utilized to 
explore cell specific expression of each of the ncRNAs.  This would be particularly 
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helpful for long non-coding RNAs (lncRNAs) as research involving them in CCI-induced 
neuropathic pain remain limited. lncRNAs have been implicated in multiple 
physiological and pathological processes throughout the body and nervous system225 but 
the literature has been limited to understanding the molecular mechanisms of only a 
handful of lncRNA and their involvement in neuropathic pain models 228, 232. One 
potential lncRNA that may be involved in our studies is Scn9a NAT, an antisense 
lncRNA that targets the mRNA Scn9a. Although we have shown decreased of this 
voltage-gated sodium channel Scn9a/Nav1.7 in the injured sciatic nerve, a recent study 
has explored its expression and relation to its antisense lncRNA in the DRG232.  These 
two genes show an opposing pattern of expression in the DRG, with higher levels of 
Scn9a mRNA and lower levels of Scn9a NAT232. However, our RNAseq studies in the 
DRG only show differential expression of the sodium voltage-gated channels 
Scn8a/Nav1.6 and Scn11a/Nav1.9 when CXB-NE is administered in the pain state and did 
not detect Scn9a. We did however detect Scn9a/Nav1.7 in the inflamed sciatic nerve 
tissue (but not in the DRG). There could be potential antisense lncRNA Scn8a/Nav1.6 
and Scn11a/Nav1.9 transcripts found within the DRG as well as the presence of Scn9a 
NAT in the injured sciatic nerve that could be explored using qPCR and FISH 
techniques. The FISH technique can be very challenging as the ncRNAs can be expressed 






5.1.6 Genes implicated in neurodegenerative disease are differentially expressed when 
CXB-NE is present in CCI  
 Although the protein-coding mRNAs explored in the sciatic nerve were those 
previously established in the literature as involved in neuropathic and inflammatory pain 
(Qiagen Array), genes implicated in non-pain disease states were implicated when 
sequencing the entire transcriptome of injured rats’ DRGs.  RNA sequencing analysis 
revealed a cluster of key genes involved in other pathological processes, including Htt in 
Huntingtin Disease, Apolipoprotein B (Apob) in Alzheimer’s disease, ataxin 10 (Atx10) 
in spinocerebellar ataxia, frataxin (Fxn) in Friedrich Ataxia, and optineurin (Optn) 
involved in optic neuropathy.  Htt shows a 3 fold increase in expression when CXB-NE is 
given, Apob  a nearly 10 fold increase, Atx10 a fold increase, Fxn a 0.04 fold decrease 
and Optn a 5 fold increase. Interestingly enough, each of these genes have some 
involvement in neurodegeneration and this may explain their expression profiles after 
CCI.  Conducting further experiments to study which cells are producing these given 
genes using fluorescent in situ hybridization (FISH) could reveal further potential 
interaction of the neuro-immune triad involved in both neuropathic pain and the axonal 
regenerative responses. Antibodies that would be examined may include IL-6, IL-18, 
Itgam/Cd11b, Act-, and potentially Flrt3 as potential neuroinflammatory genes in which 
expression spans throughout the neuro-immune triad of cells. 
 
5.2 Future Studies 
Recent studies and requirement by the National Institutes of Health are now requiring 
all pain studies involving small animals to include both males and females190. Beyond 
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studying both sexes due the clear anatomical differences, pre-clinical pain studies have 
already shown neuroimmune differences191,192. Inclusion of female data may elucidate 
differences in adaptive versus innate immune responses using this pain model and what 
may be different when nanoemulsion drug therapy is used to inhibit COX2.  Pain 
literature is currently establishing the major roles of the innate and adaptive immune 
systems based on sex differences.  Although both systems work together to respond to 
chronic pain, each may differ in their underlying molecular mechanisms given the sex in 
which it is responding.  Innate immunity involves the immediate response that recognizes 
foreign bodies or injury, mounting a mostly monocyte-derived neutrophils and 
macrophages, mast cells, T cells, glia, and inflammatory mediators like 
cytokines/chemokines.  On the other hand, the adaptive immune response is characterized 
by a later, cell-mediated, acquired and specific immunity to given foreign bodies or 
injury markers involving primarily T cells and the humoral B cell response.  Expression 
of inflammatory mediators, macrophages and T cells is the major underlying cellular 
differences in males and females.  Although helper T cells are intricately involved in the 
innate immune response, they are too involved, with cytotoxic and regulatory T cells, in 
the adaptive immune response, as well as the production of inflammatory mediators.  The 
central T-cell mediated adaptive response was first seen in female mice after induction of 
the neuropathic pain spinal nerve ligation in 2015 by Sorge and colleagues193.  Their 
studies revealed that female mice might preferentially use adaptive immune cells instead 
of microglia to produce allodynia after nerve injury, and in the absence of adaptive 




This is an important concept to address, as the Janjic laboratory designed 
nanoemulsions we use target the innate-monocyte-derived macrophage response. Since 
this may be different in females than males, the nanoemulsion will likely cause a 
different effect in terms of gene expression and thus needs to be studied more in depth. 
Furthermore, our RNA sequencing study a prominent role of the innate immune system 
using Reactome analysis in male rats given CXB-NE compared to those receiving DF-
NE. A study by our colleagues Liu and Janjic et al. 167 using the sameCOX-2 inhibiting 
nanoemulsions directed to monocyte derived macrophages shown in a Complete Freund’s 
Adjuvant (CFA) of pain in male and female mice revealed a more distinct nanoemulsion 
near infrared red  fluorescent (NIRF) signal distributions in CD68 positive macrophages 
in males compared to females167. Repeat RNA sequencing studies of CCI and the effect 
of CXB-NE on transcriptome expression in males and females rats in currently underway 
by Brooke Deal in our laboratory.  
A major part of this study relies on previous literature in which given RNAs are 
associated with a given cell type. As discussed earlier in Section 5.1.5, more experiments 
exploring RNA expression in a given cell type are required.  Fluorescent in situ 
hybridization (FISH) studies would allow future researchers to explore cell-specific RNA 
expression of protein-coding genes explored in this study.  An advantage of this 
technique is that it uses paraformaldehyde-fixed tissues, commonly collected in the 
Pollock laboratory, providing results consistent with the work done in my research.  In 
addition, multiplex FISH is a newer technique which allows for enables the detection of 
multiple targets with multiple fluorophores in a single sample.  FISH also uses highly 
specific probes and distinct fluorophores that can be imaged via confocal microscopy to 
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detect a given RNA.  Another technique that can be used to identify cell-specific 
identities within a sample is fluorescence activated cell sorting (FACS)250.  FACS is a 
commonly used immunotechnique that identifies cells within a sample using fluorophore-
attached antibody staining. Beyond exploring the major cells of the neuroimmune triad, 
subsets of macrophages could be revealed with FACS.  A study by Botchwey and 
colleagues251 explored the differential expression of classical versus non-classical 
monocyte markers after tissue injury utilizing FACS and markers used in this study to 
identify them (CX3CR1, CD11b, IL-6, and IL-1).  The major disadvantage of this 
technique is that it requires viable (not fixed) samples, and as you begin to dissociate the 
cells for sorting, a subsequent change in RNA expression may occur, leading to changes 
that could lead to altered gene expression from the NSAID-loaded, macrophage-targeted 
treatment applied.  Another technique that could provide insights in cell-specific gene 
expressions would utilize another form of RNA sequencing data, the major technique 
performed in the second aim of my study.  Cell-lineage specific data allows for the 
recovery of cell type specific expression profiles from RNA sequencing data, however, 
given cost- and time-limitations, this analysis was not performed on my data set.      
 
5.3 Conclusions 
Studying CCI in rats and the effects of a targeted theranostic nanoemulsion may 
have implications in human health.  CCI mimics neuropathic pain13, which is a common 
complication of diabetes mellitus, chemotherapeutic use, and nerve trauma, amongst 
others. In particular, diabetic neuropathy is found in at least half of the affected 
population and is characterized by distal-to-proximal nerve damage leading to 
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neuropathic pain symptoms188 and is further associated with a mortality rate of 25-50% 
within 5-10 years following the onset of diabetic neuropathy189. Understanding the 
mechanisms of neuropathic pain in rats has shown that a prevailing neuroimmune 
response contributes to the major neuroinflammation-causing pain-like behavior in the 
laboratory. Even more so by utilizing laboratory animals and techniques to explore the 
underlying genetics and subsequent pathogenesis of neuropathic pain may be useful in 
understanding the drivers of neuropathic pain in humans.  In addition, by studying a 
clinically relevant nanoemulsion to illustrate the molecular cell biological responses, it is 
possible that this particular theranostic will one day be used to treat patients in clinic with 
the same disease symptomology. 
With the advent of RNA transcriptome sequencing and quantitative PCR to analyze, 
quantify and compare gene expression in the pain state, we now have the ability to look 
at the molecular genetics in first animals, then humans in a clear way.  Studying 
neuropathic pain in humans has many limitations (pain being subjective, collecting tissue, 
sample size issues, and analyzing meta-analyses where pain is measured using different 
parameters) that can be bypassed in animals, helping to establish the fundamental 
patterns of gene expression of neuropathy.  A metanalysis focusing on combining only 
pain cohorts who have harmonization amongst them (used the same neuropathic pain 
definition and similar subjects) identified 28 genes that show association with the 
presence of neuropathy in humans233. These genes have involvement in neurons 
(specifically in ion channels and neurotransmission), cytokine production, metabolism 
and the immune response, each consistent with our findings in our CCI rat neuropathic 
pain studies.  In particular, overlapping genes in the meta-analysis of humans and our 
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studies include Scn9a and Scn11a, Comt, Gch1, Slc11a2, and IL-6. This is important as 
our studies have revealed that these genes, both found to be differentially expressed in the 
sciatic nerve or the cell bodies of the DRG, can be influenced by the NSAID celecoxib-
loaded nanoemulsion in animals suffering from peripheral neuropathy.  
 With this, altered gene expression of RNA is apparent within the entire peripheral 
nerve, including the injured sciatic nerve and L4 to L5 DRGs.  Specifically, by 
attenuating COX2 activity specifically in infiltrating macrophages, there is a subsequent 
change in expression of mRNAs associated with neuroinflammation in the injured sciatic 
nerve as well differential RNA expression in the corresponding cell bodies of the dorsal 
root ganglia.  Based on previous gene-cell localization studies, this change in expression 
is not limited to macrophages, but also genes associated with other cell types at the site of 
injury (neurons, Schwann cells, T cells, and endothelial cells). The products of some of 
these genes are known to contribute to increased infiltration of immune cells, activation 
of immune-like glial cells at the site of injury, and the production of inflammatory 
mediators as well as production of mRNAs that influence axonal regeneration. 
Furthermore, mRNAs generally associated with the cell bodies in the DRGs such as the 
Calcium channel genes Cacna1b and TrpV3 are found to be differentially expressed in 
the injured sciatic nerve. Overall, with the utilization of celecoxib-loaded nanoemulsion, 
this targeted inhibition of COX2 and reduction PGE2 in macrophages, in turn has a much 
broader influence on gene regulation and expression throughout the sciatic nerve after 
peripheral nerve injury in male rats. By introducing CXB-NE not only is there a 
reduction in hypersensitivity46, 48, 49, but there is an overall reduction in inflammation at 
the site of injury48,49 and the drug therapy is associated with widespread changes in the 
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transcriptome of various cells at the site of injury as well as the cells of the dorsal root 
ganglia.  Even though celecoxib specifically attenuates COX-2 activity in the associated 























Appendix A. Tail vein injection protocol. 
 
Based on the publication: 
M. Saleem*, A. Stevens*, B. Deal, L. Liu, J. M. Janjic, J. A. Pollock (2019) A new best 
practice for validating tail vein injections in rat with near infrared labeled agents. JoVE - 
J. Vis. Exp., e59295. *Co-authors contributed equally. 
 
Contribution Statement: 
A.S. performed optimization of tail vein injections when designing the protocol, LiCOR 
imaging, wrote the protocol and initiated the publication. 
M.S. wrote the introduction, results and conclusions of the publication and created the 
figures.   
J.A.P. overseen the entire publication and contributed to the concept and design of the 
publication and protocol. J.A.P and J.J. jointly designed the experimental approach for 
evaluating nanoemulsions in chronic constriction injury rate model for neuropathic pain.  
B.D. assisting in filming of the video’s protocol and publication.  
J.J. and L.L. contributing to editing the manuscript and designed and developed the 
nanoemulsion. L.L.  







A.1 Intravenous Tail Vein Injections  
As adapted from: 
M. Saleem*, A. Stevens*, B. Deal, L. Liu, J. M. Janjic, J. A. Pollock. A new best 
practice for validating tail vein injections in rat with near infrared labeled agents. 
Journal of Visualized Experiments 2019; e59295. *Co-authors contributed 
equally. 
 
A.1.1 Summary  
Here we present a method to validate tail vein injections in rats by utilizing near-
infrared fluorescence imaging data from dyes incorporated into agents or biological probes. 
The tail is imaged before and after the injection, the fluorescent signal is quantified, and an 
assessment of the injection quality is made.  
 
A.1.2 Abstract 
Intravenous (IV) administration of agents into the tail vein of rats can be both 
difficult and inconsistent. Optimizing tail vein injections is a key part of many experimental 
procedures where reagents need to be introduced directly into the bloodstream. 
Unwittingly, the injection can be subcutaneous, possibly altering the scientific outcomes. 
Utilizing a nanoemulsion-based biological probe with an incorporated near-infrared 
fluorescent (NIRF) dye, this method offers the capability of imaging a successful tail vein 
injection in vivo. With the use of a NIRF imager, images are taken before and after the 
injection of the agent. An acceptable IV injection is then qualitatively or quantitatively 




A.1.3 Introduction  
The route of administration of agents into small animals serves as a critical point 
of many experiments. It determines where the agent is to be delivered and, subsequently, 
what will happen to the agent thereafter. Although other routes can be used for agent 
administration194, the intravenous route of delivery is a preferred route for certain agents. 
IV injection allows agents to be directly injected into the bloodstream, bypassing first-pass 
tissue effects and the need for extraneous solute absorption194. This also allows for 
targeting cells in the bloodstream48, 72 and direct delivery to all tissues within the circulatory 
system. In rodents, several veins can be considered, including the jugular, the saphenous, 
and the tail vein. 
In this method, a NIRF dye containing a biological probe—in this case, a 
nanoemulsion (Figure 20A)71-73,195—is injected into the lateral tail vein of rats. This 
particular NIRF-containing nanoemulsion has been used previously to image and track 
neuroinflammation in vivo and ex vivo196,197 in a rat model13 of neuropathic pain20, 47,71-73, 
48, . Imaging is conducted before and after the injection with a preclinical NIR fluorescence 
imager. This serves as a tool to validate the quality of the agent administration. Imaging 
prior to the tail vein injection serves as a basis for obtaining a baseline image. 
Increasingly in animal studies, intravenously administered nanoemulsions are 
being utilized as biological probes and targeting agents198-201. It is a proven challenge to 
administer an agent via the tail vein203, 204—be it a drug, a viral vector, or another probe—
and to ensure that the entire contents of the injection have successfully entered the 
bloodstream and not the surrounding tissues203. Therefore, a method of visualizing and 
evaluating the quality of a successful injection is beneficial.  
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Typically, a heat lamp or warm water is used to warm the tail, which causes dilation 
of the vein, permitting its visualization prior to injection. While this ensures easier entry 
into the vein, there is not a quantitative way to discern whether the compound has entered 
the bloodstream in its entirety204-207. This becomes more difficult still in strains of animals 
where the vein contrasts faintly with the skin, such as in black mice. Typically, the 
investigator can gauge a failed injection by experiencing resistance during the injection 
and, in some cases, visualizing a bulge on the tail, indicating a subcutaneous leakage of the 
agent208, 209.  
In this study, NIRF imaging of the nanoemulsion injected into the lateral tail vein 
of live rats is performed on a small-animal NIRF imaging system. Rats are fed a special 
purified diet to reduce nonspecific gut fluorescence. Simultaneous image acquisition of 
white light and 800 nm fluorescence is captured using the NIRF imager and associated 
software. The relative fluorescence intensity is measured on the tail at the pre-injection and 
post-injection states. The fluorescence intensity for the region of interest (ROI) at the site 
of injection is recorded and divided by the area of the ROI. Qualitative assessments can be 
made on which injections are acceptable. Optionally, further quantitative analysis can be 
performed by setting thresholds for acceptable injections and assigning ROI measurements 
into groups, at which point statistical significance can be calculated.  
 By utilizing this validation strategy following tail vein injections, the standard of a 
research study improves due to increased consistency of agent administration. This method 
of assessing the quality of tail vein injection can be easily customized for different 






All protocols were performed in accordance with the guidelines in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health and Institutional 
Animal Care and Use Committee (IACUC) at Duquesne University. 
A.1.4.1 Preparation and anesthesia 
NOTE: Aseptic techniques are used for the entirety of the procedure. Only new 
sterile materials and autoclaved sterile instruments are to be used. Personal protective 
equipment (sterile gloves, hair bonnet, surgical mask, scrubs) needs to be worn to avoid 
contamination. 
Use adult male Sprague-Dawley rats weighing 250–300 g. Acclimate the rats to 
standard living conditions, keep them on a 12 h light/12 h dark cycle, and provide food and 
water ad libitum. House the animal socially, keep them on paper bedding, and provide a 
special diet to avoid autofluorescence during imaging. 
With the use of a properly placed heating pad, anesthetize the animal under an 
initial 5% isoflurane in 20% oxygen, followed by a maintenance level of not less than 1.5% 
isoflurane and not more than 3%, unless the animal wakes up or retains feeling.  
Confirm proper anesthesia via a lack of response to tail pinches. Monitor the blood 
flow as well via vital signs throughout the procedure. 
 
A.1.4.2 Pre-injection 
Image the animal in a preclinical NIR fluorescence imager by positioning the 
animal laterally to expose the injection site on the lateral tail to establish a baseline of 
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fluorescence in the tail (Figure 20C,E).  
Following imaging, move the animal back to the surgical table, and place it under 
anesthesia for the tail vein injection. Note: Continue monitoring the rat’s vital signs and 
recheck proper anesthetization via tail pinch.  
 
A.1.4.3 Tail vein injection with NIRF-containing agent 
With the animal in the prone position, orient the tail with the dorsal side facing up. 
Dilate the tail vasculature in warm water for a minimum of 1 min. Orient the tail vein so 
the lateral side (either right or left) is turned 30° (clockwise or counterclockwise) to expose 
the right or left tail vein (Figure 20B).  
Once a lateral tail vein has been located (which appears dark-colored upon dilation), 
sterilize the entire tail with alcohol pads, repeating 2x. 
At an appropriate dosage based on the study design, begin injections in the distal 
coccygeal vertebrae region of the tail and moving more proximal if proper needle 
placement fails. 
Insert a 25–27 G sterile needle, bevel up, into the lateral tail vein, with the tail at a 
180° angle, inserting the needle parallel to the lifted tail. Observe blood flashback in the 
rim of the needle to ensure correct placement. If no flashback is apparent, slowly move the 
needle tip (without removing it from the tail) to find vein insertion. If placed 
subcutaneously, no blood flashback will occur.  
Insert the syringe with the injectable materials into the rim of the needle. When 
proper placement is achieved, the injectable fluid will not incur resistance upon injection. 
The injection will advance smoothly and easily. Once injected, remove the needle and the 
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syringe, apply pressure with sterile gauze for at least 1 min to ensure clotting, and mark the 
spot of injection with a pen on the tail, ensuring it is visible on the white light image. Note: 
No hematoma or lesion will be visible at the site of injection.  
If the needle tip moves during the syringe insertion, remove the needle and retry 
the needle entry procedure more proximal on the ipsilateral tail vein. Do not reuse the same 
needle if a different reentry point is tried. Note: Alternatively, the injection can be 
performed with an IV catheter. This has the benefit of visual confirmation of the catheter 
during venipuncture. Insert the catheter, bevel side up, at the angle previously described. 
Observe prompt flashback in the entire length of the needle and the catheter to ensure 
correct placement. Slight back pressure can be used to pull blood into the syringe to confirm 
proper placement in the vessel before injecting. Again, no resistance will be felt.  
 
A.1.4.4 Post-injection 
Perform quality assessment after the tail vein injection in a preclinical NIR 
fluorescence imager in the same orientation as the pre-injection image. Increase the 
isoflurane anesthesia to 3% for several minutes and move the animal to the imager. Ensure 
the animal is still properly anesthetized. 
Quickly, orient the animal on its lateral side to expose the injection site (as marked) 
on the lateral tail. Check to see if a NIRF signal is present only at the site of injection as 
this is the most optimal injection, indicating a successful tail vein injection (Figure 20D). 
Note: If the signal is sparse but still within the proximal vicinity of the tail vein injection, 
the injection is acceptable and can be considered as a successful tail vein injection. If the 
signal is dispersed throughout the entire tail, it is considered to be subcutaneous and, thus, 
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unsuccessful (Figure 20F). Figure 21 shows additional examples of failed injections. 
 
A.1.4.5 Image quantification 
Note: Image quantification can be performed in the imaging software that 
accompanies the NIR imager, if this is a function of the software. Alternatively, other 
commercially available imaging software may be used25. In the post-injection image, draw 
an ROI around the area of fluorescence at the injection site and clone it in all animals in 
order to compare2,6. Perform a simultaneous image acquisition of white light (body view) 
and 785 nm excitation for 820 nm emission using the NIRF imager and associated software, 
with linked lookup tables (LUT). Perform a one-way analysis of variance (ANOVA) as a 
statistical analysis for the entire set of conditions revealing a treatment effect with a 
statistically significant p-value of 0.0024. 
Measure the area and relative fluorescence intensity and record the measurement 
of the area/intensity. Note: The researcher can decide on thresholds that discriminate good 
from bad injections or assign a percentage of quality to the injection. 
A.1.5 Representative results 
Rats were injected with NIRF-containing nanoemulsion into the lateral tail vein, 
and pre- and post-injection images were taken with the small-animal imager as described 
in the protocol. Post-injection images are qualitatively assessed for injection quality and 
placed into ‘good injection’ (n = 7) and ‘bad injection’ (n = 4) groups. Qualitative 
assessment was carried out by observing the post-injection area fluorescence intensity. In 
an optimal injection, the NIRF signal is confined to the site of injection. No signal will be 
seen if the injection is successful because the agent has been fully displaced into the 
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bloodstream. A bad-quality injection displays a NIRF signal that is dispersed along the 
length of the tail.  
Images were analyzed with the accompanying NIRF imager software. ROIs were 
drawn at the site of pre-injection images (Figure 20C, E) and around the area of 
fluorescence in post-injection images (Figure 20D, F). Images where fluorescence was 
visible throughout the length of the tail were deemed unacceptable and removed from the 
analysis (Figure 21). Measurements of the area and fluorescence intensity were recorded. 
Values for area/fluorescence intensity were calculated and plotted (Figure 20G). A 
significant difference in fluorescence intensity between pre- and postinjection images was 
observed in the ‘bad injection’ group (Figure 20G) (p = 0.0024). 
A.1.6 Figures and Legends  
 
Figure 20. NIRF based nanoemulsion and images of tail vein. (A) A nanoemulsion-
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based biological probe containing NIRF dye was injected into (B) the lateral tail vein 
and imaged in a NIRF imager. (C and D) Pre- and post-injection images of a good 
injection. (E and F) Pre- and postinjection images of a bad injection. White arrows 
indicate the point of injection. It is possible to qualitatively assess the success of a 
good injection compared to a bad injection by assessing the extent of the NIRF signal 
at the site of injection. Unacceptable injections display fluorescence throughout the 
length of the tail and were removed from the analysis (Figure 20). (G) The images 
can also be analyzed to reveal a quantitative measure of fluorescence intensity, with 
thresholds for injection quality assigned by the investigator. The error bars on the 
graph reflect the SEM. For the ‘good injection’ group, n = 7. For the ‘bad injection’ 
group, n = 4. There is a statistical difference in fluorescence intensity in the ‘bad 





Figure 21. Examples of bad injections. (A) Fluorescent signal seen in part of the tail. 
(B) Fluorescent signal seen over the full length of the tail. (C) Fluorescent signal 
dispersed heavily in the entire tail and caudal area of the animal’s body.  
 
A.1.7 Discussion  
Research laboratories incur significant costs as a result of the misadministration of 
testing agents. Tail vein injections are a difficult technique to master to attain consistent 
success rate, with the most experienced of technologists often incurring misadministration 
errors. There is no reliable way to confirm a successful injection. This protocol offers a 
solution to this problem by giving researchers a qualitative and quantitative method to 
validate the success of a murine tail vein injection. Here, a NIRF-labelled 
nanoemulsion196,197,209 incorporates the agent of choice (in this case, a drug) and is imaged 
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at the site of injection in a NIRF small-animal imager. There is also the option to develop 
a non-nanoemulsion-based agent and use the same principle of NIRF imaging by 
incorporating commercially available infra-red dyes. Additionally, ready-to-use imaging 
agents with a variety of applications, such as tumor imaging, metabolic imaging, cell 
trafficking, and apoptosis are also commercially available. An injection is performed either 
by using a sterile needle or, alternatively, an IV catheter; this depends on the preference of 
the researcher. In addition, automated tail vein injectors211 have been used to assist in this 
process and are compatible with this methodology. However, this technology has not yet 
become commercially available. 
There are important steps in the tail vein injection method that ensure a higher rate 
of correct agent administration. First, the tail should be cleaned with ethanol to remove any 
dirt or debris, allowing researchers to better visualize the vein. Dilating the vein by 
submerging the tail in warm water is also a very important step in the method, as it allows 
a greater surface area for injection. Injecting at a more distal point on the tail vein allows 
for some error, in the event that multiple attempts are required. Injection should be 
attempted at a more proximal position in the tail as the tail vein increases in size as the 
caudal aspect of the animal’s body is approached. In addition, the contralateral tail vein 
can be used if needle placement fails in more than three to five sites on the ipsilateral tail 
vein.  
A successful administration of a test agent results in little to no NIRF signal at the 
point of injection. If no resistance is felt during the administration of the injection and there 
is little to no fluorescence at the tail, then the injection can be recorded as successful. If 
resistance is felt during injection and there is a trail of NIRF signal along some length of 
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the tail, then the injection is recorded as unsuccessful and is likely partly subcutaneous. 
Fluorescence images are taken pre- and post-injection, and the quality of the injection is 
assessed by observing qualitatively or analyzing quantitatively the fluorescence signal at 
the site of injection. The software accompanying the NIR fluorescence imager is often 
capable of performing this analysis.  
The method can be adapted in several ways. It is applicable to tail vein injection in 
both mice and rats. Most small-animal NIR fluorescence imagers will be capable of 
accommodating murine rodents. Levels of anesthesia need to be adjusted depending on the 
weight of the animal, in accordance with the research laboratory’s IACUC protocol. 
Another possible modification is the preparation of a non-nanoemulsion-based probe either 
by incorporating an infrared dye into the researcher’s formulated agent or by purchasing a 
ready-to-use imaging agent, tailored to a specific biological application.  
If a rat is relatively large, it can often be difficult to position it in the small-animal 
imager. It is thus recommended that a test image is taken with the animal in the drawer 
before injecting, and a field of view ascertained where the tail is visible. It is helpful to tape 
the tail to the drawer of the imager, to ensure it does not move during imaging.  
Alternative methods seeking to assess the quality of tail vein injections in small 
animals are limited to the utilization of labeling reagents that do not interfere with 
concurrent experimental procedures and require euthanasia of the animals 
postinjection198,199. Some reagents may impact study outcomes and the therapeutic 
assessment of the animals involved, so care in experimental design is recommended.  
This method can, in the future, be refined with advances in small-animal imaging 
technology, as well as improvements in infrared fluorescent probes. Biological probes with 
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an incorporated infrared dye, designed for a variety of different applications, can be used 
at the agent administration stage of a study design to validate the quality of an injection, as 
























Appendix B. RNA Sequencing Master dataset. 
Contributions statement: The University of Pittsburgh Genomics Research Core (Dr. 
Janette Lamb and colleagues) performed RNA sequencing of L4-L5 DRG RNA for the 
three conditions tested.  
The University of Pittsburgh Genomics Analysis Core (Dr. Uma Chandran and 
colleagues) performed differential expression of data obtained from RNA sequencing. 
Experiment design, analyses, and preparation of tables was performed by Andrea Stevens 
under the supervision of Dr. John A. Pollock. 
 
Note: Datasets include only genes differentially expressed with a raw P value ≤ 0.05 
from Chapter 4 (RNA sequencing of DRG tissues).  
 
Table 15. CCI DF-NE versus naïve differential expression data (protein-coding genes). Includes 











Tmcc2 0.05 0.0168 1.0000 Kirrel 0.059 0.024 1.00 
Pdzk1 1.52 0.0459 1.0000 Tln1 0.537 0.048 1.00 
Cplx2 4.94 0.0204 1.0000 Epb41l3 2.387 0.001 0.39 
Slc9a6 0.69 0.0275 1.0000 Telo2 5.993 0.009 1.00 
Smurf1 14.23 0.0295 1.0000 Extl1 16.812 0.029 1.00 
Fbxw8 3.11 0.0186 1.0000 Fancc 9.116 0.004 1.00 
Pcbp3 3.44 0.0180 1.0000 Atrnl1 10.855 0.001 0.47 
Clip1 0.05 0.0083 1.0000 Nudt6 0.289 0.033 1.00 
Rcc1l 0.06 0.0242 1.0000 Tubb2b 0.375 0.020 1.00 
St3gal6 0.04 0.0139 1.0000 Cltb 0.197 0.017 1.00 
Dvl3 0.07 0.0451 1.0000 Usp3 0.065 0.047 1.00 
Exoc1 0.06 0.0274 1.0000 LOC108348250 4.282 0.018 1.00 
Lnx1 0.15 0.0237 1.0000 Tpbgl 3.906 0.028 1.00 
Galnt10 10.00 0.0013 0.5899 Ubap2l 6.426 0.045 1.00 
Mat2b 14.24 0.0331 1.0000 Apbb1 3.544 0.011 1.00 
Col3a1 0.42 0.0070 1.0000 Syt5 3.356 0.020 1.00 
LOC103690141 3.33 0.0427 1.0000 Pde4dip 6.048 0.030 1.00 
Trove2 0.16 0.0405 1.0000 Rabep2 8.274 0.028 1.00 
Tom1l2 3.30 0.0471 1.0000 Iffo1 6.487 0.027 1.00 
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Pkmyt1 1.44 0.0071 1.0000 Stat5b 0.037 0.002 0.80 
Hmox2 3.48 0.0036 1.0000 Pik3r2 0.066 0.040 1.00 
Col1a1 0.59 0.0234 1.0000 Hipk1 0.098 0.001 0.56 
Aldh9a1 0.16 0.0352 1.0000 Mpv17l2 1.826 0.000 0.36 
Ano3 7.37 0.0127 1.0000 Dag1 2.066 0.037 1.00 
Nalcn 7.35 0.0388 1.0000 Zmynd15 0.341 0.007 1.00 
Arhgef25 6.49 0.0286 1.0000 Ino80e 2.146 0.025 1.00 
Scn8a 3.93 0.0015 0.5938 Wbp1l 0.159 0.039 1.00 
Vsnl1 5.50 0.0128 1.0000 Rhog 24.850 0.001 0.59 
Rab3ip 14.24 0.0290 1.0000 Gsk3a 2.131 0.041 1.00 
Ngfr 1.91 0.0465 1.0000 Htra1 4.002 0.008 1.00 
Lyz2 0.34 0.0237 1.0000 Fxyd3 0.497 0.023 1.00 
Snap25 3.32 0.0052 1.0000 Tnfaip8l2 14.214 0.046 1.00 
Dync1h1 1.47 0.0364 1.0000 Nrxn2 3.114 0.016 1.00 
Trim37 2.32 0.0139 1.0000 Dnaaf5 14.237 0.040 1.00 
Klhl9 14.20 0.0352 1.0000 Pusl1 2.070 0.040 1.00 
Srgap3 3.62 0.0294 1.0000 Fkbp5 0.051 0.013 1.00 
Borcs6 0.05 0.0135 1.0000 Zdhhc2 13.429 0.000 0.29 
Il12rb2 3.58 0.0194 1.0000 Col6a6 0.047 0.007 1.00 
Slit3 5.47 0.0104 1.0000 Lrtomt 6.527 0.034 1.00 
Pcnx1 0.32 0.0113 1.0000 Fancf 0.059 0.023 1.00 
Nckap1 7.44 0.0263 1.0000 Cbarp 0.158 0.027 1.00 
Mcam 0.16 0.0499 1.0000 Mrps21 3.330 0.034 1.00 
Tagln2 0.69 0.0144 1.0000 Ppp1r1c 3.069 0.028 1.00 
Nefh 1.68 0.0000 0.1236 Mars 3.902 0.030 1.00 
Parp2 0.74 0.0071 1.0000 Abhd1 1.280 0.008 1.00 
Mtss1 0.12 0.0075 1.0000 Tril 4.419 0.043 1.00 
Trappc12 3.20 0.0456 1.0000 Gga3 1.461 0.049 1.00 
Sez6 0.07 0.0399 1.0000 LOC684988 2.166 0.014 1.00 
Tmem59 0.18 0.0075 1.0000 Wdr1 2.959 0.045 1.00 
Dync1i2 4.21 0.0078 1.0000 Kif26b 0.059 0.034 1.00 
LOC100362176 14.24 0.0322 1.0000 Cyp2t1 2.176 0.041 1.00 
Kcnh2 9.93 0.0048 1.0000 Ormdl2 7.382 0.018 1.00 
Ttc17 14.24 0.0290 1.0000 Dhx16 2.619 0.001 0.56 
Kank2 0.07 0.0424 1.0000 Ttll7 4.129 0.002 0.59 
Lama3 4.22 0.0099 1.0000 Tmem42 0.047 0.007 1.00 
Rab11a 6.00 0.0161 1.0000 Uqcrc1 3.169 0.004 1.00 
Tbck 14.26 0.0353 1.0000 Dot1l 0.084 0.000 0.36 
Vat1l 2.54 0.0287 1.0000 Prdm2 5.980 0.011 1.00 
Ifngr1 27.47 0.0005 0.3568 Mt-nd3 3.511 0.009 1.00 
Slirp 1.72 0.0328 1.0000 Apc2 2.190 0.049 1.00 
Adk 9.07 0.0052 1.0000 Uqcrc2 7.365 0.013 1.00 
Tnik 0.15 0.0025 0.8654 Fam227b 14.254 0.037 1.00 
Kif13b 3.22 0.0324 1.0000 Exoc3 3.015 0.036 1.00 
Wwc2 0.23 0.0462 1.0000 Chmp2b 14.226 0.031 1.00 
Tm9sf3 0.10 0.0036 1.0000 Marveld1 0.043 0.009 1.00 
Cela2a 5.34 0.0495 1.0000 Ncald 24.816 0.001 0.59 
Nefl 1.98 0.0005 0.3568 AABR07002068.1 2.541 0.042 1.00 
Large1 3.73 0.0264 1.0000 Klhdc8b 14.236 0.029 1.00 
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Nefm 1.70 0.0030 0.9613 AABR07000534.1 0.356 0.027 1.00 
St5 4.04 0.0337 1.0000 Ptrh1 1.333 0.015 1.00 
Acat2l1 0.62 0.0261 1.0000 Gtf3a 0.280 0.009 1.00 
Plekhb2 0.34 0.0219 1.0000 Fbln5 2.958 0.047 1.00 
Map1a 1.67 0.0004 0.3568 Nrn1 1.978 0.044 1.00 
Slc35g3 3.62 0.0258 1.0000 Card9 14.237 0.029 1.00 
Atxn10 4.95 0.0345 1.0000 Cox11 2.006 0.046 1.00 
Prune2 2.01 0.0270 1.0000 Ywhah 1.319 0.002 0.63 
Gal 0.05 0.0101 1.0000 AABR07025316.1 0.586 0.000 0.29 
Jup 0.20 0.0029 0.9459 Ttll13 0.026 0.000 0.25 
Serinc4 0.64 0.0001 0.1588 Mast2 16.873 0.016 1.00 
Polr2c 1.81 0.0283 1.0000 Nek9 19.637 0.013 1.00 
Rap1gds1 0.06 0.0397 1.0000 AABR07073400.1 16.990 0.046 1.00 
Hmgcr 0.06 0.0228 1.0000 Kat5 0.131 0.029 1.00 
Gtf3c1 0.25 0.0151 1.0000 LOC103694857 0.014 0.009 1.00 





















Table 16. CCI DF-NE versus naïve differential expression data (non-coding genes). Includes differential 





Change Raw P value FDR value 
Gm22953 miRNA 0.801 0.0204 1.00 
AC120291.1 miRNA 0.562 0.0424 1.00 
AC130391.2 miRNA 0.444 0.0084 1.00 
AC099089.1 miRNA 0.701 0.0006 0.39 
AABR07072559.1 miRNA 0.413 0.0224 1.00 
AC114096.2 miRNA 0.305 0.0000 0.12 
AC105645.3 miRNA 0.544 0.0143 1.00 
AABR07027752.3 miRNA 0.489 0.0067 1.00 
AABR07043167.3 miRNA 1.925 0.0317 1.00 


















Table 17. CCI CXB-NE versus naïve differential expression data (protein-coding genes). Includes 










value FDR  
Tmcc2 18.95 0.029 0.62 Celsr1 10.161 0.003 0.17 
Slc26a1 3.03 0.000 0.01 Tmem91 5.486 0.040 0.70 
Zbtb24 5.76 0.007 0.30 AABR07073181.1 2.658 0.015 0.46 
Pln 3.78 0.008 0.31 Pptc7 0.120 0.042 0.71 
Numa1 4.51 0.001 0.09 Reln 2.672 0.007 0.30 
Scube3 6.35 0.000 0.00 Wfikkn1 4.886 0.033 0.63 
Marcks 0.22 0.050 0.77 Kmt2e 2.727 0.017 0.49 
RT1-S3 5.06 0.002 0.12 Atp8b5p 4.943 0.039 0.69 
Pdap1 32.54 0.001 0.11 Tecr 3.373 0.026 0.58 
Ankrd61 9.13 0.002 0.16 Uba6 16.773 0.045 0.74 
Stard13 8.59 0.005 0.24 Cabp4 26.904 0.039 0.69 
Fam207a 16.70 0.031 0.62 Lrrc19 23.362 0.016 0.46 
Clip1 34.66 0.000 0.04 Primpol 16.722 0.045 0.74 
Gper1 8.60 0.007 0.30 Dennd4b 30.317 0.002 0.16 
Il3ra 16.77 0.045 0.74 Flrt1 23.227 0.016 0.46 
Mcm7 6.49 0.020 0.53 Fkbp5 30.359 0.003 0.17 
Slc8b1 21.22 0.032 0.63 Tmem126a 2.965 0.023 0.56 
Hip1 28.48 0.006 0.28 Evi2a 3.806 0.024 0.56 
Kif13a 16.62 0.041 0.71 Ccser2 0.415 0.025 0.58 
Rcc1l 21.19 0.009 0.33 Hjurp 4.039 0.010 0.36 
Hoxd4 0.44 0.020 0.53 Ppp2r3a 4.040 0.004 0.22 
Cct8 28.07 0.007 0.30 Pmel 2.886 0.037 0.69 
St3gal6 27.95 0.008 0.32 Sec61a2 6.002 0.025 0.58 
Kalrn 23.78 0.033 0.63 LOC500300 10.799 0.002 0.11 
Eif4a2 4.94 0.047 0.75 Ahctf1 5.987 0.026 0.58 
Ube2l3 18.91 0.018 0.51 Sned1 6.512 0.012 0.40 
Serpind1 4.94 0.039 0.69 Ppp2r3c 2.254 0.048 0.75 
Alcam 2.80 0.006 0.28 Plec 1.514 0.035 0.66 
Tmem50b 5.47 0.025 0.57 Man2b1 4.943 0.039 0.69 
Usp46 0.06 0.037 0.68 Ggn 23.425 0.004 0.22 
Sod1 4.62 0.044 0.73 Aco2 5.280 0.000 0.01 
RGD1311575 7.56 0.013 0.42 Pcna 0.229 0.047 0.74 
Exoc1 25.65 0.012 0.40 Senp6 18.784 0.030 0.62 
Fam175a 25.64 0.006 0.29 Kif20a 3.248 0.003 0.17 
Clock 32.51 0.002 0.15 Klhl34 2.950 0.001 0.09 
Adcy5 7.84 0.001 0.10 Nup50 28.295 0.010 0.36 
Lnx1 8.65 0.010 0.36 Ppm1e 21.190 0.008 0.31 
Eprs 3.98 0.023 0.56 Polr2b 0.443 0.000 0.01 
Slc30a10 2.63 0.044 0.73 Mrps21 0.208 0.007 0.31 
Gpatch2 5.49 0.045 0.74 Nnat 43.409 0.002 0.12 
Ero1b 3.26 0.025 0.57 Gpr183 64.230 0.000 0.00 
Mtmr1 18.99 0.023 0.56 Nup188 6.619 0.003 0.19 
Fstl1 0.58 0.046 0.74 Lrrc8a 32.253 0.001 0.09 
 
 161 
Fam104a 2.75 0.005 0.25 Gpr171 18.917 0.018 0.51 
Myo19 3.85 0.008 0.31 Fer1l6 48.109 0.000 0.00 
Klhl20 16.70 0.031 0.62 Mars 0.294 0.039 0.69 
Alg1 2.08 0.046 0.74 Nsun7 6.505 0.032 0.63 
Arr3 4.43 0.013 0.42 Jph4 16.732 0.035 0.66 
Sdhc 0.32 0.019 0.51 Zfhx2 19.604 0.000 0.00 
Hexim1 3.41 0.007 0.30 Abhd1 0.716 0.001 0.06 
Nudt16l1 30.01 0.003 0.16 Gpr17 22.117 0.000 0.00 
Tp53bp2 16.70 0.042 0.71 Myh6 17.310 0.000 0.00 
Trove2 5.93 0.036 0.68 Set 1.894 0.012 0.41 
Pnpt1 7.07 0.019 0.52 Gp1ba 16.703 0.031 0.62 
Hn1 4.94 0.039 0.69 Pex1 3.443 0.044 0.73 
Enam 18.95 0.016 0.46 Gbf1 3.395 0.036 0.67 
Wdr26 25.50 0.011 0.38 Morn5 0.684 0.015 0.46 
Flrt2 16.77 0.044 0.73 Adpgk 20.121 0.000 0.00 
Clgn 6.53 0.020 0.53 Ap2a1 3.069 0.046 0.74 
Nit1 7.04 0.023 0.56 Iqcg 21.602 0.039 0.69 
Sgca 21.14 0.018 0.50 Syt7 18.946 0.016 0.46 
Tmem94 50.68 0.000 0.01 Lrrtm3 25.058 0.000 0.00 
Ptger1 2.07 0.027 0.60 LOC102555377 4.871 0.020 0.54 
Vasn 10.72 0.002 0.12 Pmpca 1.777 0.018 0.50 
Dnah9 32.34 0.001 0.07 Disp2 4.575 0.021 0.54 
Eml5 2.75 0.036 0.68 LOC690784 30.084 0.002 0.11 
Cox20 3.24 0.001 0.09 Usp54 3.093 0.042 0.72 
Dcn 0.13 0.046 0.74 Gga3 0.607 0.014 0.44 
Cacna1b 6.54 0.024 0.56 RGD1562319 32.404 0.000 0.05 
Ofd1 7.56 0.014 0.44 Ctsw 4.942 0.039 0.69 
Angptl1 18.84 0.000 0.01 Sez6l2 4.565 0.042 0.72 
Ano3 0.12 0.022 0.54 Fbxl2 21.190 0.008 0.31 
Arid2 16.73 0.039 0.69 RGD1359290 9.120 0.006 0.28 
Flrt3 41.38 0.000 0.01 AABR07060293.1 9.687 0.006 0.28 
Erbb3 2.74 0.002 0.12 Rtel1 3.811 0.024 0.56 
Agr3 21.32 0.014 0.45 Ssx1 7.559 0.013 0.42 
Agr2 34.79 0.001 0.09 Ankrd11 4.175 0.008 0.31 
Csdc2 5.98 0.043 0.72 Cdh15 4.585 0.040 0.70 
Kcnmb1 21.13 0.010 0.37 LOC684988 0.340 0.002 0.13 
Apob 8.00 0.022 0.54 Arhgef18 6.523 0.015 0.46 
Btbd11 16.62 0.041 0.71 Mki67 23.453 0.005 0.24 
Slc10a1 43.62 0.000 0.01 Sh2b3 4.912 0.000 0.01 
Ctnna1 0.20 0.045 0.73 Myrf 27.866 0.007 0.30 
Skp1 5.46 0.044 0.73 Gnl3 7.591 0.019 0.52 
Snap25 0.35 0.008 0.32 Zc3h18 6.007 0.027 0.60 
Ezh2 3.54 0.010 0.36 Ctns 4.326 0.000 0.01 
Rfx1 5.88 0.000 0.04 Dgat1 16.844 0.049 0.76 
Steap2 16.70 0.031 0.62 Vps9d1 16.703 0.031 0.62 
LRRTM1 74.86 0.000 0.00 Eppin 4.911 0.029 0.62 
Stx18 5.47 0.001 0.10 RT1-S2 21.343 0.023 0.56 
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Trim37 0.44 0.021 0.54 Rasa1 28.105 0.005 0.24 
Wwp1 40.71 0.007 0.29 RGD1563145 4.943 0.039 0.69 
Snf8 5.93 0.049 0.76 Robo1 16.702 0.031 0.62 
Borcs6 16.74 0.043 0.73 Letmd1 3.586 0.049 0.76 
Crbn 2.46 0.047 0.75 Grina 3.273 0.018 0.50 
Fndc9 2.76 0.040 0.70 Adck5 3.022 0.025 0.58 
Pzp 3.65 0.018 0.50 AABR07000595.1 77.364 0.000 0.00 
Neb 4.09 0.027 0.60 Mt-nd2 2.181 0.012 0.41 
Sema4f 5.05 0.003 0.19 Mab21l2 7.028 0.020 0.53 
Psapl1 43.60 0.000 0.01 LOC100361645 4.215 0.011 0.39 
Casq1 43.59 0.003 0.17 Pcdh10 23.644 0.010 0.37 
Vamp2 18.95 0.041 0.71 Pogk 39.078 0.000 0.02 
Slc3a1 1.35 0.045 0.73 Acsm3 11.739 0.000 0.05 
March10  27.95 0.003 0.17 Dot1l 6.500 0.046 0.74 
Xpot 18.89 0.020 0.53 Scrib 8.158 0.006 0.28 
Cacna1c 35.10 0.002 0.12 Ptprt 4.572 0.032 0.63 
Nrdc 4.40 0.024 0.57 Dysf 6.621 0.033 0.63 
Ndrg1 0.31 0.028 0.61 Mab21l1 4.016 0.012 0.41 
Pla2g4b 3.49 0.000 0.00 Pdzd7 16.618 0.041 0.71 
Tmem132e 0.05 0.048 0.75 AC127605.1 34.445 0.001 0.10 
Kcnj9 6.28 0.000 0.04 Zrsr2 16.703 0.031 0.62 
Mcam 8.04 0.013 0.42 Cacna2d1 2.546 0.049 0.76 
Atg101 0.05 0.044 0.73 Osbpl9 2.658 0.021 0.54 
Usp1 5.98 0.031 0.62 Fam196a 4.328 0.000 0.04 
Mpdz 4.94 0.042 0.71 Ube2d4 32.346 0.002 0.14 
Timp4 59.32 0.000 0.00 Cfap126 0.315 0.012 0.40 
Tmem30b 21.19 0.008 0.31 Rps27a 18.722 0.034 0.66 
Atp8a2 2.97 0.024 0.56 Ifit2 16.703 0.031 0.62 
Ccne2 2.26 0.001 0.10 Fscn2 3.069 0.016 0.46 
Lrrc4 6.38 0.000 0.01 Uqcrc2 0.201 0.022 0.54 
Appl2 8.55 0.022 0.54 Atp6v0a1 5.499 0.034 0.65 
Orc3 5.48 0.030 0.62 Abhd12 5.979 0.026 0.58 
Slc9a8 3.82 0.026 0.58 LOC100360933 16.702 0.031 0.62 
Myo1f 5.49 0.049 0.76 Hyi 3.028 0.045 0.73 
Bsg 0.60 0.002 0.12 Erich4 30.070 0.002 0.12 
Gpr22 12.18 0.000 0.01 Spidr 7.535 0.001 0.07 
Eid1 4.99 0.002 0.12 Pram1 74.621 0.000 0.00 
Nkiras1 16.70 0.031 0.62 Ccdc152 0.653 0.004 0.21 
Smad3 8.60 0.009 0.33 Rab26 2.493 0.001 0.09 
Angptl3 32.40 0.000 0.05 AABR07006480.1 2.969 0.021 0.54 
Nefh 0.67 0.002 0.12 Ahdc1 18.948 0.022 0.54 
Pnisr 3.00 0.000 0.05 Cep192 18.849 0.031 0.62 
Orc1 8.56 0.016 0.46 AABR07005040.1 25.676 0.004 0.21 
Adamts10 5.96 0.030 0.62 U2af1 0.119 0.036 0.68 
Parp2 0.44 0.000 0.00 Ralgapa1 0.180 0.027 0.59 
Pcdh17 8.11 0.011 0.37 Znf750 23.638 0.013 0.42 
Foxj2 16.65 0.039 0.69 AC133403.1 0.725 0.022 0.54 
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Mtss1 9.13 0.004 0.21 Thyn1 2.231 0.021 0.54 
Thra 3.11 0.000 0.00 Lrrtm2 12.724 0.000 0.00 
Atp6v1d 5.47 0.042 0.71 Cdan1 7.537 0.000 0.04 
Sez6 25.68 0.002 0.13 AC115420.2 2.063 0.020 0.53 
LOC102552055 5.86 0.001 0.07 Mdn1 7.038 0.043 0.73 
Tas1r1 4.94 0.050 0.77 Olr338 18.920 0.019 0.53 
Lgals1 0.71 0.026 0.59 Cyp2ac1 8.806 0.011 0.38 
LOC100151767 0.65 0.001 0.10 Myo18b 3.242 0.020 0.53 
Smarcd3 3.17 0.023 0.56  11.486 0.000 0.00 
Azi2 19.13 0.031 0.62 AABR07000534.1 14.005 0.000 0.00 
Eps15 6.02 0.031 0.62 Pdss1 7.018 0.016 0.47 
Ipo7 4.18 0.004 0.20 Kdm4b 6.055 0.008 0.32 
Mycbp2 10.17 0.004 0.22 Adamtsl4 2.854 0.030 0.62 
Smarcd2 2.90 0.025 0.57 Sh3gl1 3.711 0.003 0.18 
Megf11 43.25 0.000 0.04 Dnajc19 2.060 0.031 0.62 
Plekhh1 7.05 0.009 0.34 Gtf3a 3.143 0.026 0.58 
E2f5 23.43 0.005 0.24 Nrn1 0.290 0.001 0.09 
Arrdc4 4.94 0.039 0.69 Dopey2 5.787 0.013 0.42 
Nfe2l3 32.41 0.000 0.05 Col10a1 3.804 0.023 0.56 
Bmp1 7.51 0.018 0.50 AC132720.1 6.040 0.037 0.69 
Pigh 4.17 0.004 0.20 Exosc8 18.946 0.016 0.46 
Has1 8.61 0.004 0.22 Slc24a1 5.471 0.023 0.56 
Cep295 21.31 0.000 0.00 AC132539.1 0.048 0.046 0.74 
Ank2 1.85 0.010 0.36 Ahsa2 4.016 0.012 0.41 
Tenm4 16.81 0.047 0.75 Arhgef40 2.058 0.001 0.06 
RGD1359634 2.16 0.016 0.46 Ak3 2.924 0.045 0.74 
Lrp2bp 21.19 0.008 0.31 Itpr3 2.176 0.010 0.36 
Tfdp2 21.17 0.036 0.67 AC130391.3 0.746 0.030 0.62 
Masp2 7.72 0.000 0.00 Slc48a1 16.702 0.031 0.62 
Slc37a4 18.95 0.016 0.46 AC103090.1 1.704 0.014 0.44 
Kif3c 3.81 0.033 0.63 Lama5 21.189 0.008 0.31 
Ccdc39 3.71 0.002 0.15 B3gnt9 41.051 0.000 0.04 
Arfgef3 5.73 0.011 0.39 Sim2 3.603 0.031 0.62 
Ap3m1 4.60 0.000 0.02 Ywhah 0.667 0.000 0.00 
Psip1 1.94 0.032 0.63 AABR07025316.1 10.187 0.000 0.00 
Gcsh 21.19 0.008 0.31 AC141521.2 2.607 0.017 0.48 
Rnf146 4.57 0.023 0.56 Fam46b 18.946 0.016 0.46 
Dusp4 25.98 0.027 0.60 Gls 2.389 0.031 0.62 
Galnt7 18.92 0.019 0.53 Ttll13 83.654 0.000 0.00 
Col17a1 18.95 0.016 0.46 LOC102552324 25.761 0.003 0.17 
Dst 1.59 0.005 0.24 Alas1 4.937 0.042 0.71 
Slirp 0.51 0.014 0.43 Muc6 6.490 0.000 0.04 
Unc45a 18.85 0.022 0.54 Scn3b 3.716 0.010 0.37 
Glyatl2 32.53 0.001 0.10 Adamts5 3.082 0.013 0.42 
Tnik 7.27 0.001 0.07 Pfkm 4.574 0.031 0.62 
Cemip 19.05 0.029 0.62 AABR07020815.1 0.426 0.026 0.58 
Tlcd1 0.76 0.000 0.00 Plcb2 16.641 0.038 0.69 
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Gpr18 4.84 0.001 0.11 Cfap99 2.497 0.032 0.62 
Espl1 23.71 0.012 0.41 RGD1562378 0.042 0.008 0.31 
Uaca 21.21 0.009 0.33 Srrm2 2.998 0.001 0.10 
Mov10 3.73 0.002 0.14 AC106292.2 1.337 0.026 0.58 
Metap1 8.08 0.007 0.31 Fbxl3 8.605 0.004 0.22 
Lrig1 4.87 0.028 0.61 Has3 5.143 0.000 0.04 
Atpif1 0.18 0.019 0.53 Itgb1bp1 23.479 0.006 0.26 
Ccdc150 4.94 0.039 0.69 Cc2d2a 19.044 0.024 0.56 
Tm9sf3 10.16 0.005 0.23 AABR07035428.2 4.359 0.002 0.14 
Ralbp1 4.08 0.038 0.69 AABR07059140.1 23.474 0.005 0.26 
Nefl 0.63 0.024 0.56 Ypel4 3.806 0.030 0.62 
Megf10 18.79 0.036 0.67 Kdm5d 12.288 0.000 0.04 
Tnip2 16.70 0.031 0.62 AC128154.1 3.819 0.030 0.62 
P2ry14 32.42 0.001 0.07 Rnf114 18.789 0.029 0.62 
Gpr87 21.28 0.019 0.52 AABR07058091.2 16.464 0.000 0.01 
Sbno2 0.63 0.000 0.00 Kmt2d 4.274 0.000 0.05 
Jade1 19.21 0.040 0.70 Plxnb3 18.992 0.036 0.67 
Kifc3 21.50 0.022 0.54 Rbm4b 9.898 0.000 0.01 
Omg 16.22 0.001 0.07 Myo1e 23.340 0.012 0.41 
Evi2b 3.80 0.045 0.74 Cfap100 18.946 0.016 0.46 
Tns1 0.49 0.048 0.75 F2rl2 8.160 0.000 0.00 
P2ry1 16.70 0.031 0.62 Slc26a2 18.915 0.021 0.54 
Capn5 3.14 0.031 0.62 Acadvl 4.797 0.000 0.00 
Josd1 16.84 0.049 0.76 Abca1 3.029 0.044 0.73 
Nav2 6.51 0.015 0.46 Slc16a4 34.649 0.000 0.03 
Plcxd3 19.10 0.033 0.64 Mgat4a 25.644 0.015 0.46 
Btbd6 3.41 0.005 0.25 Aak1 4.189 0.020 0.53 
Chrnb1 4.94 0.039 0.69 Prpf18 3.597 0.001 0.11 
Tmbim1 4.32 0.003 0.16 Apoe 0.665 0.022 0.54 
Zfyve28 7.03 0.024 0.56 Prr14 16.720 0.033 0.63 
Mas1 34.61 0.000 0.04 Iffo1 0.228 0.039 0.69 
Myo7b 84.51 0.000 0.00 Pprc1 0.253 0.040 0.70 
Dmpk 25.76 0.003 0.17 Abcb6 25.769 0.007 0.31 
Lrrc39 1.97 0.031 0.62 Slc16a11 3.399 0.005 0.25 
Timm21 23.43 0.004 0.21 Gsn 0.422 0.049 0.76 
Gal 16.79 0.037 0.68 Sod2 3.533 0.007 0.30 
Etfa 23.49 0.007 0.29 Chp2 0.048 0.046 0.74 
Spsb3 1.91 0.010 0.36 Pik3r2 18.945 0.016 0.46 
Serpine2 0.18 0.006 0.29 Glb1l 28.060 0.012 0.40 
Serinc4 1.35 0.007 0.30 Stx4 16.654 0.036 0.68 
Otud7a 25.55 0.006 0.28 Fchsd2 4.060 0.041 0.70 
Ptgds 0.31 0.002 0.14 Hipk1 10.676 0.001 0.10 
Plpp5 5.97 0.046 0.74 Sult1a1 9.647 0.003 0.17 
LOC100125364 13.93 0.000 0.03 Lrfn4 7.980 0.015 0.46 
LOC690507 11.24 0.001 0.10 Egfl7 25.434 0.049 0.76 
Parva 5.89 0.000 0.01 Mpv17l2 0.701 0.043 0.73 
Ube3a 2.95 0.026 0.59 Rec8 30.117 0.006 0.27 
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Elmo3 10.84 0.000 0.00 Trpv3 31.107 0.000 0.00 
Add2 7.04 0.024 0.56 Csrnp2 12.268 0.000 0.02 
Rap1gds1 21.07 0.018 0.50 Rsbn1 16.720 0.033 0.63 
Plekhg1 7.38 0.023 0.56 Ints11 1.663 0.014 0.45 
Macf1 2.22 0.049 0.76 Exoc8 4.943 0.039 0.69 
Lrrc14 3.78 0.001 0.06 Sipa1l2 5.466 0.022 0.54 
Gpr162 2.75 0.010 0.36 Slc5a2 1.655 0.016 0.46 
Strn4 2.60 0.032 0.62 Tmem198 3.401 0.045 0.74 
Spata2L 6.36 0.005 0.23 Eef1g 0.227 0.015 0.46 
Gtf3c1 3.40 0.026 0.58 Sirt2 4.026 0.019 0.52 
Myo9b 6.04 0.005 0.23 Il4i1 3.247 0.027 0.59 
Creb3 2.86 0.033 0.63 Tbc1d17 6.001 0.026 0.58 
Tmem204 10.19 0.002 0.14 Scgb1a1 18.946 0.016 0.46 
Pllp 23.43 0.004 0.22 Asrgl1 5.055 0.003 0.18 
Dgat2 16.65 0.039 0.69 Atp1a3 2.805 0.012 0.41 
Mlf2 0.20 0.004 0.22 Cntnap1 25.676 0.004 0.21 
Dtna 25.69 0.008 0.31 Pdcd11 18.906 0.022 0.55 
Angptl2 4.57 0.023 0.56 Ezh1 5.989 0.022 0.54 
Tmc7 16.70 0.035 0.66 Best1 0.644 0.000 0.01 
Angpt2 7.56 0.013 0.42 Apc 2.769 0.033 0.63 
Prpf4b 30.14 0.001 0.11 Hcn3 0.201 0.022 0.54 
Fanca 2.52 0.005 0.25 Cd81 4.032 0.003 0.18 
Pcif1 8.15 0.000 0.00 Nsmce4a 0.057 0.047 0.75 
Inpp5d 16.70 0.031 0.62 Ripk3 16.646 0.045 0.74 
Kcne3 16.70 0.031 0.62 Bcl2l12 4.557 0.000 0.05 
Tbc1d22a 25.78 0.008 0.32 Lipe 3.796 0.007 0.30 
Slc25a46 0.29 0.040 0.70 Ceacam1 8.082 0.007 0.31 
Cyp27a1 19.08 0.039 0.69 Dcst1 27.254 0.020 0.53 
Tubb3 1.38 0.048 0.75 Celf3 36.891 0.000 0.02 
Slc22a23 4.55 0.002 0.12 Gif 23.433 0.004 0.21 
Igsf6 4.57 0.031 0.62 Ppp2r5b 6.512 0.012 0.40 
Kcnt1 4.94 0.039 0.69 Sphk2 9.602 0.000 0.01 
Cab39 2.74 0.012 0.41 Lsr 7.528 0.000 0.00 
Atrnl1 0.19 0.006 0.27 Fxyd1 16.702 0.031 0.62 
Nudt6 5.24 0.001 0.07 Fxyd3 3.451 0.000 0.00 
Htr2b 9.65 0.002 0.16 Nrxn2 0.198 0.003 0.17 
Fbxl22 2.42 0.028 0.61 Gramd1a 8.095 0.009 0.34 








Table 18. CCI CXB-NE versus naïve differential expression data (non-coding genes). Includes differential 
expression data using one-way ANOVA analyses of pooled L4-L5 DRGs from RNA sequencing. 
Gene Gene Biotype Fold Change Raw P value FDR 
Mir3065 miRNA 30.161 0.001 0.091 
Mir3588 miRNA 26.147 0.012 0.407 
Mir3074 miRNA 12.945 0.000 0.000 
AABR07031182.1 miRNA 16.702 0.031 0.622 
AABR07073453.1 lincRNA 25.676 0.004 0.210 
AC099089.1 miRNA 0.790 0.039 0.692 
AABR07062800.1 lincRNA 7.281 0.004 0.222 
AABR07033249.1 lincRNA 27.947 0.003 0.169 
AABR07033570.1 lincRNA 12.285 0.000 0.026 
AABR07051515.2 lincRNA 7.585 0.012 0.405 
AABR07037523.2 miRNA 0.146 0.021 0.539 
AABR07035926.2 lincRNA 30.197 0.003 0.169 
AABR07006713.1 lincRNA 18.946 0.016 0.456 
Rn60_1_2212.2 lincRNA 5.542 0.000 0.000 
Rn60_1_2212.3 lincRNA 2.631 0.042 0.717 
















Table 19. CCI DF-NE vs CCI CXB-NE differential expression data (protein-coding genes). Includes 













Slc26a1 2.656 0.000 0.005 Telo2 6.155 0.003 0.138 
Tmem175 26.281 0.006 0.217 Cmtm5 6.164 0.004 0.169 
Pdzk1 1.838 0.002 0.108 Wdr37 5.376 0.027 0.479 
Zbtb24 3.231 0.014 0.327 Pcif1 6.240 0.000 0.000 
Pln 5.957 0.000 0.026 Rnf25 27.582 0.006 0.203 
Asf1a 33.638 0.000 0.007 Fancc 12.978 0.000 0.005 
Scube3 6.934 0.000 0.000 Acly 1.565 0.031 0.498 
Reep3 0.192 0.012 0.310 Clcn7 13.987 0.037 0.558 
Jmjd1c 3.184 0.034 0.530 Lmntd2 14.034 0.031 0.498 
Srrd 4.699 0.023 0.444 Kcne3 16.187 0.012 0.310 
RT1-M3-1 14.017 0.029 0.487 Tbc1d22a 24.968 0.002 0.119 
RT1-S3 2.972 0.013 0.317 Slc22a23 4.939 0.000 0.030 
Ankrd61 6.497 0.002 0.115 Kcnt1 20.525 0.005 0.194 
Fbxw8 3.756 0.003 0.146 Map3k4 5.976 0.045 0.620 
Gatc 4.080 0.012 0.310 Spns1 7.387 0.019 0.391 
Agpat3 3.828 0.032 0.512 Htr2b 4.857 0.003 0.142 
Pcbp3 3.221 0.022 0.425 Mylpf 4.378 0.040 0.587 
Gpr146 5.385 0.033 0.523 Ccdc172 14.017 0.029 0.487 
P2rx4 13.958 0.039 0.577 Inpp4a 2.716 0.024 0.451 
Por 14.022 0.030 0.496 LOC108348250 5.640 0.001 0.079 
C2cd2 3.048 0.048 0.646 Optn 4.907 0.027 0.486 
Slc51a 18.355 0.005 0.194 Mvb12a 22.724 0.003 0.132 
Itpr2 20.693 0.017 0.364 F2rl2 10.425 0.000 0.000 
Ube2l3 18.318 0.006 0.220 Slc22a8 16.145 0.023 0.446 
Slc7a4 16.292 0.027 0.486 Acadvl 2.458 0.001 0.064 
Ptpn13 18.306 0.007 0.225 Srrm1 5.003 0.007 0.235 
RGD1311575 5.381 0.008 0.241 Syt5 3.570 0.009 0.259 
Helq 14.058 0.033 0.523 Pde4dip 7.329 0.013 0.317 
Adcy5 3.695 0.010 0.286 Ccar2 5.121 0.017 0.356 
Mark1 13.954 0.040 0.583 Aak1 4.124 0.012 0.309 
Trim41 5.411 0.038 0.571 Cul9 4.791 0.031 0.498 
Fam129a 0.168 0.012 0.310 Prpf18 2.256 0.014 0.331 
Galnt10 9.186 0.003 0.127 Per3 20.377 0.009 0.264 
Cdkl2 6.009 0.032 0.512 Unc13a 6.652 0.017 0.357 
Ero1b 6.651 0.000 0.034 Rabep2 10.955 0.014 0.330 
Gemin5 8.484 0.005 0.194 Otud4 0.267 0.021 0.417 
Zfp692 16.210 0.015 0.347 Plekhb1 2.694 0.004 0.153 
Sstr2 15.908 0.033 0.522 Patz1 5.723 0.011 0.301 
Myo19 5.623 0.001 0.045 Pold4 18.306 0.007 0.225 
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Myh10 2.297 0.049 0.658 Nisch 2.520 0.009 0.263 
Arr3 17.860 0.000 0.004 RGD1308134 5.058 0.009 0.263 
Srr 1.413 0.050 0.661 Pik3ip1 2.097 0.034 0.530 
Gadd45gip1 3.171 0.033 0.520 Klhdc7a 14.019 0.029 0.490 
Plcd3 20.525 0.005 0.194 Myh7b 6.502 0.001 0.063 
Serpinf1 0.126 0.024 0.456 Ifit1 27.143 0.001 0.060 
Hexim1 3.382 0.003 0.138 Rmi1 18.324 0.008 0.236 
Nudt16l1 29.053 0.001 0.046 Scamp2 6.011 0.027 0.479 
Col3a1 0.524 0.034 0.523 Emc9 0.631 0.000 0.017 
Ogt 5.440 0.038 0.566 Acsl4 0.140 0.044 0.613 
Slc6a4 14.017 0.029 0.487 Glb1l 8.111 0.016 0.350 
Tom1l2 3.510 0.042 0.597 Ubqln1 3.540 0.040 0.589 
Ubxn4 16.107 0.016 0.350 Fchsd2 5.196 0.009 0.254 
Wdr26 7.150 0.044 0.618 Sult1a1 11.716 0.000 0.033 
Clgn 4.650 0.043 0.607 Trpv1 20.687 0.012 0.309 
Hmox2 2.934 0.012 0.310 Rec8 8.414 0.023 0.444 
Pitpna 4.614 0.045 0.620 Ipo4 20.574 0.008 0.235 
Cep350 4.261 0.023 0.446 Pld2 14.034 0.031 0.498 
Tmem94 5.908 0.003 0.138 Trpv3 12.111 0.000 0.000 
Tcaim 7.920 0.015 0.348 Csrnp2 6.174 0.000 0.009 
Ptger1 2.071 0.015 0.339 Aspa 16.272 0.038 0.566 
Vasn 4.135 0.016 0.350 Ubxn1 0.299 0.043 0.607 
Abca8a 2.701 0.003 0.149 Jmjd8 0.774 0.018 0.378 
Dnah9 9.187 0.001 0.061 Actn3 11.545 0.010 0.288 
Eml5 2.312 0.043 0.607 Sipa1l2 6.646 0.013 0.314 
Camta2 3.984 0.007 0.225 Scand1 5.973 0.048 0.644 
Lrrc52 14.019 0.029 0.490 Tmem198 6.175 0.002 0.117 
Elk3 6.210 0.035 0.535 Rab40c 16.186 0.012 0.310 
Ddx39a 9.789 0.007 0.225 Eef1g 0.205 0.005 0.196 
Brd1 16.233 0.016 0.351 Scgb1a1 18.356 0.005 0.194 
Cox20 5.128 0.000 0.002 Asrgl1 9.165 0.000 0.004 
Dcn 0.115 0.003 0.149 Gmpr2 3.269 0.002 0.094 
Ofd1 3.804 0.020 0.404 Kif22 16.116 0.016 0.352 
Fkbp3 10.411 0.003 0.133 Ezh1 24.864 0.001 0.065 
Mta3 14.167 0.048 0.644 Best1 0.588 0.000 0.000 
Muc15 1.690 0.030 0.495 Hdac4 7.961 0.015 0.347 
Angptl1 7.194 0.000 0.030 Rhog 20.605 0.003 0.138 
Arf6 0.126 0.004 0.174 Apc 2.536 0.025 0.462 
Flrt3 6.871 0.000 0.030 Col5a3 2.162 0.014 0.338 
Erbb3 2.365 0.002 0.118 Lipe 4.829 0.001 0.055 
Agr3 20.648 0.005 0.183 Ceacam1 9.822 0.001 0.077 
Agr2 33.680 0.000 0.031 Snrnp70 3.095 0.010 0.288 
Arhgef25 7.294 0.007 0.225 Ltbp4 0.200 0.017 0.356 
Sec16b 14.017 0.029 0.487 Celf3 6.126 0.004 0.169 
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Kif5a 1.760 0.007 0.231 Frmd8 18.379 0.008 0.251 
Scn8a 2.509 0.046 0.626 Gif 6.645 0.040 0.583 
Rassf5 3.082 0.025 0.464 Ppp2r5b 3.279 0.028 0.486 
Gna11 5.375 0.027 0.479 Sphk2 3.894 0.002 0.098 
Kcnmb1 20.466 0.007 0.225 Lsr 4.087 0.000 0.004 
Pkp4 13.872 0.046 0.626 Fxyd3 1.710 0.012 0.310 
LOC686013 6.125 0.004 0.169 Tnfaip8l2 22.858 0.007 0.235 
Apob 9.657 0.008 0.244 Mark2 14.016 0.029 0.487 
Zbtb44 14.155 0.041 0.592 Lix1l 7.871 0.019 0.389 
Slc10a1 12.364 0.000 0.004 Celsr1 3.197 0.046 0.632 
Dmtf1 5.138 0.014 0.331 Wfikkn1 6.155 0.012 0.309 
Ezh2 3.371 0.006 0.220 Mpp6 14.034 0.031 0.498 
LRRTM1 21.265 0.000 0.000 Atp8b5p 20.526 0.002 0.118 
Stx18 4.412 0.001 0.065 Tnpo3 0.298 0.050 0.662 
RGD1310352 0.466 0.030 0.490 RT1-M6-1 5.455 0.041 0.593 
Dync1h1 1.753 0.001 0.056 Dhx37 0.061 0.047 0.642 
Fkbp4 14.017 0.029 0.487 Lrrc19 22.627 0.005 0.194 
Snf8 7.288 0.017 0.356 mrpl24 2.916 0.040 0.583 
Crbn 2.830 0.009 0.265 Luzp1 12.355 0.001 0.049 
Fndc9 5.681 0.002 0.112 LOC102546864 5.139 0.017 0.355 
Neb 6.034 0.003 0.134 LOC100360821 18.470 0.026 0.470 
Psapl1 42.204 0.000 0.001 AABR07052585.1 5.856 0.045 0.625 
Casq1 4.820 0.047 0.641 Zdhhc2 8.552 0.009 0.254 
Ano6 3.526 0.046 0.626 Ilf3 14.017 0.029 0.487 
10-Mar 27.061 0.001 0.050 Tmem126a 10.127 0.000 0.005 
Cacna1c 10.071 0.003 0.149 Evi2a 3.067 0.019 0.391 
Il12rb2 4.023 0.004 0.172 Tmem184b 3.537 0.042 0.596 
Mroh8 0.611 0.022 0.428 Hjurp 5.194 0.000 0.035 
Pla2g4b 6.008 0.000 0.000 Ppp2r3a 5.218 0.000 0.020 
Gdf11 7.294 0.007 0.225 Proca1 2.512 0.007 0.231 
Kcnj9 11.274 0.000 0.001 LOC500300 7.679 0.003 0.127 
C8a 14.017 0.029 0.487 Cldn20 6.651 0.017 0.355 
Timp4 16.811 0.000 0.000 Ahctf1 7.258 0.025 0.456 
Ncoa2 7.434 0.015 0.347 Ncbp1 7.222 0.029 0.487 
Ssb 7.282 0.006 0.212 Tmem176a 0.449 0.027 0.484 
Fos 0.233 0.012 0.310 Plec 1.684 0.005 0.190 
Cinp 6.636 0.041 0.596 Cmya5 25.220 0.029 0.490 
Atp8a2 2.371 0.034 0.530 Ggn 6.647 0.013 0.317 
Ccne2 1.823 0.010 0.278 Aco2 4.873 0.000 0.002 
Kcnh6 7.270 0.024 0.452 Klhl34 2.218 0.004 0.156 
Lrrc4 8.379 0.000 0.000 Tnrc18 4.804 0.001 0.084 
Plpp3 0.299 0.038 0.567 Nup50 27.398 0.003 0.132 
Tagln2 0.690 0.009 0.261 Arhgap22 16.269 0.035 0.535 
Orc3 6.668 0.017 0.363 Ppm1e 6.011 0.027 0.479 
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Slc9a8 3.751 0.010 0.287 Polr2b 0.357 0.000 0.000 
Sbf1 3.801 0.021 0.412 Pcolce 3.036 0.031 0.510 
Bsg 0.650 0.005 0.180 Gpr183 4.707 0.003 0.140 
Gpr22 5.917 0.000 0.005 Nup188 4.494 0.009 0.258 
Eid1 6.444 0.000 0.012 Tmem130 2.734 0.047 0.642 
Rundc3b 25.205 0.005 0.194 Fer1l6 7.987 0.000 0.009 
Nkiras1 16.186 0.012 0.310 Usp7 3.432 0.006 0.212 
Invs 14.017 0.029 0.487 Zfhx2 7.106 0.000 0.000 
Angptl3 5.381 0.008 0.241 Gpr17 7.141 0.000 0.000 
Cops2 4.068 0.019 0.389 Myh6 22.701 0.000 0.000 
Plekha5 16.087 0.032 0.512 Set 1.707 0.024 0.456 
Pnisr 2.121 0.004 0.169 Krt80 18.749 0.029 0.488 
Mpp5 20.516 0.007 0.231 Tspan32 25.170 0.011 0.290 
Parp2 0.328 0.000 0.000 Gbf1 3.356 0.026 0.479 
Sec24c 3.626 0.008 0.252 Adpgk 5.439 0.000 0.005 
Thra 2.547 0.000 0.004 Rpl11 0.632 0.024 0.456 
Immt 16.115 0.016 0.352 Lrrtm3 32.088 0.000 0.000 
Otub2 4.658 0.043 0.607 LOC102555377 3.352 0.034 0.523 
Nub1 0.251 0.030 0.494 Disp2 4.068 0.019 0.389 
Fbxo2 16.071 0.044 0.613 LOC690784 4.986 0.020 0.404 
Pgp 9.130 0.011 0.301 Snx17 4.632 0.004 0.172 
Xpa 0.368 0.027 0.481 RGD1562319 9.186 0.003 0.127 
LOC102552055 4.759 0.001 0.046 Sez6l2 9.745 0.006 0.215 
Lrrn2 18.678 0.025 0.462 Fbxl2 6.011 0.027 0.479 
Tstd2 1.441 0.012 0.310 Sgsm2 5.030 0.007 0.225 
Dync1i2 3.142 0.047 0.641 Faxdc2 1.779 0.023 0.446 
Camk2g 5.018 0.001 0.070 AABR07060293.1 6.831 0.003 0.138 
Cdkn3 4.720 0.019 0.389 Ssx1 9.187 0.001 0.049 
Frg1 14.017 0.029 0.487 Nbeal2 0.455 0.010 0.285 
Slfnl1 16.082 0.035 0.535 Ankrd11 3.613 0.011 0.297 
LOC100151767 0.672 0.002 0.091 Cdh15 5.775 0.016 0.350 
Ctps1 3.136 0.016 0.353 Cryzl1 14.017 0.029 0.487 
Stard9 3.831 0.001 0.065 Arhgef18 4.648 0.013 0.317 
Dgkh 4.274 0.023 0.446 Cpa2 18.357 0.005 0.194 
Smarcd3 4.173 0.002 0.108 Sh2b3 6.363 0.000 0.000 
Eif4b 2.522 0.001 0.071 Tctn1 2.136 0.003 0.145 
Prrc2b 2.216 0.043 0.607 Hmcn1 16.187 0.012 0.310 
Dixdc1 7.883 0.015 0.347 Szt2 1.595 0.027 0.480 
Trim32 7.309 0.007 0.231 Ctns 2.697 0.002 0.093 
Dhx29 5.024 0.036 0.551 Dgat1 16.323 0.021 0.414 
Ipo7 6.903 0.000 0.043 Eppin 4.418 0.010 0.283 
Mycbp2 12.429 0.000 0.015 Acan 24.821 0.001 0.085 
Sp2 6.465 0.009 0.265 Dhx30 12.377 0.010 0.286 
Cryab 0.316 0.017 0.355 RGD1563145 20.527 0.002 0.118 
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Nr2c2 2.987 0.042 0.596 RT1-N2 23.195 0.011 0.301 
Plekhh1 3.564 0.020 0.404 Rnf213 3.532 0.041 0.596 
Cmtm3 16.220 0.014 0.332 Mt-nd5 1.265 0.024 0.451 
Rpl32 0.261 0.004 0.170 Robo3 18.491 0.011 0.305 
E2f5 6.662 0.015 0.347 Ormdl2 9.869 0.001 0.079 
Kpna4 0.056 0.044 0.618 Dhx16 2.427 0.002 0.092 
Arrdc4 20.525 0.005 0.194 Adck5 3.880 0.007 0.229 
Ccdc22 6.058 0.040 0.587 Mroh1 3.341 0.032 0.512 
Nfe2l3 5.382 0.003 0.127 Ankrd52 2.903 0.032 0.512 
Bmp1 9.184 0.007 0.231 Lmf2 14.000 0.042 0.603 
Pigh 2.385 0.022 0.431 AABR07000595.1 12.822 0.000 0.000 
Ermp1 2.799 0.007 0.231 RGD1561034 2.101 0.018 0.378 
Taf1d 14.016 0.029 0.487 RGD1561114 18.749 0.029 0.488 
Has1 6.126 0.001 0.077 Mt-nd2 2.259 0.004 0.167 
Cep295 14.560 0.000 0.000 Mt-nd4l 3.255 0.008 0.236 
Copg2 2.184 0.032 0.513 Carm1 2.063 0.016 0.351 
Htt 3.408 0.016 0.351 LOC100361645 4.159 0.006 0.218 
Ank2 1.956 0.002 0.089 Mt-atp6 1.874 0.026 0.479 
Lrp2bp 20.527 0.002 0.118 Uqcrc1 2.587 0.012 0.310 
Masp2 3.047 0.001 0.064 Acsm3 3.124 0.018 0.367 
Lama3 3.550 0.021 0.417 Scn11a 3.047 0.023 0.446 
Rictor 14.000 0.042 0.603 Mab21l1 7.241 0.001 0.046 
Rbsn 4.325 0.050 0.661 AC127605.1 33.346 0.000 0.036 
Kif3c 2.604 0.048 0.642 Zrsr2 16.187 0.012 0.310 
Adgrg6 14.017 0.029 0.487 AABR07072400.1 0.401 0.001 0.060 
Pde3b 6.759 0.038 0.570 Mapk8ip3 1.907 0.018 0.368 
Ccdc39 3.757 0.001 0.049 Mt-nd3 5.112 0.000 0.010 
Tbck 16.273 0.017 0.355 Fam196a 4.454 0.000 0.003 
Arfgef3 5.029 0.016 0.351 Atp8a1 18.356 0.005 0.194 
Ap3m1 1.979 0.021 0.421 Fscn2 3.032 0.008 0.243 
Psip1 2.806 0.000 0.036 Iqck 9.091 0.015 0.347 
Il16 18.473 0.028 0.486 LOC100360933 16.186 0.012 0.310 
Foxp3 2.350 0.001 0.065 Ulk1 18.356 0.005 0.194 
Fbxo34 16.447 0.033 0.523 Hyi 3.965 0.008 0.243 
Sat2 16.132 0.033 0.523 Kdm6b 14.016 0.029 0.487 
Sgk1 3.343 0.032 0.512 Erich4 8.533 0.002 0.117 
Galnt7 18.331 0.007 0.225 Spidr 3.591 0.004 0.169 
Ifngr1 20.537 0.002 0.120 Eif2b5 2.378 0.045 0.626 
Cstf3 3.045 0.005 0.184 Pram1 8.729 0.000 0.002 
Xrcc3 3.538 0.043 0.607 Cfap157 1.915 0.013 0.317 
Dst 1.729 0.000 0.035 Pate4 14.017 0.029 0.487 
Med26 2.607 0.024 0.451 Ccdc152 0.588 0.000 0.010 
Exosc4 14.017 0.029 0.487 AC126960.1 16.119 0.050 0.662 
Glyatl2 9.171 0.006 0.208 Adgrg5 5.417 0.037 0.557 
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Zmym4 7.330 0.008 0.253 Rab26 2.361 0.001 0.055 
Zfp598 14.016 0.029 0.487 Ccdc122 3.639 0.017 0.356 
Isl1 13.859 0.048 0.645 Marveld1 0.195 0.029 0.487 
Grin3b 2.038 0.004 0.160 Ccdc188 5.376 0.027 0.479 
Tlcd1 0.703 0.000 0.000 AABR07006480.1 3.827 0.003 0.149 
Gpr18 2.887 0.017 0.356 LOC687707 14.029 0.032 0.512 
Cables1 3.522 0.032 0.512 Ncald 14.072 0.032 0.512 
Tmem259 5.380 0.028 0.486 Fdps 0.640 0.037 0.558 
Espl1 22.965 0.007 0.224 AABR07005040.1 24.865 0.001 0.065 
Odf3 7.262 0.015 0.347 U2af1 0.074 0.000 0.022 
Vps41 3.544 0.041 0.589 RT1-T24-3 6.064 0.045 0.620 
Mov10 2.485 0.012 0.310 Irgq 3.852 0.032 0.513 
Mettl3 2.506 0.008 0.248 Dbi 16.153 0.014 0.330 
Cacna1d 3.352 0.037 0.558 Thyn1 1.920 0.025 0.463 
Wnt4 7.895 0.022 0.435 Lrrtm2 4.381 0.000 0.000 
Ccdc150 6.011 0.027 0.479 Bptf 5.403 0.032 0.512 
Casz1 9.145 0.006 0.201 Card14 0.441 0.040 0.585 
Appl1 16.088 0.032 0.512 Cdan1 16.177 0.000 0.001 
Tex2 3.705 0.004 0.174 Cabyr 3.055 0.043 0.607 
Elavl3 18.356 0.005 0.194 AC115420.2 2.415 0.003 0.129 
Dcaf1 4.637 0.028 0.486 Klhdc8b 20.525 0.005 0.194 
P2ry14 3.785 0.024 0.451 Olr338 18.331 0.007 0.225 
Gpr87 20.616 0.012 0.310 LOC300308 18.468 0.026 0.479 
Arhgap26 6.646 0.013 0.314 Apeg3 1.384 0.045 0.625 
Itpkc 7.915 0.010 0.287 Myo18b 5.390 0.001 0.069 
Ntrk1 0.232 0.033 0.513 Nynrin 14.017 0.029 0.487 
Acat2l1 0.664 0.036 0.549 Pros1 0.065 0.040 0.584 
Sbno2 0.701 0.000 0.000 AABR07000534.1 4.943 0.000 0.000 
Gfod1 20.693 0.017 0.363 Pdss1 29.175 0.001 0.053 
Jade1 18.614 0.016 0.350 Kdm4b 2.864 0.039 0.576 
Pold2 0.496 0.013 0.317 Adamtsl4 6.945 0.000 0.021 
Omg 6.372 0.002 0.092 Sh3gl1 10.434 0.000 0.000 
Map1a 1.733 0.000 0.010 Myh2 9.015 0.023 0.442 
Plce1 3.616 0.035 0.535 Pdia6 20.490 0.009 0.256 
Josd1 16.323 0.021 0.414 Cstf2t 4.695 0.007 0.225 
Zfhx3 2.132 0.047 0.642 Ttc16 2.154 0.043 0.607 
S1pr3 3.150 0.047 0.639 Col10a1 3.759 0.009 0.261 
Fxyd4 18.502 0.019 0.382 Ppp1r12b 2.072 0.030 0.498 
Sigmar1 14.141 0.043 0.607 Nwd2 13.978 0.040 0.583 
Atxn10 4.616 0.048 0.645 Usp34 3.412 0.045 0.626 
Cbfb 3.805 0.034 0.532 Ahsa2 12.364 0.000 0.004 
Chrnb1 20.525 0.005 0.194 Arhgef40 2.440 0.000 0.002 
Tmbim1 21.271 0.000 0.000 AABR07034980.1 1.824 0.010 0.273 
Mas1 9.813 0.001 0.055 Ak3 3.750 0.017 0.362 
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Arhgef11 6.502 0.004 0.157 AC130391.3 0.675 0.002 0.091 
Myo7b 23.855 0.000 0.000 Ccpg1 3.703 0.010 0.272 
Dmpk 7.331 0.008 0.249 Lama5 20.525 0.005 0.194 
Prune2 2.096 0.015 0.347 B3gnt9 3.698 0.028 0.487 
Lrrc39 2.009 0.016 0.350 Sim2 11.092 0.000 0.015 
Timm21 22.696 0.002 0.118 Rps8 0.491 0.016 0.351 
Fxn 0.049 0.013 0.317 Pex13 5.376 0.027 0.480 
Coro2b 3.219 0.021 0.417 Setd1a 14.017 0.029 0.487 
Spsb3 2.493 0.000 0.020 Ncor1 1.894 0.035 0.535 
Rpl13 0.629 0.035 0.532 Vom2r80 16.513 0.038 0.565 
Sfxn3 5.421 0.039 0.581 Mrfap1 0.474 0.035 0.535 
Ubxn11 16.187 0.012 0.310 AABR07025316.1 5.967 0.000 0.000 
Otud7a 24.744 0.002 0.094 Fam46b 18.356 0.005 0.194 
Ticrr 14.023 0.030 0.492 LOC102552324 24.947 0.001 0.084 
Ptgds 0.360 0.004 0.174 Kcnab1 2.638 0.024 0.450 
Plpp5 7.358 0.015 0.347 Muc6 11.632 0.000 0.001 
Suv39h2 16.187 0.012 0.310 Cav1 0.492 0.045 0.625 
LOC100125364 3.727 0.007 0.228 Abr 4.066 0.020 0.396 
Wdr34 1.633 0.032 0.513 Scn3b 3.915 0.003 0.133 
LOC690507 13.594 0.000 0.023 Obscn 7.946 0.025 0.456 
Taok1 15.924 0.041 0.592 AABR07013154.2 24.867 0.001 0.065 
E2f4 10.427 0.005 0.190 Cfap99 2.656 0.008 0.253 
Parva 4.266 0.000 0.010 RGD1562378 0.031 0.000 0.041 
Myl12b 0.371 0.013 0.317 Col12a1 3.542 0.034 0.529 
Ube3a 4.367 0.002 0.089 Col2a1 3.308 0.048 0.644 
Elmo3 8.640 0.000 0.000 Nek9 18.399 0.013 0.317 
Ctsa 0.392 0.012 0.310 Sptbn2 3.608 0.001 0.074 
Ap2s1 14.039 0.032 0.512 Fbxl3 4.331 0.011 0.289 
Plekhg1 5.384 0.027 0.481 Has3 8.530 0.000 0.001 
Lrrc14 6.707 0.000 0.001 Itgb1bp1 6.685 0.017 0.355 
Gpr162 2.424 0.015 0.347 Cc2d2a 18.451 0.009 0.253 
Spata2L 5.717 0.001 0.064 Avpr2 11.379 0.001 0.074 
Sema4c 3.146 0.040 0.583 Thbs3 6.659 0.016 0.350 
Myo9b 4.170 0.007 0.225 AABR07059140.1 22.736 0.003 0.139 
Cotl1 0.212 0.015 0.347 Ypel4 6.909 0.001 0.050 
Plcd4 2.592 0.048 0.644 Kdm5d 4.814 0.001 0.046 
Pcsk4 3.181 0.043 0.607 Wdfy3 1.754 0.045 0.625 
Pltp 0.583 0.011 0.289 AABR07058091.2 6.349 0.000 0.025 
Tmem204 7.258 0.001 0.061 LOC103694857 0.012 0.006 0.216 
Dgat2 16.133 0.016 0.351 Phf10 3.046 0.024 0.451 
RGD1561517 5.393 0.030 0.490 Kmt2d 3.105 0.001 0.079 
Dtna 7.339 0.011 0.304 Scamp1 6.021 0.010 0.286 
Angpt2 9.186 0.003 0.127 Rbm4b 4.082 0.000 0.032 
Fanca 2.834 0.001 0.055 LOC679342 20.620 0.004 0.162 
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Table 20.  CCI DF-NE vs CCI CXB-NE differential expression data (non-coding genes). Includes 
differential expression data using one-way ANOVA analyses of pooled L4-L5 DRGs from RNA 
sequencing. 
Gene Gene Biotype Fold Change Raw P value FDR 
Mir3065 miRNA 8.551 0.001 0.079 
Mir3074 miRNA 16.267 0.000 0.000 
Gm22953 miRNA 0.676 0.000 0.005 
AABR07067736.1 miRNA 16.258 0.019 0.392 
AABR07055846.1 miRNA 8.607 0.007 0.225 
AABR07073453.1 lincRNA 24.865 0.001 0.065 
AABR07027811.1 miRNA 0.392 0.001 0.045 
AC130391.2 miRNA 0.280 0.000 0.007 
AABR07058935.1 lincRNA 14.017 0.029 0.487 
AC099089.1 miRNA 0.554 0.000 0.000 
AABR07012583.1 miRNA 0.485 0.001 0.055 
AABR07062800.1 lincRNA 15.776 0.000 0.005 
AC114096.2 miRNA 0.256 0.000 0.000 
AABR07033249.1 lincRNA 27.061 0.001 0.050 
AABR07027752.1 miRNA 0.433 0.023 0.446 
AABR07033570.1 lincRNA 50.960 0.000 0.000 
AC105645.3 miRNA 0.486 0.003 0.129 
AABR07027752.3 miRNA 0.360 0.000 0.015 
AABR07021465.2 lincRNA 0.554 0.013 0.317 
AABR07035926.2 lincRNA 5.094 0.013 0.313 
AABR07006713.1 lincRNA 5.375 0.027 0.479 
AABR07026509.1 lincRNA 15.885 0.038 0.571 
AABR07027811.3 miRNA 0.302 0.000 0.002 
Rn60_1_2212.2 lincRNA 4.974 0.000 0.000 
Rn60_1_2212.3 lincRNA 4.166 0.005 0.194 











Table 21. PANTHER Gene Ontology classifications of genes differentially expressed between CCI DF-NE 
and CCI CXB-NE animals. *Number of genes indicates the number of total genes annotated within the 




Genes P value FDR 
gene expression (GO:0010467) 727 6.65E-09 8.37E-05 
response to drug (GO:0042493) 451 3.00E-08 1.89E-04 
response to organic cyclic compound 
(GO:0014070) 426 3.48E-08 1.46E-04 
response to toxic substance (GO:0009636) 239 6.52E-08 2.05E-04 
cellular response to drug (GO:0035690) 178 4.25E-07 1.07E-03 
protein stabilization (GO:0050821) 85 3.84E-06 8.06E-03 
sensory perception of chemical stimulus 
(GO:0007606) 44 1.35E-05 2.42E-02 
detection of chemical stimulus (GO:0009593) 39 1.86E-05 2.92E-02 
sensory perception of smell (GO:0007608) 35 2.18E-05 3.05E-02 
detection of chemical stimulus involved in 
sensory perception (GO:0050907) 30 2.38E-05 3.00E-02 
detection of chemical stimulus involved in 
sensory perception of smell (GO:0050911) 24 3.25E-05 3.72E-02 
    
    
Molecular Function 
Number of 
Genes P value FDR 
molecular transducer activity (GO:0060089) 268 5.66E-10 1.79E-06 
signaling receptor activity (GO:0038023) 253 6.65E-09 1.05E-05 
structural molecule activity (GO:0005198) 227 2.73E-07 2.88E-04 
transmembrane signaling receptor activity 
(GO:0004888) 215 4.64E-07 3.67E-04 
G protein-coupled receptor activity 
(GO:0004930) 106 2.92E-06 1.85E-03 
structural constituent of ribosome (GO:0003735) 95 3.29E-05 1.74E-02 
olfactory receptor activity (GO:0004984) 24 3.51E-05 1.59E-02 
    
Cellular Component 
Number of 
Genes P value FDR 
membrane-bounded organelle (GO:0043227) 4105 1.94E-05 3.37E-02 
intracellular membrane-bounded organelle 
(GO:0043231) 3864 2.55E-05 2.21E-02 
cytoplasmic part (GO:0044444) 3391 5.22E-05 3.02E-02 
organelle lumen (GO:0043233) 1739 5.96E-05 2.59E-02 
membrane-enclosed lumen (GO:0031974) 1739 7.44E-05 2.58E-02 
intracellular organelle lumen (GO:0070013) 1738 1.48E-04 4.29E-02 
whole membrane (GO:0098805) 550 2.03E-04 5.03E-02 
ribonucleoprotein complex (GO:1990904) 427 2.06E-04 4.48E-02 
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mitochondrial part (GO:0044429) 365 2.26E-04 4.36E-02 
perinuclear region of cytoplasm (GO:0048471) 316 2.93E-04 5.08E-02 
ribosome (GO:0005840) 138 3.07E-04 4.84E-02 
mitochondrial protein complex (GO:0098798) 131 3.12E-04 4.52E-02 
ribosomal subunit (GO:0044391) 116 3.21E-04 4.28E-02 
oxidoreductase complex (GO:1990204) 56 3.52E-04 4.36E-02 
respirasome (GO:0070469) 51 3.53E-04 4.09E-02 
respiratory chain complex (GO:0098803) 49 3.85E-04 4.18E-02 
mitochondrial respirasome (GO:0005746) 46 4.01E-04 4.09E-02 
DNA packaging complex (GO:0044815) 31 4.01E-04 3.86E-02 
nucleosome (GO:0000786) 26 5.55E-04 5.07E-02 
cytoplasmic side of rough endoplasmic reticulum 
membrane (GO:0098556) 18 5.64E-04 4.89E-02 
    
    
Reactome Pathway 
Number of 
Genes P value FDR 
Innate Immune System (R-RNO-168249) 340 2.01E-05 3.02E-02 
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